

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
26 August 2004 (26.08.2004)

PCT

(10) International Publication Number
WO 2004/072231 A2

- (51) International Patent Classification: C12N
- (21) International Application Number: PCT/US2004/002013
- (22) International Filing Date: 10 February 2004 (10.02.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 10/361,002 10 February 2003 (10.02.2003) US
- (71) Applicant (for all designated States except US): CLEAR-ANT, INC. [US/US]; Suite 650, 11111 Santa Monica Boulevard, Los Angeles, CA 90025 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): MCKENNEY, Keith [US/US]; 11918 Glen Mill Road, Potomac, MD 20854 (US). GILLMEISTER, Lidja [US/US]; 9419 Lee Highway, Fairfax, VA 22031 (US). MARLOWE, Kristina [US/US]; 9419 Lee Highway, Fairfax, VA 22031 (US). ARMISTEAD, David [US/US]; 1810 North Wayne Street, Arlington, VA 22201 (US).
- (74) Agents: MCPHAIL, Donald, R. et al.; Fleishner & Kim, LLP, P.O. Box 221200, Chantilly, VA 20153-1200 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAH (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PATHOGEN INACTIVATION ASSAY

(57) Abstract: The present invention relates to methods for determining the level of potentially active biological pathogens, such as viruses, bacteria (including inter- and intracellular bacteria, such as mycoplasmas, ureaplasmas, nanobacteria, chlamydia, rickettsias), fungi (including yeasts) and single cell parasites, which may be found in a biological material. The present invention particularly relates to methods of determining the level of potentially active biological pathogens in a biological material using quantitative PCR.

WO 2004/072231 A2

PATHOGEN INACTIVATION ASSAY

BACKGROUND OF THE INVENTION

5 1. Field of the Invention

The present invention relates to methods for determining the level of potentially active biological pathogens, such as viruses, bacteria (including inter- and intracellular bacteria, such as mycoplasmas, ureaplasmas, nanobacteria, chlamydia, rickettsias), fungi (including yeasts), and single- and multi-cell parasites, which may be found in a biological
10 material. The present invention particularly relates to methods of determining the level of potentially active biological pathogens in a biological material using quantitative PCR, and so may be particularly useful for determining the effectiveness of a sterilization process that has been applied to the biological material.

15 2. Background of the Related Art

Many biological materials that are prepared for human, veterinary, diagnostic and/or experimental use may contain unwanted and potentially dangerous biological pathogens, such as viruses, bacteria, in both vegetative and spore states, (including inter- and intracellular bacteria, such as mycoplasmas, ureaplasmas, nanobacteria, chlamydia,
20 rickettsias), fungi (including yeasts), and single- and multi-cell parasites. This may also be true of biological materials that are produced in or exported from locations where certain biological pathogens may exist to locations where those biological pathogens are not endemic. Consequently, it is of utmost importance that any biological pathogen in the

biological material be inactivated before the material is used. This is especially critical when the biological material is to be administered directly to a patient, for example in tissue implants, blood transfusions, blood factor replacement therapy, organ transplants, and other forms of human and/or other animal therapy corrected or treated by surgical implantation, intravenous, intramuscular or other forms of injection or introduction. This is also critical for the various biological materials that are prepared in media or via the culture of cells, or recombinant cells which contain various types of plasma and/or plasma derivatives or other biological materials and which may be subject to mycoplasmal, prion, ureaplasma, bacterial, viral and/or other biological pathogens.

All living cells and multi-cellular organisms can be infected with viruses and other pathogens. Thus, the products of unicellular natural or recombinant organisms or tissues virtually always carry a risk of pathogen contamination. In addition to the risk that the producing cells or cell cultures may be infected, the processing of these and other biological materials also creates opportunities for environmental contamination. The risks of infection are more apparent for multi-cellular natural and recombinant organisms, such as transgenic animals.

Interestingly, even products from species as different from humans as transgenic plants carry risks, both due to processing contamination as described above, and from environmental contamination in the growing facilities, which may be contaminated by pathogens from the environment or infected organisms that co-inhabit the facility along with the desired plants. For example, a crop of transgenic corn grown in a field could be expected to be exposed to rodents such as mice during the growing season. Mice can harbor

serious human pathogens such as the frequently fatal Hanta virus. Since these animals would be undetectable in the growing crop, viruses shed by the animals could be carried into the transgenic material at harvest. Indeed, such rodents are notoriously difficult to control, and may gain access to a crop during sowing, growth, harvest or storage. Likewise, contamination from overflying or perching birds has the potential to transmit such serious pathogens as the causative agent for psittacosis. Thus, any biological material, regardless of its source, may harbor serious pathogens that must be removed or inactivated prior to administration of the material to a recipient human or other animal.

Accordingly, many procedures for producing human compatible biological materials have involved methods that screen or test the biological materials for one or more particular biological pathogens rather than removal or inactivation of the pathogen(s) from the biological material. The typical protocol for disposition of materials that test positive for a biological pathogen simply is non-use/discarding of that material.

Examples of screening procedures for contaminants include testing for a particular virus in human blood and tissues from donors. Such procedures, however, are not always reliable and are not able to detect the presence of certain viruses, and prions, particularly those present in very low numbers. This reduces the value, certainty, and safety of such tests in view of the consequences associated with a false negative result, which can be life threatening in certain cases, for example in the case of Acquired Immune Deficiency Syndrome (AIDS). Furthermore, in some instances it can take weeks, if not months, to determine whether or not the material is contaminated. Moreover, to date, there is no commercially available, reliable test or assay for identifying ureaplasmas, mycoplasmas, and

chlamydia within a biological material that is fully suitable for screening out potential donors or infected material (*Advances in Contraception* 10(4):309-315(1994)). This serves to heighten the need for an effective means of destroying ureaplasmas, mycoplasmas, chlamydia, etc., within a biological material, while still retaining the desired activity of that material.

5 Therefore, it is highly desirable to apply techniques that kill or inactivate biological pathogens during and/or after manufacturing and/or harvesting the biological material.

More recent efforts have focussed on methods to remove or inactivate contaminants in products intended for use in humans and other animals. Particularly useful methods are those that alter the genetic material of a biological pathogen, such as the addition of

10 chemical inactivants or sensitizers to a biological material or irradiation of a biological material.

The use of chemical inactivants or sensitizers involves the addition of noxious agents which bind to the DNA/RNA of the virus, and which are activated either by UV or other radiation. This radiation produces reactive intermediates and/or free radicals which bind to

15 the DNA/RNA of the virus, break the chemical bonds in the backbone of the DNA/RNA, and/or cross-link or complex it in such a way that the virus can no longer replicate.

Irradiating a biological material with ionizing radiation, such as gamma, UV or e-beam radiation, is another method of sterilizing a product. The direct effects of gamma radiation are particularly useful for destroying the genetic material within viruses and

20 bacteria, particularly when given in total doses of at least 25 kGy (*See* Keathly, *et al.*, "Is There Life After Irradiation? Part 2," *BioPharm* July-August, 1993, and Leitman, "Use of Blood Cell Irradiation in the Prevention of Post Transfusion Graft-vs-Host Disease,"

Transfusion Science 10:219-239(1989)).

The use of such sterilization methods does not, however, remove any biological pathogens from the sterilized biological material. Rather, these methods render inactive any biological pathogens that may be present in the biological material by altering the genetic material within the pathogen, including cleaving, deleting, oxidizing, reducing, covalently bonding, cross-linking and/or complexing that genetic material or a component thereof.

For many potentially active biological pathogens, a single modification in their genome may be sufficient to render them inactive. Significantly, most presently available tests for the detection or quantification of biological pathogens, such as ELISA tests for surface antigens, will not indicate that the biological pathogen has been rendered inactive. Moreover, conventional genetic detection tests, such as the PCR reaction described below, examine only a small portion of the genome and may fail to detect sites of alteration that render the biological pathogen inactive, irrespective of whether there are several such sites or only one. In practice, these tests may frequently report a high level of false positive results, leading to inappropriate product quarantine or destruction

Accordingly, there is a need for methods to examine the genomes of potentially active biological pathogens in biological materials that have been subjected to sterilization in order to differentiate between biological pathogens that have been rendered inactive and those that are still potentially active. By doing so, such a method permits the determination of how effective a particular sterilization technique may be with respect to a particular biological pathogen. No presently available test provides such information.

PCR (polymerase chain reaction) is a method for increasing the concentration of a segment of a target sequence in a mixture of nucleic acid sequences without cloning or purification. (See K. B. Mullis *et al.*, U.S. Pat. Nos. 4,683,195 and 4,683,202). This process for amplifying the target sequence consists of introducing two oligonucleotide primers to the sample containing the desired target nucleic acid sequence, followed by thermal cycling in the presence of a DNA polymerase. The two primers are complementary to their respective strands of the target sequence. To effect amplification, the genetic material within the sample is first denatured and then the primers are annealed to their complementary sequences within the target molecule. Following annealing, the primers are extended with a polymerase so as to form a new pair of complementary strands. The steps of denaturation, annealing and extension can be repeated many times (*i.e.*, denaturation, annealing and extension constitute one "cycle"; there can be numerous "cycles") to obtain a high concentration of an amplified segment of the desired target sequence. The length of the amplified segment of the desired target sequence is determined by the relative positions of the primers with respect to each other, and therefore, this length is a controllable parameter. Because the desired amplified segments of the target sequence become the predominant sequences (in terms of concentration) in the mixture, they are said to be "PCR amplified". The segment of genetic material that has been amplified is generally referred to as an "amplicon". The conditions employed for PCR reactions, including aspects of the timing, temperature(s) and particular polymerase selection are typically optimized for examining relatively short segments of nucleic acids, generally in the range of 50-200 nucleic acid residues. With PCR, it is possible to amplify a single copy of a specific target sequence in

genomic DNA to a level detectable by several different methodologies (e.g., hybridization with a labelled probe; incorporation of biotinylated primers followed by avidin-enzyme conjugate detection; incorporation of ^{32}P -labelled deoxynucleotide triphosphates, e.g., dCTP or dATP, into the amplified segment). In addition to genomic DNA, any oligonucleotide
5 sequence can be amplified with the appropriate set of primer molecules.

End-point PCR is a polynucleotide amplification protocol. The amplification factor that is observed is related to the number (n) of cycles that have occurred and the efficiency of replication at each cycle (E), which, in turn, is a function of the priming and extension efficiencies during each cycle. Amplification has been observed to follow the form E^n , until
10 high concentrations of the PCR product have been made.

At these high product concentrations, the efficiency of replication tends to drop significantly. It has been suggested that this is probably due to the displacement of the primers by the longer complementary strands of the PCR product. At concentrations in excess of 10^{-8} M, the rate of the two complementary PCR amplified product strands finding
15 each other during the priming reactions becomes sufficiently fast that it may occur before or concomitantly with the extension step of the PCR process. This ultimately leads to a reduced priming efficiency, and, consequently, a reduced cycle efficiency. Continued cycles of PCR lead to declining increases of PCR product molecules, until the PCR product eventually reaches a plateau concentration (the "end-point"), usually a concentration of
20 approximately 10^{-8} M. As a typical reaction volume is about 100 microliters, this corresponds to a yield of about 6×10^{11} double stranded product molecules.

Real-time PCR is also a polynucleotide amplification protocol, but PCR product

analysis occurs simultaneously with amplification of the target sequence. Detecting agents, such as DNA dyes or fluorescent probes, can be added to the PCR mixture before amplification and used to analyze PCR products during amplification. Sample analysis occurs concurrently with amplification in the same tube within the same instrument. This
5 combined approach decreases sample handling, saves time, and greatly reduces the risk of product contamination, as there is no need to remove the samples from their closed containers for further analysis. The concept of combining amplification with product analysis has become known as "real time" or "quantitative" PCR. (*See, e.g.*, WO/9746707A2, WO/9746712A2 and WO/9746714A1).

10 Originally, monitoring fluorescence each cycle of PCR involved the use of ethidium bromide. *See* Higuchi *et al.*, "Simultaneous amplification and detection of specific DNA sequences," *Bio/Technology* 10:413-417 (1992); Higuchi *et al.*, "Kinetic PCR analysis: real time monitoring of DNA amplification reactions," *Bio/Technology* 11:1026-1030 (1993). In that system, fluorescence was measured once per cycle as a relative measure of product
15 concentration. Ethidium bromide detects double stranded DNA; thus, if the desired target nucleic acid sequence is present, fluorescence intensity increases with temperature cycling (otherwise no fluorescence). Furthermore, the cycle number where an increase in fluorescence is first detected increases inversely proportionally to the log of the initial target sequence concentration. Other fluorescent systems have since been developed that are
20 capable of providing additional data concerning the nucleic acid concentration.

In view of the difficulties and problems discussed above, there remains a need for a simple, yet accurate method of determining the efficiency of methods of sterilizing biological

materials that act upon the genetic material of potentially active biological pathogens.

Each of the above references is incorporated by reference herein where appropriate for teachings of additional or alternative details, features and/or technical background.

5

SUMMARY OF THE INVENTION

An object of the invention is to solve at least the problems and/or disadvantages of the relevant art, and to provide at least the advantages described hereinafter.

Accordingly, it is an object of the present invention to provide methods of determining the level of potentially active biological pathogens in a biological material.

10 Other objects, features and advantages of the present invention will be set forth in the detailed description of preferred embodiments that follows, and in part will be apparent from the description or may be learned by practice of the invention. These objects and advantages of the invention will be realized and attained by the compositions and methods particularly pointed out in the written description and claims hereof.

15 In accordance with these and other objects, a first embodiment of the present invention is directed to a method for determining the level of potentially active biological pathogens in a biological material, which comprises: (i) adding to a biological material an effective amount of at least two nucleic acid primer pairs, wherein a first nucleic acid primer pair hybridizes under stringent conditions to a first target nucleic acid sequence found in the
20 biological pathogen and a second nucleic acid primer pair hybridizes under stringent conditions to a second target nucleic acid sequence found in the biological pathogen, and

further wherein first and second target nucleic acid sequences are not identical and the second target nucleic acid sequence contains more nucleic acid residues than the first; (ii) amplifying the target nucleic acid sequences by polymerase chain reaction, which comprises adding at least one polymerase to the biological material containing the primer pairs to form
5 an amplification mixture and thermally cycling this amplification mixture between at least one denaturation temperature and at least one elongation temperature for a period of time sufficient to amplify the target nucleic acid sequences; and (iii) detecting and quantifying the target nucleic acid sequences, wherein the quantity of the first target nucleic acid sequence is proportional to the number of biological pathogens in the biological material and the
10 quantity of the second target nucleic acid sequence is proportional to the number of potentially active biological pathogens in the biological material.

Additional advantages, objects, and features of the invention will be set forth in part in the description which follows and in part will become apparent to those having ordinary skill in the art upon examination of the following or may be learned from practice of the
15 invention. The objects and advantages of the invention may be realized and attained as particularly pointed out in the appended claims.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the complete genomic nucleic acid sequence of human Parvovirus
20 B19 (SEQ ID NO. 1), and indicates exemplary sequences for preparing suitable forward and reverse primers and probes.

Figure 2 shows the complete genomic nucleic acid sequence of hepatitis B virus (SEQ ID NO. 2), and indicates exemplary sequences for preparing suitable forward and reverse primers and probes.

Figure 3 shows the complete genomic nucleic acid sequence of porcine Parvovirus (SEQ ID NO. 3), and indicates exemplary sequences for preparing suitable forward and reverse primers and probes.

Figure 4 shows the complete genomic nucleic acid sequence of Sindbis virus (SEQ ID NO. 4), and indicates exemplary sequences for preparing suitable forward and reverse primers and probes.

Figure 5 shows the complete genomic nucleic acid sequence of West Nile virus (SEQ ID NO. 5), and indicates exemplary sequences for preparing suitable forward and reverse primers and probes.

Figures 6A and 6B show the genomic nucleic acid sequence of the 16S ribosomal RNA gene (SEQ ID NO. 6) and the 23S ribosomal RNA gene of *Escherichia coli* (SEQ ID NO. 7), and indicate exemplary sequences for preparing suitable forward and reverse primers and probes.

Figures 7A and 7B show the genomic nucleic acid sequence of the 18S ribosomal RNA gene (SEQ ID NO. 8) and the 25S ribosomal RNA gene of yeast (*S. cerevisiae*) (SEQ ID NO. 9), and indicate exemplary sequences for preparing suitable forward and reverse primers and probes.

Figure 8 shows the complete nucleic acid sequence of human mitochondrial DNA

(SEQ ID NO. 10), and indicates exemplary sequences for preparing suitable forward and reverse primers and probes.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

5 A. *Definitions*

Unless defined otherwise, all technical and scientific terms used herein are intended to have the same meaning as is commonly understood by one of ordinary skill in the relevant art.

As used herein, the singular forms "a," "an," and "the" include the plural reference
10 unless the context clearly dictates otherwise.

As used herein, the term "biological material" is intended to mean any substance derived or obtained from a living organism. Illustrative examples of biological materials include, but are not limited to, the following: cells; tissues; blood or blood components; proteins, including recombinant and transgenic proteins, and proteinaceous materials;
15 enzymes, including digestive enzymes, such as trypsin, chymotrypsin, alpha-galactosidase and iduronate-2-sulfatase; immunoglobulins, including mono and polyclonal immunoglobulins; botanicals; food and the like. Preferred examples of biological materials include, but are not limited to, the following: ligaments; tendons; nerves; bone, including demineralized bone matrix, grafts, joints, femurs, femoral heads, etc.; teeth; skin grafts; bone marrow, including
20 bone marrow cell suspensions, whole or processed; heart valves; cartilage; corneas; arteries and veins; organs, including organs for transplantation, such as hearts, livers, lungs, kidneys, intestines, pancreas, limbs and digits; lipids; carbohydrates; collagen, including native,

afibrillar, atelomeric, soluble and insoluble, recombinant and transgenic, both native sequence and modified; chitin and its derivatives, including NO-carboxy chitosan (NOCC); stem cells, islet of Langerhans cells and other cells for transplantation, including genetically altered cells; red blood cells; white blood cells, including monocytes; and platelets.

5 Additional examples of biological materials include forensic samples, human or animal remains, stomach contents, mummified remains of a once-living organism, fossilized remains, a product of manufacture containing or previously in contact with a biological material, and fomites.

As used herein, the term "biological pathogen" is intended to mean a biological pathogen that, upon direct or indirect contact with a biological material, may have a deleterious effect on the biological material or upon a recipient thereof. Such biological pathogens include, but are not limited to, the various viruses, bacteria (whether in the vegetative or spore state, including inter- and intracellular bacteria, such as mycoplasmas, ureaplasmas, nanobacteria, chlamydia, rickettsias), fungi (including yeasts) and/or single- or

15 multi-cell parasites and pests known to those of skill in the art to generally be found in or infect biological materials.

Illustrative examples of some biological pathogens include, but are not limited to, the following: viruses, such as human immunodeficiency viruses and other retroviruses, herpes viruses, filoviruses, circoviruses, paramyxoviruses, cytomegaloviruses, hepatitis viruses (including hepatitis A, B, C, and D variants thereof, among others), pox viruses, toga viruses, Ebstein-Barr viruses and parvoviruses; bacteria, such as *Escherichia*, *Bacillus*, *Campylobacter*, *Clostridium*, *Streptococcus* and *Staphylococcus*; nanobacteria; single- and multi-cell parasites, such

20

as *Trypanosoma* and malarial parasites, including *Plasmodium* species; fungi; yeasts; mycoplasmas and ureaplasmas; chlamydia; rickettsias, such as *Coxiella burnetii*; and multi-cell pests and the like.

- Additional non-limiting examples of pathogens found in biological materials include
- 5 the following bacteria: *Escherichia*, *Bacillus*, *Campylobacter*, *Helicobacter*, *Lysteria*, *Clostridium*, *Streptococcus*, *Enterococcus*, *Staphylococcus*, *Brucella*, *Haemophilus*, *Salmonella*, *Yersinia*, *Pseudomonas*, *Serratia*, *Enterobacter*, *Klebsiella*, *Proteus*, *Citrobacter*, *Corynebacterium*, *Propionibacterium* and *Coxiella*, such as *Staphylococci* (including, for example, *S. aureus*, *S. epidermidis*, *S. saprophyticus*, among others), *Chlamydia* (including,
- 10 for example, *C. pneumoniae*, among others), *Streptococci* (including, for example, the viridians group of *Streptococci*: *S. sanguis*, *S. oralis* (mitis), *S. salivarius*, *S. mutans*, and others; and other species of *Streptococci*, such as *S. bovis* and *S. pyogenes*), *Enterococci* (for example, *E. faecalis* and *E. faecium*, among others), various fungi, and the AHACEK group of gram-negative bacilli (*Haemophilus parainfluenzae*, *Haemophilus aphrophilus*,
- 15 *Actinobacillus actinomycetemcomitans*, *Cardiobacterium hominis*, *Eikenella corrodens*, and *Kingella kingae*), *Neisseria gonorrhoeae*, *Clostridia* sp., *Listeria monocytogenes*, *Salmonella* sp., *Bacteroides fragilis*, *Escherichia coli*, *Proteus* sp, and *Klebsiella-Enterobacter-Serratia* sp., among others.

- Still other non-limiting examples of pathogens found in biological materials include
- 20 the following viruses: Adeno-associated Virus (AAV), California Encephalitis Virus, Coronavirus, Coxsackievirus-A, Coxsackievirus-B, Eastern Equine Encephalitis Virus (EEEV), Echovirus, Hantavirus, Hepatitis A Virus (HAV), Hepatitis C Virus (HCV),

Hepatitis Delta Virus (HDV), Hepatitis E Virus (HEV), Hepatitis G Virus (HGV), Human Immunodeficiency Virus (HIV), Human T-lymphotrophic Virus (HTLV), Influenza Virus (Flu Virus), Measles Virus (Rubeola), Mumps Virus, Norwalk Virus, Parainfluenza Virus, Polio virus, Rabies Virus, Respiratory Syncytial Virus, Rhinovirus, Rubella Virus, Saint Louis
5 Encephalitis Virus, Western Equine Encephalitis Virus (WEEV), Yellow Fever Virus, Adenovirus, Cytomegalovirus (CMV), Epstein-Barr Virus (EBV), Hepatitis B Virus (HBV), Herpes Simplex Virus 1 (HHV1), Herpes Simplex Virus 2 (HHV2), Molluscum contagiosum, Papilloma Virus (HPV), Smallpox Virus (Variola), Vaccinia Virus, Venezuelan Equine Encephalitis Virus (VEEV), Ebola Virus, West Nile Virus, Human Parvovirus B19
10 and Rotavirus.

As used herein, the term "potentially active biological pathogen" is intended to mean a biological pathogen that is capable of causing a deleterious effect, either alone or in combination with another factor, such as a second biological contaminant or pathogen or a native protein (wild-type or mutant) or antibody, in the biological material and/or a recipient
15 thereof.

As used herein, the term "wild-type" in reference to a nucleic acid sequence an amino acid sequence is intended to refer to the corresponding sequence found in naturally occurring organisms, such as biological pathogens, including such variants and mutants as are known to those skilled in the art.

20 As used herein, the term "sterilize" is intended to mean a reduction in the level of at least one potentially active biological pathogen found in the biological material being treated.

As used herein, the term "radiation" is intended to mean radiation of sufficient energy to sterilize at least some component of the irradiated biological material. Types of radiation include, but are not limited to, the following: (i) corpuscular (streams of subatomic particles such as neutrons, electrons, and/or protons); (ii) electromagnetic (originating in a varying electromagnetic field, such as radio waves, visible (both mono and polychromatic) and invisible light, infrared, ultraviolet radiation, x-radiation, and gamma rays and mixtures thereof); and (iii) sound and pressure waves. Such radiation is often described as either ionizing (capable of producing ions in irradiated materials) radiation, such as gamma rays, and non-ionizing radiation, such as visible light. The sources of such radiation may vary and, in general, the selection of a specific source of radiation is not critical provided that sufficient radiation is given in an appropriate time and at an appropriate rate to effect sterilization. In practice, gamma radiation is usually produced by isotopes of Cobalt or Cesium, while UV and X-rays are produced by machines that emit UV and X-radiation, respectively, and electrons are often used to sterilize materials in a method known as "E-beam" irradiation that involves their production via a machine. Visible light, both mono- and polychromatic, is produced by machines and may, in practice, be combined with invisible light, such as infrared and UV, that is produced by the same machine or a different machine.

B. Particularly Preferred Embodiments

A first preferred embodiment of the present invention is directed to a method for determining the level of potentially active biological pathogens in a biological material, which

comprises:

(i) adding to a biological material an effective amount of at least two nucleic acid primer pairs,

wherein a first nucleic acid primer pair hybridizes under stringent conditions to a first target nucleic acid sequence found in the biological pathogen and a second nucleic acid primer pair hybridizes under stringent conditions to a second target nucleic acid sequence found in the biological pathogen, and further wherein first and second target nucleic acid sequences are not identical and the second target nucleic acid sequence contains more nucleic acid residues than the first;

(ii) amplifying the target nucleic acid sequences by polymerase chain reaction, which comprises adding at least one polymerase to the biological material containing the primer pairs to form an amplification mixture and thermally cycling this amplification mixture between at least one denaturation temperature and at least one elongation temperature for a period of time sufficient to amplify the target nucleic acid sequences; and

(iii) detecting and quantifying the target nucleic acid sequences, wherein the quantity of the first target nucleic acid sequence is proportional to the number of biological pathogens in the biological material and the quantity of the second target nucleic acid sequence is proportional to the number of potentially active biological pathogens in the biological material.

The first and second target nucleic acid sequences employed in the methods of the present invention are preferably selected to be specific for a particular biological pathogen of

interest. That is, it is preferred that at least one, and more preferably both, of the first and second nucleic acid sequences is found only in the biological pathogen of interest and not in any other component of the biological material. According to these embodiments of the present invention, such a selection (or selections) for the target nucleic acid sequence(s) allows for the selective determination of the levels of biological pathogen, including the total number of biological pathogens present (potentially active and inactive) as well as the number of potentially active pathogens and the number of inactive pathogens.

One skilled in the art may determine suitable target nucleic acid sequences empirically, based on factors such as the particular biological pathogen(s) of interest, the biological material being tested and the PCR conditions selected.

Preferably, the first target nucleic acid sequence contains between about 50 and about 500 nucleic acid residues. More preferably, the first target nucleic acid sequence contains between about 50 and about 250 nucleic acid residues, and most preferably between about 50 and about 150 nucleic acid residues.

The second target nucleic acid sequence preferably contains between about 500 and about 50,000 nucleic acid residues. More preferably, the second target nucleic acid sequence contains between about 1000 and about 10,000 nucleic acid residues, even more preferably between about 2000 and about 5000 nucleic acid residues and most preferably between about 2500 and about 5000 nucleic acid residues.

The first and second target nucleic acid sequences may be completely different or they may overlap by some or all of the shorter of the two. According to certain preferred

embodiments of the present invention, the first target nucleic acid sequence and the second nucleic acid sequence contain at least 16 contiguous nucleic acid residues in common.

As noted, the first and second target nucleic acid sequences are preferably selected to be specific for a biological pathogen of interest. According to such embodiments of the present invention, the biological pathogen is preferably selected from the group consisting of bacteria, viruses, mycoplasmas, fungi and single cell parasites.

According to these embodiments of the present invention, at least one of the first and second target nucleic acid sequences, and more preferably both the first and second target nucleic acid sequence, are at least 30% homologous to a wild-type nucleic acid sequence found in the biological pathogen of interest. More preferably, the first and/or second target nucleic acid sequence is at least 50% homologous to a wild-type nucleic acid sequence found in the biological pathogen of interest, and even more preferably at least 70% homologous. Most preferably, the first and/or second target nucleic acid sequence is at least 90% homologous to a wild-type nucleic acid sequence found in the biological pathogen of interest. According to certain preferred embodiments, the first and/or second target nucleic acid sequence is substantially identical to a wild-type nucleic acid sequence found in the biological pathogen of interest.

According to particularly preferred embodiments of the present invention, at least one of the first and second target nucleic acid sequences, and more preferably both, is a nucleic sequence that is highly conserved among different species, different genera or even different families of biological pathogens.

For example, if the biological pathogen of interest is bacteria, then the first and/or second target nucleic acid sequences are preferably sequences that are found in the gene encoding the 16S ribosomal RNA or the gene encoding the 23S ribosomal RNA. According to these preferred embodiments of the present invention, the first target nucleic acid sequence is even more preferably a nucleic acid sequence found in the gene encoding the 16S ribosomal RNA of bacteria. Preferably, such a sequence is conserved among different species and genera of bacteria.

Thus, as shown in Figure 6A, suitable primers and probes were prepared from the gene encoding the 16S ribosomal RNA of bacteria (SEQ ID NO. 6) that were useful for a wide range of bacterial biological pathogens, including *Escherichia coli*, *Bacteroides forsythus*, *Porphyromonas gingivalis*, *Prevotella melaninogenica*, *Cytophaga baltica*, *Campylobacter jejuni*, *Helicobacter pylori*, *Treponema denticola*, *Treponema pallidum*, *Leptotrichix mobilis*, *Tbionmicrospira denitrificans*, *Neisseria meningitidis*, *Actinobacillus actinomycetemcomitans*, *Haemophilus influenzae*, *Salmonella typhi*, *Vibrio cholerae*, *Coxiella burnetii*, *Legionella pneumophila*, *Pseudomonas aeruginosa*, *Caulobacter vibrioides*, *Rhodospirillum rubrum*, *Nitrobacter winogradskyi*, *Wolbachia sp.*, *Mycococcus xanthus*, *Corynebacterium diptheriae*, *Mycobacterium tuberculosis*, *Streptomyces coelicolor*, *Actinomyces odontolyticus*, *Bacillus subtilis*, *Staphylococcus aureus*, *Listeria monocytogenes*, *Enterococcus faecalis*, *Lactobacillus acidophilus*, *Streptococcus mutans*, *Clostridium botulinum*, *Peptostreptococcus micros*, *Veillonella dispar*, *Fusobacterium nucleatum*, *Clamydia trachomatis*, *Mycoplasma pneumoniae*.

According to these particularly preferred embodiments of the present invention, i.e. if the biological pathogen of interest is bacteria, then the second target nucleic acid sequence is preferably a nucleic acid sequence found in both the gene encoding the 16S ribosomal RNA

and the gene encoding the 23S ribosomal RNA. According to these embodiments, the second target nucleic acid sequence is even more preferably a nucleic acid sequence found in the gene encoding the 16S ribosomal RNA and at least a portion of the gene encoding the 23S ribosomal RNA, as well as the non-coding nucleic sequence found therebetween in bacterial genomes.

Similarly, if the biological pathogen of interest is fungi, then the first and/or second target nucleic acid sequences are preferably sequences that are found in the gene encoding the 18S ribosomal RNA or the gene encoding the 25S ribosomal RNA. According to these embodiments of the present invention, the first target nucleic acid sequence is even more preferably a nucleic acid sequence found in the gene encoding the 18S ribosomal RNA of fungi. Preferably, such a sequence is conserved among different species and genera of fungi.

According to these particularly preferred embodiments of the present invention, *i.e.* if the biological pathogen of interest is fungi, then the second target nucleic acid sequence is preferably a nucleic acid sequence found in both the gene encoding the 18S ribosomal RNA and the gene encoding the 25S ribosomal RNA. According to these embodiments, the second target nucleic acid sequence is even more preferably a nucleic acid sequence found in the gene encoding the 18S ribosomal RNA and at least a portion of the gene encoding the 25S ribosomal RNA and the non-coding nucleic sequence found therebetween in fungal genomes, and most preferably a nucleic acid sequence found in the gene encoding the 18S ribosomal RNA, at least a portion of the gene encoding the 25S ribosomal RNA and the gene encoding the 5.8S ribosomal RNA, as well as both non-coding nucleic sequences found therebetween in fungal genomes.

The first and second pairs of nucleic acid primers are each selected based on their ability to generate the desired target nucleic acid sequences under the appropriate PCR conditions. Accordingly, each primer must be specific for the desired target nucleic acid sequence. Similarly, each primer must be selected so that they are not self-complementary or
5 complementary to another primer (or probe, if present).

According to certain preferred embodiments of the present invention, at least one member of each pair of nucleic acid primers is substantially identical, *i.e.* one of the first pair of nucleic acid primers and one of the second pair of nucleic acid primers are substantially identical.

10 According to other preferred embodiments of the present invention, the two pairs of nucleic acid primers are completely different, *i.e.*, neither of the first pair of nucleic acid primers is substantially identical to either of the second pair of nucleic acid primers.

According to still other preferred embodiments of the present invention, the two pairs of nucleic acid primers are substantially identical, *i.e.* one of the first pair of nucleic acid
15 primers is substantially identical to one of the second pair of nucleic acid primers and the other one of the first pair is identical to the other one of the second pair. According to such embodiments, two distinct target sequences may still be obtained, for example, in the case where one or both members of each primer pair hybridize to more than one sequence, for example, as in the case where the first and second target sequences are part of a circular
20 nucleic acid sequence, such as a plasmid, where the hybridization location of the primers on the circular nucleic acid sequence is such that transcription in different directions leads to two different amplicons. Similarly, in cases where the first and target sequences are highly

homologous, particularly at their respective 5' and 3' ends, then the primers will hybridize to both, such that transcription leads to two different amplicons.

The polymerize chain reaction employed in the inventive methods is performed according to the methods and techniques known to those skilled in the art, *i.e.*, a nucleic acid primer pair is added to the biological material containing the sequence of interest to form an amplification mixture that is then thermally cycled for a sufficient period of time to amplify the desired sequence. The thermal cycling generally comprises cycling the amplification mixture between at least one denaturation temperature and at least one elongation temperature. Preferably, the thermal cycling comprises cycling the amplification mixture between at least one denaturation temperature, at least one annealing temperature and at least one elongation temperature.

Specific temperatures for use in denaturation, elongation and/or annealing may be determined empirically by one skilled in the art based, for example, on the specific target sequence being amplified and the particular probes employed. Likewise, the specific time(s) that the amplification mixture is maintained at the various denaturation, elongation and/or annealing temperature(s) may be determined empirically by one skilled in the art based on similar considerations.

According to particularly preferred embodiments of the present invention, the elongation temperature selected for use in the PCR of the inventive methods is not more than about 70°C. More preferably, the elongation temperature selected is between about 60°C and about 69°C, and even more preferably between about 65°C and about 69°C. Most

preferably, the elongation temperature employed in the PCR of the inventive methods is about 68°C.

According to additional preferred embodiments of the present invention, the denaturation temperature selected for use in the PCR of the inventive methods is not more than about 95°C. More preferably, the denaturation temperature selected is between about 90°C and about 95°C, and even more preferably between about 92°C and about 95°C. Most preferably, the denaturation temperature employed in the PCR of the inventive methods is about 94°C.

According to other preferred embodiments of the present invention, when the thermal cycling includes an annealing temperature, the annealing temperature selected is about 5-10°C below the melting temperature of the primers being employed. Preferably, the annealing temperature selected is not more than about 65°C. More preferably, the annealing temperature selected is between about 57°C and about 63°C, and even more preferably between about 58°C and about 62°C. Most preferably, the annealing temperature employed in the PCR of the inventive methods is about 60°C.

According to additional preferred embodiments of the present invention, during each thermal cycle, the amplification mixture is maintained at the elongation temperature for a period of not less than about 1 minute. More preferably, during each thermal cycle, the amplification mixture is maintained at the elongation temperature for a period of not less than about 2 minutes, and even more preferably for a period of not less than about 3

minutes.

According to particularly preferred embodiments of the present invention, the amplification mixture is maintained at the elongation temperature for a period of not less than about 2 minutes during the first cycle of the thermal cycling, and then the period during
5 which said amplification mixture is maintained at the elongation temperature is increased by a period of about 5 seconds for each successive thermal cycle. Thus, for example, according to such embodiments of the present invention, if the amplification mixture was maintained at the elongation temperature for a period of 2 minutes during the first cycle of the thermal cycling, it would be maintained at the elongation temperature for a period of 2 minutes, 5
10 seconds for the second cycle, 2 minutes, 10 seconds for the third cycle, 2 minutes, 15 seconds for the fourth cycle, and so on until the thermal cycling is completed.

According to additional preferred embodiments of the present invention, during each thermal cycle, the amplification mixture is maintained at the denaturation temperature for a period of not more than about 1 minute. More preferably, during each thermal cycle, the
15 amplification mixture is maintained at the denaturation temperature for a period of not more than about 45 seconds, and even more preferably for a period of not more than about 30 seconds, and still even more preferably for a period of not more than about 20 seconds. Most preferably, during each thermal cycle, the amplification mixture is maintained at the denaturation temperature for a period of not more than about 15 seconds, such as a period
20 of about 10 seconds.

According to still other preferred embodiments of the present invention, when the thermal cycling includes an annealing temperature, the amplification mixture is maintained at

the annealing temperature for a period of not less than about 30 seconds. More preferably, according to such embodiments, during each thermal cycle, the amplification mixture is maintained at the annealing temperature for a period between 30 seconds and 2 minutes, and even more preferably for a period of not less than about 45 seconds. Most preferably, during each thermal cycle, the amplification mixture is maintained at the annealing temperature for a period of about 1 minute.

The number of thermal cycles employed in the PCR of the inventive methods may be determined empirically by one skilled in the art depending, for example, on the suspected concentration of the target sequence of interest in the biological material being tested.

According to preferred embodiments of the present invention, the amplification mixture is subjected to at least about 30 cycles of thermal cycling, and even more preferably at least about 40 cycles. Most preferably, the amplification mixture is subjected to at least about 50 cycles of thermal cycling.

The polymerase employed in the PCR of the inventive methods may be any of the suitable polymerases known to those skilled in the art. Preferably, the polymerase employed is a thermostable polymerase, *i.e.* a polymerase that is not adversely affected by the higher temperatures involved in thermal cycling. More preferably, the polymerase may be a *Taq* polymerase, or a suitable derivative thereof and/or a proof-reading polymerase.

According to particularly preferred embodiments of the present invention, at least two polymerases are employed in the PCR of the inventive methods. Preferably, at least one of the polymerases is a *Taq* polymerase or a suitable derivative thereof, such as TaqMan DNA polymerase (available from Applied BioSystems), and the other polymerase is a proof-

reading polymerase, such as ProofStart DNA polymerase (available from Qiagen).

According to certain preferred embodiments of the present invention, the amplification mixture further contains at least one thermostable inorganic pyrophosphatase. Suitable amounts of thermostable inorganic pyrophosphatase may be determined empirically
5 by one skilled in art. Generally, when present, the ratio of thermostable inorganic pyrophosphatase to *Taq* polymerase is at least about 1:20, more preferably at least about 1:10 and even more preferably at least about 1:5.

The remaining parameters employed in the PCR of the inventive methods, such as the primer concentration (generally about 100-500 nM and preferably about 200 nM),
10 magnesium concentration (generally 1.5-6 mM and preferably about 1.5 mM of magnesium sulfate and/or magnesium chloride), deoxyribonucleotide triphosphates (dNTP) concentration (generally about 0.2-0.4 mM each and preferably about 0.2 mM each), probe concentration (if present, generally about 50-800 nM, and preferably about 100 nM), may each be determined empirically by one skilled in the art using any of the known methods and
15 techniques.

According to certain particularly preferred embodiments of the present invention, the deoxyribonucleotide triphosphates (dNTP) that are employed in the PCR of the inventive methods are selected from the group consisting of C, T, G and A. Preferably, substantially no dUTP is present in the amplification mixture of the inventive methods. According to still
20 further preferred embodiments, substantially no uracil N-glycosylase is present in the amplification mixture of the inventive methods.

According to certain particularly preferred embodiments of the present invention, the amplification mixture further comprises at least one buffer solution. Suitable buffer solutions are known and available to those skilled in the art. Particularly preferred buffer solutions include pH modifying buffers, such as buffers containing Tris-HCl, and buffers
5 which maintain salt concentration, particular magnesium concentration, such as buffers containing KCl and/or $(\text{NH}_4)_2\text{SO}_4$.

After amplification using PCR, the first and second target nucleic acid sequences are detected and quantified. This detecting and quantifying may be conducted using any of the methods and techniques known to those skilled in the art. For example, detecting and
10 quantifying of the first and second nucleic acid sequences may be conducted by adding a suitable detecting agent, such as an intercalating dye, directly to the amplification mixture or by adding a suitable nucleic acid probe to the mixture, preferably either a suitable nucleic acid probe in combination with a detecting agent or a suitable nucleic acid probe having a detectable label covalently or ionically attached thereto or complexed therewith.

15 Preferably, the first and second target nucleic acid sequences are detected by adding at least one nucleic acid probe to the biological material being tested. If the first and second target nucleic acid sequences were amplified in a single reaction vessel, then it is preferable to use at least two nucleic acid probes, one of which is specific for the first target nucleic acid sequence and the other of which is specific for the second target nucleic acid sequence.
20 Conversely, if the first and second target nucleic acid sequences were amplified in separate reaction vessels, then the same nucleic acid probe may be used for detecting both the first target nucleic acid sequence and the second target nucleic acid sequence.

Any nucleic acid probe employed in the inventive methods should contain sufficient nucleic acid residues to hybridizes selectively under stringent conditions to a specific desired nucleic acid sequence, *i.e.* suitable probes will generally contain at least 16 nucleic acid residues, and preferably hybridizes selectively under stringent conditions to a specific nucleic acid sequence of the first and/or second target nucleic acid sequence that is not the same as the nucleic acid sequence of any of the primers. Suitable nucleic acid probes include, but are not limited to, 5' nuclease probes, hairpin probes, adjacent probes, sunrise probes and scorpion probes.

According to certain preferred embodiments of the present invention, the nucleic acid probe employed in the inventive methods has an endogenous passive dye, such as Tamra or the like. In other preferred embodiments, such an endogenous passive dye may be replaced by a passive dye that is not covalently bound to the probe, such as Rox or the like.

According to certain particularly preferred embodiments of the present invention, prior to step (i), the biological material being tested has been subjected to a process that alters at least one wild-type nucleic acid sequence in the biological pathogen of interest. Such processes may cause the wild-type nucleic acid sequence to break, cross-link and/or complex. An illustrative, but non-limiting, example of such a process is irradiation of the biological material with ionizing radiation, such as UV or gamma radiation.

Although not limited in application, the inventive methods are particularly useful in determining the effectiveness of processes that alter nucleic acid sequences, such as the inactivation of biological pathogens by gamma irradiation. More specifically, conventional PCR testing methods only determine whether a particular biological pathogen is present in a

biological material, not whether that biological pathogen is active or inactive. The methods of the present invention, however, may be used to determine not only whether a particular biological pathogen is present in a biological material as shown by amplification of the first target sequence, but also whether that biological pathogen is inactive by virtue of an altered wild-type nucleic acid sequence as shown by a relative delay in the amplification of the second target sequence (the greater the delay in amplification, the greater the reduction in the level of potentially active biological pathogens). Thus, the inventive methods are useful for evaluating the effectiveness of sterilization processes because they determine both the original level and the residual level of potentially active biological pathogens.

EXAMPLES

The following examples are illustrative, but not limiting, of the present invention. Other suitable modifications and adaptations are of the variety normally encountered by those skilled in the art and are fully within the spirit and scope of the present invention.

Example 1

Purpose: To demonstrate linear amplification of B19 DNA.

Materials:

1. B19 virus, titer 7.6×10^{11} iu/ml from Bayer;
2. SNAP whole blood DNA isolation kit;
3. Forward Primer: Prism 5 (Figure 1) (SEQ ID NO. 18);
4. Reverse Primer: Prism 6 (Figure 1) (SEQ ID NO. 20);
5. Probe 3 (Figure 1) (SEQ ID NO. 19) labeled with FAM at 5'

end and TAMRA at 3' end;

6. TaqMan Universal Master Mix, (ABI; cat. no. 4304437);

7. DNASE, RNASE free water;

8. ABI 96 well plate and adhesive cores;

5

9. ANI 7000.

Procedure:

1. Followed SNAP protocol for extraction of 100 l B19

sample, eluted in 100 l TE;

2. Diluted primers to 18 M with TE;

3. Diluted probe to 5 M with TE;

10

4. Prepared the following master mix:

TaqMan Master Mix: 25 l;

Prism 5 (SEQ ID NO. 18): 2.5 l;

Prism 6 (SEQ ID NO. 20): 2.5 l;

Taqman Probe 2.5 l;

15

Water: 12.54 l;

5. Added 45 l of master mix per well;

6. Serially diluted B19 DNA, adding water to the NTC well;

7. Sealed and centrifuged the plate at 2300 rpm for about 30

seconds;

20

8. Ran PCR program for 50 cycles.

Results: A standard dilution curve was observed for B19 infected plasma, validating primer pair Prism 5 (SEQ ID NO. 18) and Prism 6 (SEQ ID NO. 20) with Probe 3 (SEQ

ID NO. 19).

Example 2

Purpose: To examine irradiated and unirradiated samples containing PPV using a 549
5 bp amplicon.

Materials: 1. PPV (irradiated at 0 kGy, 50 kGy, 65 kGy, 75 kGy or 85
kGy);

2. SNAP Protein Degradar;

3. Cell Lysis Buffer;

10 4. Tris-HCl;

5. Primers: Prism 11 and Prism 12 (Figure 3) (SEQ ID NOS.:

40 and 42, respectively); and

6. Probe 6 (Figure 3) (SEQ ID NO. 41).

Procedure: 1. To 100 µl viral sample, added 50 µl tris-HCl buffer, 60 µl

15 protein degrader, and 200 µl cell lysis buffer;

2. Mixed and incubated for 25 minutes (5 minutes at 70°C);

3. Diluted samples to 1/50, 1/500, 1/5000, 1/25000, 1/50000,

1/250000 and 1/500000;

4. Ran PCR for 55 cycles.

20 Results: Results showed that unirradiated material had regular dilution series curves,
irradiated material (50 kGy) behaved differently, dilute material did not amplify showing a

reduction in the number of copies of the target sequence.

Example 3

Purpose: To determine effects of gamma irradiation (0 kGy sample, 50 kGy sample, mixture of 0+50kGy sample and 75 kGy sample) on samples containing PPV analyzed by PCR.

Materials:

1. PPV (irradiated at 0 kGy, 50 kGy or 75 kGy);
2. Primers: Prism 11 & Prism 12, Probe 6 (Figure 3) (SEQ ID NOS.: 40, 42, and 41, respectively);
3. Primers: Prism 1 & Prism 2, Probe 1 (Figure 3) (SEQ ID NOS.: 43, 45, and 44, respectively)

Procedure:

1. Diluted samples containing PPV to 1/100, 1/1000, 1-2000, 1/10000, 1/20000, 1/40000 and 1/400000 (0 kGy, 50 kGy, 0+50 kGy and 75 kGy);
2. Ran PCR program for 55 cycles.

Results: Irradiation to 50 kGy of PPV material reduced amplification of 549 bp amplicon.

Example 4

Purpose: To examine the relative effectiveness of Qiagen and Taqman reagents on samples containing PPV.

Materials:

1. PPV DNA (phenol extracted);
2. Taq PCR Core Kit;
3. ProofStart DNA polymerase;
4. Taqman Universal PCR Master Mix;
5. Prism 1, 2, 11 and 17 (Figure 3) (SEQ ID NOS.: 43, 45, 40,
and 47, respectively);
6. Probes 1 and 6 (Figure 3) (SEQ ID NOS.: 44 and 41,
respectively);
7. Agarose;
8. TAE;
9. EtBr.

Procedure:

1. Prepared the following four master mixes:
 - a. Qiagen:

	1	2
10x buffer:	30 μ l	25 μ l
dNTP's:	9 μ l	7.5 μ l
pA:	8.34 μ l	6.95 μ l
pB:	8.34 μ l	6.95 μ l
taq:	6 μ l	5 μ l
H ₂ O:	187.32 μ l	156.1 μ l
probe:	15 μ l	12.5 μ l
 - b. Taqman:

	3	4
--	---	---

	Master Mix:	150 μ l	125 μ l
	pA:	15 μ l	12.5 μ l
	pB:	15 μ l	12.5 μ l
	probe:	15 μ l	12.5 μ l
5	H ₂ O:	69 μ l	57.5 μ l

2. Pipetted 44 μ l of master mix 1 into row D, wells 1 and 2;
row E, wells 1 and 2; and row H, well 1, of a well plate;
3. Pipetted 44 μ l of master mix 2 into row D, wells 3 and 4;
and row E, wells 3 and 4, of a well plate;
- 10 4. Pipetted 44 μ l of master mix 3, into row F, wells 1 and 2;
row G, wells 1 and 2; and row H, well 3, of a well plate;
5. Pipetted 44 μ l of master mix 4 into row F, wells 3 and 4; and
row G, wells 3 and 4, of a well plate;
6. Added 1 μ l of ProofStart taq to row D, wells 1-4 and row F,
15 wells 1-4 and added 1 μ l water to remaining wells;
7. Added 5 μ l water to row H, wells 1 and 3 and added 5 μ l
PPV DNA to remaining wells;
8. Ran PCR for 40 cycles.

Results: QiaGen Master with ProofStart taq produced functional large amplicons in
20 realtime PCR with PPV DNA more efficiently than the TaqMan master mix.

Example 5

Purpose: To examine the effects of proofstart in amplifying large amplicons and to examine the effects of 50 kGy irradiation on PPV.

Materials:

1. PPV DNA (irradiated to 0 kGy and 50 kGy);
2. Taq PCR Core Kit;
3. Proofstart DNA polymerase;
4. Prism 11, 16 and 17 (Figure 3) (SEQ ID NOS.: 40, 46, and 47, respectively);
5. Agarose;
6. Ethidium Bromide;
7. TAE buffer.

Procedure:

1. Set up PCR master mix as follows:

10x buffer:	50 l
dNTP's:	15 l
pA:	13.9 l (primer 11 (SEQ ID NO. 40))
taq:	10 l
water:	347.2 l
2. Placed aliquots into PCR tubes;
3. Added either primer 16 or 17 (SEQ ID NOS.: 46 or 47, respectively) to PCR tubes;
4. Added PPV DNA (diluted to 1:100) to each PCR tube;

5. Added 10 μ l proofstart to half of the samples (2 at 0 kGy and 2 at 50 kGy);

6. Performed PCR (about 55 cycles)

7. Poured a 1% gel and ran at 100 V for 20 minutes.

- 5 Results: Addition of a proofreading polymerase resulted in improved amplification of longer amplicons. Delay in amplification of target sequence in irradiated samples is proportional to damage done to viral genetic material.

Example 6

- 10 Purpose: To examine the effect of TSP concentration on amplification of large target amplicons in gamma irradiated and unirradiated PPV.

Materials:

1. TSP (cat. no. M02965);
2. Qiagen Core kit;
3. ProofStart DNA polymerase;
- 15 4. PPV (irradiated to 0 kGy or 50 kGy).

Procedure:

1. Prepared a master mix (standard PCR set-up) for each (TSP: Taq 1:20, 1:10, 1:5);
2. Added 43.61 μ l of each master mix (TSP titration) to PCR tubes;
- 20 3. Added 1.39 μ l of primers 16, 17 or 19 (Figure 3) (SEQ ID NOS.: 46, 47, or 49, respectively) to appropriate PCT tubes;

4. Added 5 l water to the negative control, which contained primer pair 11, 16 (Figure 3) (SEQ ID NOS.: 40 and 46, respectively).

5. Diluted PPV 1:100;

6. Added PPV to PCR tubes;

5 7. Performed PCR;

8. Poured a 1% gel and ran at 100 V for 20 minutes.

Results: Under these conditions, addition of TSP resulted in increased amplification of target amplicons in both irradiated and unirradiated samples, but irradiation of PPV resulted in decreased amplification of target amplicon.

10

Example 7

Purpose: To examine the effects of gamma irradiation on amplification of PPV target amplicons of various sizes.

Materials:

15

1. PPV DNA (irradiated to 0 kGy or 50 kGy);

2. Taq PCR Core Kit;

3. ProofStart DNA Polymerase;

4. Prism 11, 16, 17, 18 and 19 (Figure 3) (SEQ ID NOS.: 40, 46, 47, 48, and 49, respectively);

5. Agarose;

6. TAE;

7. Ethidium Bromide.

Procedure:

1. Prepared PCR Master Mix as follows:

	10x Buffer	5 l
5	dNTPs	1.5 l
	pA	1.39 l
	pB	1.39 l
	taq	1 l
	water	33.72 l
10	PPV	5 l

2. Aliquoted samples into PCR tubes;

3. Ran PCR;

4. Poured a 1% agarose gel and ran at 120 V for about 1.5 hours.

15 Results: Irradiation to 50 kGy resulted in decreased amplification of larger target amplicons.

Example 8

Purpose: To examine PCR sensitivity and determine log reduction of PPV in samples

irradiated to 50 kGy and having a starting concentration of 2.5×10^7 gEq.

Materials:

1. Standard PCR reagents (Qiagen Core Kit, TSP, Proofstart, etc.);
2. Primers 11 and 17 (Figure 3) (SEQ ID NOS.: 40 and 47, respectively);
3. PPV extract.

Procedure:

1. Prepared master mix with primers 11 and 17 (SEQ ID NOS.: 40 and 47, respectively);
2. Performed a 10 fold dilution series from 107 to 100 of PPV extract;
3. Pipetted 45 l of master mix into PCR tubes;
4. Pipetted 5 l of each PPV dilution into appropriate PCR tubes;
5. Added 5 l water to control;
6. Ran PCR;
7. Ran samples in 1% agarose at 100V for about 47 minutes.

Results:

Irradiation of sample to 50 kGy resulted in decreased amplification of target amplicon across all concentration ranges.

Example 9

Purpose:

To examine PCR sensitivity and determine log reduction of PPV in samples

irradiated to 50 kGy and having a starting concentration of 2.5×10^7 gEq.

Materials:

1. TSP;
2. Standard PCR kit (Qiagen with ProofStart Polymerase);
3. Primers 11 and 19 (Figure 3) (SEQ ID NOS.: 40 and 49,
5 respectively);
4. PPV Extract (Irradiated to 0 kGy and 50 kGy).

Procedure:

1. Prepared master mix with primers 11 and 19 (SEQ ID
NOS.: 40 and 49, respectively);
2. Performed a 10 fold dilution series from 10^7 to 10^9 of PPV
10 extract;
3. Pipetted 45 μ l of master mix into PCR tubes;
4. Pipetted 5 μ l of each PPV dilution into appropriate PCR
tubes;
5. Added 5 μ l water to control;
- 15 6. Ran PCR as follows: 95°C for 2 minutes (1 cycles)
94°C for 10 seconds (40 cycles)
60°C for 1 minute (40 cycles)
68°C for 2 minutes (40 cycles);
7. Cooled to 4°C;
- 20 8. Ran samples on 1% agarose gel in 1x TAE and 5 μ l/100 ml
ethidium bromide at 100 V for 52 minutes (5 μ l on gel).

Results: Irradiation to 50 kGy resulted in decreased amplification of target amplicon across all concentration ranges. For unirradiated samples, relative band strength of observed target amplicon decreased with decreasing concentration.

5 Example 10

Purpose: Primer validation for B19 using probe 7 (SEQ ID NO. 12) and various primers.

Materials:

1. B19 IGIV Paste (irradiated to 0 kGy or 50 kGy);
2. EXB;
- 10 3. Proteinase;
4. yeast tRNA
5. phenol chloroform isoamyl alcohol;
6. 3M NaAc;
7. isopropanol;
- 15 8. 70% EtOH;
9. TE buffer;
10. Prisms 5, 6, 20, 21, 22, 23, 24, 25, 26 (Figure 1) (SEQ ID NOS.: 18, 20, 11, 13, 14, 15, 16, 17, and 21, respectively);
11. Qiagen reagents;
- 20 12. Ampligold Taq;
13. ProofStart Polymerase;

14. Agarose;
15. TAE;
16. Ethidium Bromide.

Procedure:

1. Prepared a Master Mix as follows:

5	Buffer	5 μ l
	DNTP	1.5 μ l
	Taq	1 μ l
	DNA	5 μ l
	water	34.72 μ l

- 10 2. Pipetted Master Mix into PCR tubes;
3. Added the following primer pairs to appropriate PCR tubes:
 20&21 (SEQ ID NOS.: 11 and 13, respectively); 20&22 (SEQ ID NOS.: 11 and 14,
 respectively); 20&23 (SEQ ID NOS.: 11 and 15, respectively); 20&24 (SEQ ID NOS.: 11
 and 16, respectively); 20&25 (SEQ ID NOS.: 11 and 17, respectively); 20&6 (SEQ ID NOS.:
 15 11 and 20, respectively); 20&26 (SEQ ID NOS.: 11 and 21, respectively); 5&6 (SEQ ID
 NOS.: 18 and 20, respectively);
4. Ran PCR;
5. ran 1% gel for about 1 hour.

Results: All tested primers yielded desired target amplicons.

Example 11

Purpose: Use of PCR multiplexing with target amplicons of about 112 bp and about 2.4 kbp for B19 virus in samples irradiated to 0 kGy or 50 kGy.

- 5 **Materials:**
1. TSP thermostable inorganic pyrophosphatase
 2. Standard PCR reagents;
 3. B19 viral extract (irradiated to 0 kGy and 50 kGy);
 4. Primers 5, 6, 20 and 25 (Figure 1) SEQ ID NOS.: 18, 20, 11,
and 17, respectively);
 - 10 5. Taq;
 6. ProofStart Polymerase.

- Procedure:**
1. Prepared standard PCR set-up with 3x master mixes, for each
primer set (primer sets: 5&6 (SEQ ID NOS.: 18 and 20, respectively); 20&25 (SEQ ID
NOS.: 11 and 17, respectively); 5&6 (SEQ ID NOS.: 18 and 20, respectively); and 20&25
15 (SEQ ID NOS.: 11 and 17, respectively));
 2. Prepared appropriate PCR tubes containing the following
primer pairs: (5, 6) 0 kGy; (5, 6) 50 kGy; (20, 25) 0 kGy; (20, 25) 50 kGy; (5, 6) & (20, 25), 0
kGy; and (5, 6) and (20, 25), 50 kGy;
 3. Added 5 µl B19 to PCR tubes containing 45 µl of
20 appropriate master mix;
 4. Added 5 µl water to control;

5. Ran PCR.

6. Ran samples on 1% agarose gel at 100 V for about 17

minutes.

Results: PCR multiplexing is effective for mixtures containing large target amplicons

5 and small target amplicons. Irradiation to 50 kGy resulted in decreased amplification of the large target amplicon relative to the small target amplicon.

Example 12

Purpose: Irradiated and unirradiated samples containing B19 viral material were

10 examined using real time PCR.

Materials:

1. B19 viral material (irradiated to 0 kGy and 50 kGy);

2. Prism pairs (20, 21) (SEQ ID NOS.: 11 and 13, respectively)

and (20, 26) (SEQ ID NOS.: 11 and 21, respectively) (Figure 1)

3. Qiagen PCR reagents;

15 4. Qiagen ProofStart;

5. Agarose;

6. TAE (1x);

7. sample loading buffer (SLB).

Procedure:

20 to 10¹ dilution series;

2. Ran PCR (40 cycles);

3. Ran gel on 1% agarose (8 μ l PCR product, 1 μ l SLB) at 100

V for about 20 minutes.

Results: Unirradiated and irradiated samples amplified in a regular pattern for a dilution series with a small amplicon. As amplicon size increased, unirradiated material

5 maintained a regular dilution pattern while irradiated material did not.

Example 13

Purpose: To investigate the effect of gamma irradiation on samples containing HBV clone and irradiated to 50 kGy.

10 Materials:

1. HBV (irradiated to 0 kGy and 50 kGy);
2. Taq PCR Core Kit;
3. ProofStart DNA polymerase;
4. Primers 34, 9, 10, 15, 29, 30, 31, 36 and 37 (SEQ ID NOS.:
31, 22, 24, 25, 27, 32, 34, 28, and 29, respectively);
5. Agarose;
6. TAE Buffer;
7. ethidium bromide.

15

Procedure:

1. Prepared PCR master mix as follows:

	10x PCR buffer	5 μ l
20	dNTPs	1.39 μ l
	primers	1.39 μ l

DNA and irradiated to 50 kGy.

Materials:

1. HBV DNA material (irradiated to 0 kGy and 50 kGy);
2. Taq PCR Core Kit (Qiagen, cat. no. 201223);
3. ProofStart Taq Polymerase (Qiagen, cat. no. 20);
- 5 4. Prisms 10, 13, 30, 36 and 37 (Figure 2) (SEQ ID NOS.: 24, 26, 32, 28, and 29, respectively);
5. Agarose;
6. TAE Buffer;
7. Ethidium Bromide.

10 Procedure:

1. Prepared the following master mix:

	10x buffer	60 μ l
	dNTP	18 μ l
	primer 36 (SEQ ID NO. 28)	16.68 μ l
	Taq	12 μ l
15	ProofStart	12 μ l
	water	440.64 μ l;

2. Pipetted 46.61 μ l of master mix into PCR tubes;
3. Added 1.39 μ l of reverse primer (10, 13, 30 or 37) (SEQ ID NOS.: 24, 26, 32, or 29, respectively) and 2 μ l HBV DNA (0 kGy and 50 kGy) to
- 20 appropriate tubes;
4. Ran PCR for 50 cycles;

5. Poured a 1% agarose gel (8 μ l PCR product + 1 μ l sample buffer) at 100 V for about 20 minutes.

Results: Irradiated samples showed no band, indicating degradation of HBV DNA by irradiation to 50 kGy.

5

Example 15

Purpose: HBV amplification of nested primer set (about 80 bp, 400 bp and 697 bp) in samples containing ascorbate, including digestion of 0 kGy and 50 kGy samples with exonuclease I prior to PCR amplification.

- 10 Materials:
1. HBV DNA (irradiated to 0 kGy and 50 kGy, with and without ascorbate);
 2. Primer sets: (9, 10) (SEQ ID NOS.: 22 and 24, respectively); (9, 15) (SEQ ID NOS.: 22 and 25, respectively); and (9, 13) (SEQ ID NOS.: 22 and 26, respectively) (Figure 2);

15

3. Exonuclease I;
4. Standard PCR reagents.

Procedure:

1. Diluted HBV samples to 1/500, 1/2000 and 1/10000;
2. Digested 1 μ l raw HBV extract in 0.25 μ l Exonuclease I, 10 μ l 10x Exonuclease I buffer and 88.75 μ l water at 37°C for 30 minutes, inactivated at 80°C for 20 minutes;
3. Dilutes digested HBV to 1/2000 and 1/10000;

4. Ran 55 cycles PCR.

Results: Irradiated and unirradiated samples coamplified with an 80 bp product. Only unirradiated samples amplified with a 697 bp product.

5 Example 16

Purpose: To investigate the amount of bacterial and fungal DNA present in pulverized tendon samples.

Materials:

1. E. Coli samples (tendon) – 0 or 50 kGy + stabilizer
(6.65×10^{10} CFU/ μ l);
2. C. Albicans samples (tendon) – 0 or 50 kGy + stabilizer
(3.55×10^9 CFU/ μ l);
3. Staph. Aureus samples;
4. Control tendon;
5. Dneasey tissue kit (Qiagen, cat. no. 69504);
6. Taq PCR Core Kit (Qiagen, cat. no. 201223);
7. ProofStart Taq Polymerase (Qiagen, cat. no. 202205);
8. Primers: Ribo 7 and 8, and Ribo 10, 11, 12, 13, 14 (Figures 6A and 6B) (SEQ ID NOS.: 69, 70, 71, 72, and 73, respectively) and Fungi 1, 2, 3, 4, 5, 6, 7, 8 (Figures 7A and 7B) (SEQ ID NOS.: 75, 77, 78, 79, 80, 81, 82 and 83, respectively);
9. Probes: FAM-RIBO;
Fungi Probe

(Figure 7A) (SEQ ID NO.: 76) labeled with FAM at 5' end and TAMRA at 3' end;

10. Microcon YM Centrifugal Filter Unit;

Procedure: 1. Using 0.05 tendon samples for *E. coli* and *C. albicans*, followed the Qiagen extraction profile;

5 2. Prepared the following master mixes:

	Mix 1	Mix 2
10x buffer	150 µl	85 µl
dNTPs	45 µl	25.5 µl
Ribo 7 41.7	41.7 µl	---
10 Fungi 1 (SEQ ID NO. 75)	---	23.65 µl
Taq	30 µl	17 µl
ProofStart	30 µl	17 µl
Water	936.6 µl	530.74 µl
FAM-RIBO	75 µl	---
15 Fungi Probe	---	42.5 µl

3. Filtered master mixes using Microcon filter units for 30 minutes at 100x g;

4. Pipetted 43.6 µl of Mix 1 into: rows A-D, columns 1-6; rows A-C, column 9; and row E, column 12;

20 5. Pipetted 43.6 µl of Mix 2 into: rows E-F, columns 1-7 and row H, column 12;

6. Pipetted 1.39 µl of reverse primer into appropriate well;
7. Pipetted 5 µl DNA into appropriate wells;
8. Ran PCR.

Results: Irradiation with 50 kGy resulted in decreased amplification of large target

- 5 amplicons, indicating degradation of the pathogen genetic material caused by irradiation.

Example 17

Purpose: To show functionality of E. coli primers for RT-PCR using large target amplicons.

- 10 Materials:
1. E. coli prepared from overnight culture;
 2. Dneasy Tissue Kit (Qiagen, cat. no. 96504);
 3. Taq PCR Core Kit (Qiagen, cat. no. 201223)
 4. ProofStart DNA polymerase (Qiagen, cat. no. 202205);
 5. Microcon YM-100 Centrifugal Filter Unit (cat. no. 42413);
 - 15 6. Primers: Ribo 1-9;
 7. Agarose;
 8. TAE Buffer;
 9. Ethidium Bromide.

- Procedure:
1. Pipetted 1 ml of E. coli culture into each of 10 1.5 tubes;
 - 20 2. Centrifuged all 10 tubes for 5 minutes at maximum speed;
 3. Discarded supernatant;

4. Placed 8 tubes in -80°C and used 2 tubes for extraction following the Qiagen protocol;

5. Prepared Master Mix as follows:

	10x Buffer	5 μl
5	dNTPs	1.5 μl
	pA	1.39 μl (Ribo 1 (SEQ ID NO. 62)) or (Ribo 7)
	pB	1.39 μl (Ribo 2, 3, 4, 5, or 6) (SEQ ID NOS.: 64, 65, 66, 67, or 68, respectively) or (Ribo 8 or 9)
10	Taq	1 μl
	ProofStart	1 μl
	Water	33.22 μl
	TSP	0.5 μl

6. Mixed Master Mix by inversion;

15 7. Pipetted Master mix into a Microcon Centrifugal Filter Unit and centrifuged for 30 minutes at 100x g;

8. Pipetted 43.61 μl of Master Mix into PCR tubes;

9. Added appropriate reverse primer and DNA or water to create the following primer pairs: (1, 2) + 5 μl DNA; (1, 2) + 1 μl ; (1, 3) + 5 μl DNA; (1, 3)
20 + 1 μl DNA; (1, 4) + 5 μl DNA; (1, 4) + 1 μl DNA; (1, 5) + 5 μl DNA; (1, 5) + 1 μl DNA;
(1, 6) + 5 μl DNA; (1, 6) + 1 μl DNA; (5, 8) + 5 μl DNA; (7, 8) + 1 μl DNA; (7, 9) + 5 μl

DNA; (7, 9) + 1 μ l DNA; and (1, 2) + 5 (1, 4) + 5 μ l water;

10. Ran PCR;

11. Ran 1 % Agarose gel at 100 V for about 20 min.

Results: All E. coli primers showed amplification of target sequences, regardless of
5 size.

Example 18

Purpose: To investigate the effects of 50 kGy irradiation on samples containing E. coli.

Materials: 1. E. coli spiked tendon (irradiated to 0 kGy and 50 kGy) +
10 6.65x10¹⁰ CFU/ μ l;

2. Taq PCR Core Kit (Qiagen, cat. no. 201223);

3. ProofStart Taq Polymerase (Qiagen, cat. no. 202205);

4. Primers: Ribo 7 and 8, and Ribo 13, 14 and 15 (SEQ ID

NOS.: 72, 73, and 74 respectively);

15 5. Agarose;

6. TAE Buffer;

7. Ethidium Bromide;

8. Microcon Centrifugal Filter Unit.

Procedure: 1. Prepared Master Mix as follows:

20 10x Buffer 60 μ l
dNTP 18 μ l

90, 92, 95, 96; and 97, respectively);

4. MITO Probe 1 (Figure 8) (SEQ ID NO.: 91);

5. Human DNA;

6. Qiagen PCR Reagents;

5 7. Qiagen ProofStart.

Procedure:

1. Prepared the following mixtures:

	Buffer	1.5 μ l
	dNTPs	1.5 μ l
	MITO 1	2.5 μ l (SEQ ID NO. 90)
10	reverse primer	2.5 μ l (MITO 2, 3, 4 or 5) (SEQ

ID NOS.: 92, 95, 96, or 97, respectively)

	MITO Probe	2.5 μ l
	Taq	1 μ l
	PS	1 μ l
15	1/10 ROX	1 μ l
	water	28 μ l
	DNA	5 μ l

2. Ran 40 PCR;

3. Ran 1% agarose gel (8 μ l product + 1 μ l sample loading
20 buffer) at 100 V for about one hour.

Results: Mt-DNA primers were functional, regardless of amplicon size.

Having now fully described this invention, it will be understood to those of ordinary skill in the art that the methods of the present invention can be carried out with a wide and equivalent range of conditions, formulations and other parameters without departing from the scope of the invention or any embodiments thereof. Moreover, the methods of the present invention may also be applied to situations other than the preferred embodiments described above. For example, instead of determining the level of potentially active pathogens, the methods described above may be used to determine the number of cells having an altered genetic sequence, such as tumour cells or genetically modified cells, in a tissue sample.

10 All patents and publications cited herein are hereby fully incorporated by reference in their entirety. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that such publication is prior art or that the present invention is not entitled to antedate such publication by virtue of prior invention.

WHAT IS CLAIMED IS:

1. A method for determining the level of potentially active biological pathogens in a biological material, said method comprising:

- (i) adding to said biological material an effective amount of at least two
5 nucleic acid primer pairs,

wherein a first nucleic acid primer pair hybridizes under stringent conditions to a first target nucleic acid sequence found in said biological pathogen and a second nucleic acid primer pair hybridizes under stringent conditions to a second target nucleic acid sequence found in said biological pathogen, and

- 10 further wherein said first target nucleic acid sequence and said second target nucleic acid sequence are not identical and said second target nucleic acid sequence contains more nucleic acid residues than said first target nucleic acid sequence;

- (ii) amplifying said target nucleic acid sequences by polymerase chain reaction, said polymerase chain reaction comprising adding at least one polymerase to said
15 biological material containing said nucleic acid primer pairs to form an amplification mixture and thermally cycling said amplification mixture between at least one denaturation temperature and at least one elongation temperature for a period of time sufficient to amplify said target nucleic acid sequences; and

- (iii) detecting and quantifying said first and second target nucleic acid
20 sequences, wherein the quantity of said first target nucleic acid sequence is proportional to the number of said biological pathogens in said biological material and the quantity of said second target nucleic acid sequence is proportional to the number of potentially active

biological pathogens in said biological material.

2. The method according to claim 1, wherein said first target nucleic acid sequence contains between about 50 and about 500 nucleic acid residues

5

3. The method according to claim 1, wherein said second target nucleic acid sequence contains between about 500 and about 50,000 nucleic acid residues.

4. The method according to claim 1, wherein the nucleic acid sequence of said first target nucleic acid sequence and the nucleic acid sequence of said second target nucleic acid sequence contain at least 16 contiguous nucleic acid residues in common.

15

5. The method according to claim 1, wherein said step (i) further comprises adding at least one nucleic acid probe to said biological material.

6. The method according to claim 5, wherein said nucleic acid probe is selected from the group consisting of 5' nuclease probes, hairpin probes, adjacent probes, sunrise probes and scorpion probes.

20

7. The method according to claim 1, wherein, prior to step (i), said biological material has been subjected to a process that alters at least one wild-type nucleic acid sequence in said biological pathogen.

8. The method according to claim 7, wherein said process comprises irradiating said biological material with gamma radiation.
- 5 9. The method according to claim 1, wherein one of said first pair of nucleic acid primers and one of said second pair of nucleic acid primers are substantially identical.
10. The method according to claim 1, wherein neither of said first pair of nucleic acid primers is substantially identical to either of said second pair of nucleic acid primers.
- 10 11. The method according to claim 1, wherein said first pair of nucleic acid primers and said second pair of nucleic acid primers are substantially identical.
12. The method according to claim 5, wherein said nucleic acid probe contains at
15 least 16 nucleic acid residues.
13. The method according to claim 1, wherein said biological pathogen is selected from the group consisting of bacteria, viruses, fungi and single cell parasites.
- 20 14. The method according to claim 1, wherein said first target nucleic acid sequence is at least 30% homologous to a wild-type nucleic acid sequence found in said biological pathogen.

15. The method according to claim 1, wherein said second target nucleic acid sequence is at least 30% homologous to a wild-type nucleic acid sequence found in said biological pathogen.

5

16. The method according to claim 14 or 15, wherein said biological pathogen is selected from the group consisting of *Aspergillus*, *Candida*, *Histoplasma*, *Saccharomyces*, *Coccidioides* and *Cryptococcus*.

10

17. The method according to claim 14 or 15, wherein said biological pathogen is selected from the group consisting of *Escherichia*, *Bacillus*, *Campylobacter*, *Helicobacter*, *Listeria*, *Clostridium*, *Streptococcus*, *Enterococcus*, *Staphylococcus*, *Brucella*, *Haemophilus*, *Salmonella*, *Yersinia*, *Pseudomonas*, *Serratia*, *Enterobacter*, *Klebsiella*, *Proteus*, *Citrobacter*, *Corynebacterium*, *Propionibacterium* and *Coxiella*.

15

18. The method according to claim 14 or 15, wherein said biological pathogen is selected from the group consisting of Adeno-associated Virus (AAV), California Encephalitis Virus, Coronavirus, Coxsackievirus-A, Coxsackievirus-B, Eastern Equine Encephalitis Virus (EEEV), Echovirus, Hantavirus, Hepatitis A Virus (HAV), Hepatitis C Virus (HCV), Hepatitis Delta Virus (HDV), Hepatitis E Virus (HEV), Hepatitis G Virus (HGV), Human Immunodeficiency Virus (HIV), Human T-lymphotrophic Virus (HTLV), Influenza Virus (Flu Virus), Measles Virus (Rubeola), Mumps Virus, Norwalk Virus,

20

Parainfluenza Virus, Polio virus, Rabies Virus, Respiratory Syncytial Virus, Rhinovirus, Rubella Virus, Saint Louis Encephalitis Virus, Western Equine Encephalitis Virus (WEEV), Yellow Fever Virus, Adenovirus, Cytomegalovirus (CMV), Epstein-Barr Virus (EBV), Hepatitis B Virus (HBV), Herpes Simplex Virus 1 (HHV1), Herpes Simplex Virus 2
5 (HHV2), Molluscum contagiosum, Papilloma Virus (HPV), Smallpox Virus (Variola), Vaccinia Virus, Venezuelan Equine Encephalitis Virus (VEEV), Ebola Virus, West Nile Virus, Human Parvovirus B19 and Rotavirus.

19. The method according to claim 15, wherein said wild-type nucleic acid
10 sequence comprises the 16S ribosomal RNA gene coding sequence.

20. The method according to claim 15, wherein said wild-type nucleic acid sequence comprises the 16S ribosomal RNA gene coding sequence and a portion of the 23S ribosomal RNA gene coding sequence.

15

21. The method according to claim 15, wherein said wild-type nucleic acid sequence comprises the 16S ribosomal RNA gene coding sequence and a portion of the 23S ribosomal RNA gene coding sequence and the non-coding sequence therebetween.

22. The method according to claim 14, wherein said wild-type nucleic acid
20 sequence comprises the 18S ribosomal RNA gene coding sequence.

23. The method according to claim 14, wherein said wild-type nucleic acid sequence comprises the 18S ribosomal RNA gene coding sequence and the 5.8S ribosomal RNA gene coding sequence.

5 24. The method according to claim 14, wherein said wild-type nucleic acid sequence comprises the 18S ribosomal RNA gene coding sequence and the 5.8S ribosomal RNA gene coding sequence and the non-coding sequence therebetween.

25. The method according to claim 14, wherein said wild-type nucleic acid
10 sequence comprises the 18S ribosomal RNA gene coding sequence and the 5.8S ribosomal RNA gene coding sequence and a portion of the 28S ribosomal RNA gene coding sequence.

26. The method according to claim 14, wherein said wild-type nucleic acid sequence comprises the 18S ribosomal RNA gene coding sequence and the 5.8S ribosomal
15 RNA gene coding sequence and a portion of the 28S ribosomal RNA gene coding sequence and the non-coding sequences therebetween.

27. The method according to claim 1, wherein said polymerase is a thermostable polymerase.

20

28. The method according to claim 27, wherein said thermostable polymerase is a *Taq* polymerase.

29. The method according to claim 1, wherein said polymerase chain reaction thermally cycling said amplification mixture between at least one denaturation temperature, at least one annealing temperature and at least one elongation temperature for a period of time sufficient to amplify said target nucleic acid sequence.

30. The method according to claim 7, wherein said process fragments said at least one wild-type nucleic acid sequence in said biological pathogen.

31. The method according to claim 7, wherein said process cross-links said at least one wild-type nucleic acid sequence in said biological pathogen.

32. The method according to claim 7, wherein said process covalently modifies said at least one wild-type nucleic acid sequence in said biological pathogen.

33. The method according to claim 1, wherein said biological material is selected from the group consisting of: cells; tissues; blood or blood components; proteins; enzymes; immunoglobulins; botanicals; and food.

34. The method according to claim 1, wherein said biological material is selected from the group consisting of: ligaments; tendons; nerves; bone; teeth; skin grafts; bone marrow; heart valves; cartilage; corneas; arteries and veins; organs; lipids; carbohydrates;

collagen; chitin and its derivatives; forensic samples, mummified material; human or animal remains; stem cells; islet of Langerhans cells; cells for transplantation; red blood cells; white blood cells; and platelets.

CI0043PCTseqlisting.ST25
SEQUENCE LISTING

<110> Clearant, Inc.
McKenney, Keith
Gillmeister, Lidja
Marlowe, Kristina
Armistead, David

<120> Pathogen Inactivation Assay

<130> CI-0043

<150> 10/361,002

<151> 2003-02-10

<160> 99

<170> PatentIn version 3.2

<210> 1

<211> 5594

<212> DNA

<213> B19 virus

<400> 1

ccaaatcaga	tgccgccggt	cgccgccggt	aggcgggact	tccggtacaa	gatggcggac	60
aattacgtca	tttctgtga	cgatctttcc	tgtgacgtca	cttccggtgg	gcgggacttc	120
cggaattagg	gttggtcttg	ggccagcttg	cttggggttg	ccttgacact	aagacaagcg	180
g'gcgcgcgct	tgtcttagtg	gcacgtcaac	cccaagcgct	ggcccagagc	caaccctaata	240
tccggaagtc	ccgccaccgc	gaagtgcgt	cacaggaagt	gacgtcacag	gaaatgacgt	300
aattgtccgc	catcttgtag	cggaaagtc	gcctaccggc	ggcgaccggc	ggcatctgat	360
ttggtgtctt	cttttaaatt	ttagcgggct	tttttccgc	cttatgcaaa	tgggcagcca	420
ttttaagtgt	ttactataa	ttttattggt	cagttttgta	acgggtaaaa	tgggcggagc	480
gtaggcgggg	actacagtat	atatagcagc	gcactgccgc	agctctttct	ttctgggctg	540
ctttttcctg	gactttcttg	ctgttttttg	tgagctaact	aacagggtatt	tatactactt	600
gttaacatac	taacatggag	ctatttagag	gggtgcttca	agttttctct	aatgttcttg	660
actgtgctaa	cgataactgg	tgggtgctct	tactggattt	agacacttct	gactgggaac	720
cactaactca	tactaacaga	ctaattggca	tatacttaag	cagtgtggct	tctaagcttg	780
actttaccgc	ggggccacta	gcgggggtgct	tgtacttttt	tcaagtagaa	tgtaacaaat	840
ttgaagaagg	ctatcatatt	catgtgggta	ttggggggcc	aggggtaaac	cccgaatacc	900
tcacagtgtg	tgtagagggg	ttatttaata	atgtacttta	tcaccttgta	actgaaaatg	960
taaaagctaa	atttttgcca	ggaatgacta	caaaaggcaa	atactttaga	gatggagagc	1020
agtttataga	aaactattta	atgaaaaaaa	tacctttaa	tggtgtatgg	tgtgttacta	1080
atattgatgg	atatatagat	acctgtattt	ctgctacttt	tagaaggggg	gcttgccatg	1140
ccaagaatac	ccgcattacc	acagccataa	atgacactag	tagtgatgct	ggggagtgcta	1200
gcggcacagg	ggcagaggtt	gtgccaatga	atgggaagg	aactaaggct	agcataaagt	1260
ttcaaacat	ggtaaacctg	ttgtgtgaaa	acagagtgtt	tacagaggat	aagtggaaac	1320

CI0043PCTseq1isting.ST25

tagttgactt taaccagtac actttactaa gcagtagtca cagtggaaagt tttcaaattc	1380
aaagtgcact aaaactagca atttataaag caactaattt agtgcctaca agcacatttc	1440
tattgcatac agactttgag cagggttatgt gtattaaaga caataaaatt gttaaattgt	1500
tactttgtca aaactatgac cccctattag tggggcagca tgtgttaaag tggattgata	1560
aaaaatgtgg caagaaaaat acactgtggt tttatgggcc gccaaagtaca ggaaaaacaa	1620
acttggcaat ggcattgtct aaaagtgttc cagtatatgg catgtttaac tggaaataatg	1680
aaaactttcc atttaattgat gtagcagggg aaagcttggg ggtctgggat gaaggtatta	1740
ttaagctcac aattgtagaa gctgcaaaag ccattttagg cgggcaaccc accagggtag	1800
atcaaaaaat gcgtggaagt gtagctgtgc ctggagtacc tgtggttata accagcaatg	1860
gtgacattac ttttgttgta agcgggaaca ctacaacaac tgtacatgct aaagccttaa	1920
aagagcgaat ggtaaaagta aactttactg taagatgcag ccctgacatg gggttactaa	1980
cagaggctga tgtacaacag tggccttacat ggtgtaatgc acaaagctgg gaccactatg	2040
aaaactgggc aataaactac acttttgatt tccttggaa taatgcagat gccctccacc	2100
cagacctcca aaccaccca attgtcacag acaccagat cagcagcagt ggtgtggtaa	2160
gctctgaaga actcagtga agcagctttt ttaacctcat cccccaggc gcctggaaca	2220
ctgaaccccc gcgctctagt acgcccattc ccgggaccag ttcaggagaa tcatttgtcg	2280
gaagctcagt ttctcccgaa gttgtagctg catcgtggga agaagccttc tacacacctt	2340
tggcagacca gtttcgtgaa ctgttagttg gggttgatta tgtgtgggac ggtgaaggg	2400
gtttacctgt gtgtgtgtg caacatatta acaatagtg gggaggcttg ggaacttgtc	2460
cccattgcat taatgtagg gcttggata atggatgaa atttcgagaa tttacccag	2520
atttggctgc gtgtagctgc catgtgggag cttctaacc cttttctgtg ctaacctgca	2580
aaaaatgtgc ttacctgtct ggattgcaaa gctttgtaga ttatgagtaa agaaagtggc	2640
aaatgttggg aaagtgatga taaatttgct aaagctgtgt atcagcaatt tgtggaattt	2700
tatgaaaagg ttactggaac agacttagag cttattcaaa tattaaga tcactataat	2760
atttctttag ataattccct agaaaaacca tcctctctgt ttgacttagt tgctctgtatt	2820
aaaaataacc ttaaaaactc tccagactta tatagtcac attttcaaag tcatggacag	2880
ttatctgacc acccccatgc cttatcatcc agtagcagtc atgcagaacc tagaggagaa	2940
aatgcagtat tatctagtga agacttacac aagcctgggc aagttagcgt acaactacc	3000
ggtactaact atgttggggc tggcaatgag ctacaagctg ggccccgc aagtgtctgt	3060
gacagtgtcg caaggattca tgactttagg tatagccaac tggctaaagt gggataaat	3120
ccatatactc attgagctgt agcagatgaa gagcttttaa aaaatataaa aaatgaaact	3180
gggtttcaag cacaagtagt aaaagactac ttacttttaa aaggtgcagc tgccccgtg	3240
gcccattttc aaggaaagtt gccggaagtt ccgccttaca acgctcaga aaaataccca	3300
agcatgactt cagttaattc tgcagaagcc agcactgggt caggaggggg tggcagtaat	3360

CI0043PCTseq1isting.ST25

cctgtcaaaa	gcattgtggag	tgagggggccc	acttttagtg	ccaactctgt	aacttgatca	3420
ttttccagac	agtttttaat	tccttagtac	ccagagcacc	attataaggt	gttttctccc	3480
gcagcaagca	gctgccacaa	tgccagtgga	aaggaggcaa	aggtttgac	aattatgtccc	3540
ataatgggat	actcaacccc	atggagatat	ttagatttta	atgctttaaa	tttatttttt	3600
tcacctttag	agtttcagca	cttaattgaa	aattatggaa	gtatagctcc	tgatgtctta	3660
actgtaacca	tatcagaaat	tgctgttaag	gatgttacag	acaaaactgg	aggggggggta	3720
caggttactg	acagcactac	aggggcgccta	tccatgttag	tagaccatga	atacaagtac	3780
ccatatgtgt	taggacaagg	tcaggatact	ttagccccag	aacttcttat	ttgggtatatac	3840
tttccccctc	aattatgtcta	cttaacagta	ggagatgtta	acacacaagg	aattctctgga	3900
gacagcaaaa	aattagcaag	tgaagaatca	gcattttatg	ttttggaaca	cagtctcttt	3960
cagcttttag	gtacaggagg	tacagcaact	atgtcttata	agtttctctc	agtgccccc	4020
gaaaatttag	agggtcgac	tcaacacttt	tatgaaatgt	acaatccctt	atacggatcc	4080
cgcttagggg	ttctcgacac	attaggaggt	gacccaaaat	ttagatcttt	aacacatgaa	4140
gaccatgcaa	ttcagcccca	aaacttcacg	ccaggggcac	tagtaaaact	agtgctctaca	4200
aaggagggag	acagctctaa	tactggagct	ggaaaagcct	taacaggcct	tagcacaggc	4260
acctctcaaa	acactagaat	atccttacgc	cctgggcccag	tgtcacagcc	ataccaccac	4320
tgggacacag	ataaatatgt	tccaggaata	aatgccattt	ctcatgggtca	gaccacttat	4380
ggtaacgctg	aagacaaga	gtatcagcaa	ggagtgggta	gatttccaaa	tgaaaagaa	4440
cagctaaaaa	agttacaggg	tttaaacatg	cacacctatt	tccccataa	aggaaccag	4500
caatatacag	atcaaatgga	gcgcccccta	atggtgggtt	ctgtatggaa	cagaagagcc	4560
cttcaactatg	aaagccagct	gtggagtaaa	attccaatt	tagatgacag	ttttaaaaact	4620
cagtttgacg	ccttaggagg	atgggggttg	catcagccac	ctcctcaaat	atttttaaaa	4680
atattaccac	aaagtgggccc	aattggaggt	attaaatcaa	tggaattac	tacttagatt	4740
cagtaatgccg	tggaatttat	gacagtaact	atgacattta	aattggggcc	ccgtaaaagt	4800
acgggacggt	ggaatcctca	acctggagta	tatccccgc	acgcagcagg	tcattttacca	4860
tatgtactat	atgaccccc	agctacagat	gcaaaacaac	accacaggca	tggaatagaa	4920
aagcctgaag	aattgtggag	agccaaaagc	cgtgtgcacc	cattgtaaac	actctccacc	4980
gtgcctctag	ccaggatgag	taactaaacg	cccaccagta	ccaccagac	tgtaactgccc	5040
ccctctctga	cctataagac	agcctaacac	aaaagatata	gacaatgtag	aatttaagta	5100
cttaaccaga	tatgaacaac	atgttattag	aattgttaaga	ttgtgttaata	tgatacaaaa	5160
tttagaaaaa	taaacatttg	ttgtggttaa	aaaattatgt	tggtgcgctt	taaaaaattta	5220
aaagaagaca	ccaatcaga	tgccgcgggt	cgccgcgggt	aggcgggact	tccgggtacaa	5280
gatggcggac	aattacgtca	tttctgtga	cgtaatttcc	tgtagcgtca	cttcgggtgg	5340
gcgggacttc	cggaattagg	gttggtctg	ggccagcgct	tggggttgac	gtgcacttaa	5400

CI0043PCTseqlisting.ST25

gacaagcggc gcgccgcttg tcttagtgtc aaggcaaccc caagcaagct ggcccagagc 5460
 caaccctaata tccggaagtc ccgcccacgc gaagtgaact cacaggaat gacgtcacag 5520
 gaaatgacgt aattgtccgc catcttgatc cggaagtcgc gcctaccggc ggcgaccggc 5580
 ggcattctgat ttgg 5594

<210> 2
 <211> 3221
 <212> DNA
 <213> Hepatitis B virus

<400> 2
 ttccactgcc ttccaccaag ctctgcaaga cccagagtc aggggtctgt attttctgct 60
 tgggtggctcc agttcaggaa cagtaaaccc tgctccgaat attgcctctc acatctcgctc 120
 aatctccgcgc aggaccgggg accctgtgac gaacatggag aacatcacat caggattcct 180
 aggaccctgc cccgtgttac aggcgggggt tttcttgctg acaagaatcc tcacaatacc 240
 gcagagtcta gactcgtggt ggactctctc caattttcta gggggatcac cgtgtgtgct 300
 tggcctaaat tcgcgatccc caacctcaa tcactcacca acctctgctc ctccaatttg 360
 tcttggttat cgtcggatgt gctcggcggc ttttatcata ttctcttca tctgtgctgt 420
 atgctctatc ttcttattgg ttctcttgga ttatcaaggt atgtgccccg tttgtctct 480
 aattctagga tcaacaacaa ccagtacggg accatgcaa acctgcacga ctctgcttca 540
 aggcaactct atgtttccct catgttgctg tacaaaacct acggatggaa attgcacctg 600
 tattcccatc ccactgtctt ggcctttcgc aaaataccta tgggagtgga cctcagtcgc 660
 tttctcttgg ctcatgttac tagtgccatt tgttcagtgg ttcgtagggc tttccccac 720
 tgtttggcct tcagctatat ggatgatgtg gtattggggg ccaagtctgt acagcatcgt 780
 gaggctcctt ataccgctgt taccaatttt cttttgtctc tgggtataca tttaaacctt 840
 aacaaaacaa aaagatgggg ttattcccta aacttcattg gttatgtaat tggaaattgg 900
 ggaacattgc cacagatgca tattgtacaa aaaatcaaac actgttttag aaaacttctt 960
 gtaaacaggc ctattgattg gaaagtatgt caaagaattg tgggtctttt gggctttgct 1020
 gtccttttta cacaatgtgg atatcctgcc ttaatgccct tgatgcatg tatacaagct 1080
 aaacaggctt tcactttctc gccaacttac aaggcctttc taagtaacaa gtacatgaac 1140
 ctttaccctg ttgctcgcca acggcctggt ctgtgccaa gatttgctga tgcaaccccc 1200
 actggctggg gcttggccat aggcctatcag cgcattgcgc gaacctttgt ggcctctctg 1260
 cgcattcata ctgcggaact cctagccgct tgttttgctc gcagccggtc tggagcgaaa 1320
 ctcatcgga ctgacaattc tgtcgtcctc tcgcggaaat atacctcgtt tccatggcta 1380
 ctaggctgtg ctgccaactg gatccttcgc gggacgtcct ttgtttacgt cccgtcggcg 1440
 ctgaatccgc cgacgaccc ctctcggggc cgttggggac tctctcgtcc ccttctccgt 1500
 ctgccgttcc agccgaccac ggggcgcacc tctctttacg cggtctcccc gtctgtgcct 1560

CI0043PCTseqlisting.ST25

tctcatctgc	cggtccgtgt	gcacttcgct	tcacctctgc	acgttgcatg	gagaccaccg	1620
tgaacgccca	tcagatcctg	cccaaggctc	tacataagag	gactcttgga	ctcccagcaa	1680
tgtaacagac	cgaccttgag	gcctacttca	aagactgtgt	gtttaaggac	tgggaggagc	1740
tggggaggga	gattagggtta	aaggctcttg	tattaggagg	ctgtaggcat	aaattggtct	1800
gcgcaccagc	accatgcaac	tttttcacct	ctgcctaata	atctcttgta	catgtcccac	1860
tgttcaagcc	tccaagctgt	gccttggtgt	gctttggggc	atggacattg	acccttataa	1920
agaatttgga	gctactgtgg	agttactctc	gtttttgcct	tctgacttct	ttccttcctg	1980
cagagatctc	ctagacaccg	cctcggctct	gtatcgggaa	gccttagagt	ctcctgagca	2040
ttgtccacct	caccataccg	cactcaggca	agccattctc	tgctgggggg	aattgatgac	2100
tctagctacc	tgggtgggta	ataatttgga	agatccagca	tccagggtac	tagtagtcaa	2160
ttatgttaat	actaacatgg	gattaaagat	caggcaactc	ttgtggttct	atatctcttg	2220
ccttactttt	ggaagagaaa	ctgtacttga	atatttggtc	tctttcggag	tgtggattcg	2280
cactctctca	gcctatagac	caccaaatac	ccctatctta	tcaacacttc	cggaaactac	2340
tgtttgtaga	cgacgggacc	gaggcaggct	ccctagaaga	agaactccct	gcctctcgag	2400
acgcagatct	caatcgccgc	gtcgcagaag	atctcaatct	cgggaatctc	aatgttagta	2460
ttccttgga	tcataagggt	ggaaacttca	ctgggcctta	ttcctctaca	gcacctatct	2520
ttaatcctga	atggcaaaat	ccttcctttc	ctaaaaatca	tttaacagag	gacattatta	2580
ataggtgtca	acaatttgtg	ggccctctca	ctgtaaatga	aaagagaaga	ttgaaattaa	2640
ttatgcctgc	tagattctat	cctaccaca	ctaaatattt	gcccttagac	aaaggaatta	2700
aaccttatta	tccagatcag	gtagttaatc	attacttcca	aaccagacat	tatttaccata	2760
ctcttttgaa	ggcgggtatt	ctatataaga	gagaaaccac	acgtagcgca	tcattttgcg	2820
ggtcaccata	ttcttgggaa	caagagctac	agcatggggag	gttgggtcatc	aaaacctcgc	2880
aaaggcatgg	ggacgaatct	ttctgttccc	aacctctcgg	gattctttcc	cgatcatcag	2940
ttggaccctg	tattcgggag	caactcaaac	aatccagatt	gggacttcaa	ccccatcaag	3000
gaccactggc	cagcagccaa	ccaggtagga	gtgggagcat	tcgggccagg	gttcacccct	3060
ccacacggcg	gtgttttggg	gtggagccct	caggctcagg	gcattgtgac	cccagtgta	3120
acaattcctc	ctctgcctc	cgccaatcgg	cagtcaggaa	ggcagcctac	tcccatctct	3180
ccactcttaa	gagacagtca	tcctcaggcc	atgcagtgga	a		3211

<210> 3
 <211> 5075
 <212> DNA
 <213> Porcine parvovirus

<400> 3						
aatcttttaa	ctgaccaact	gtctttgcgt	atggtgacgt	gatgacgcgc	gctacgcgcg	60
ctgccttcgg	cagtcacacg	tcaccatcag	caaagacagt	tggtcaggtt	aaagattaat	120
aagacattcc	attggtcgaa	aagaggcggg	aaattcaaaa	aaagaggcgg	gaaaaaaga	180

CI0043PCTseqlisting.ST25

ggaggagcct aacactataa atacagtgc ttacttcagt tagttccttt ctgcttcaga	240
ctgcacttcg ctccagagac acagctacaa actactctca gctactgcag catggcagcg	300
ggaaacactt actcgaaga ggtactaaaa gctaccaact ggcttcaaga taatgctcaa	360
aaagaagcat tctcttatgt atttaaaaca caaaaagtca atctaaatgg aaaagaaatt	420
gcttggaata actacaacaa agatacaaca gatgcggaaa tgataaacct acaagagga	480
gcagaacat catgggacca ggcaacagac atggaatggg aatcagaaat cgacagcctc	540
acaaaacggc aagtactgat ttttgactct cttgttaaaa aatgtctctt tgaaggata	600
ttgcaaaaga acctaatgct aagtactgc tactggttca tacagcatga acatggtcaa	660
gatactggct atcactgcca tgtactacta ggtgaaaaag gcttacaaca agcaatggga	720
aatggttca gaaaacaatt aaacaattta tggagtagat ggtaataat gcaatgcaaa	780
gtacctctaa caccagtga aagaataaaa ttaagggaaat tagcagagga tggtagtggtg	840
gtatcgctac taacctacac tcacaaacaa actaaaaaac aatatacaaa aatgactcat	900
tttggaaata tgattgctta ctacttccta aataaaaaaa gaaagacaa tgaaagagag	960
catggatatt atctcagctc agattctggc ttcattgacaa atttcttaaa agaaggcgag	1020
agacacttag tcagtcacct atttactgaa gcaataaaac ctgaaactgt ggaacaacg	1080
gttactacag ctacaggaagc caaaagaggc agaatacaaa caaaaaaga agtaagcata	1140
aatgcaaaa taagagactt ggtaataaaa agatgtacta gcatagaaga ctggatgatg	1200
acagatccag acagttatat agaatgatg gctcaaacg gaggaagaaa ttaatatcaa	1260
aatacactag aaataacaac tcttactcta gcaagaacaa aaacagcata tgacttaata	1320
cttgaaaagg caaaaccaag catgctacca acatttaata ttagcaatac aagaacatgt	1380
aaaatattca gcatgcacaa ttggaactac attaaagtct gccatgctat aacttggtg	1440
ctaaacagac aaggaggaaa aagaataaca attctatttc atgggccagc atcaacagga	1500
aaaagtataa ttgctcaaca cattgcaaac ttgattggta atgttggttg ctacaatgca	1560
gccaatgtga actttccatt taatgactgt acaataaaaa acttaatatg gattgaagaa	1620
gcaggaaact tctctaacca agtaaaccaa ttcaaagcca tatgttcagg tcaacaatt	1680
agaattgacc aaaaaggtaa aggaagcaaa caaattgaac caactcctgt aataatgact	1740
acaaatgaag acataactaa agttagaata ggatgcgagg aaagaccaga acatacaca	1800
ccaataagag acagaatggt aaacataaac ctacacagaa aactgccagg tgattttgga	1860
cttttagaag aaactgaatg gccactaata tgtgcttggt tggtaaagaa aggttacc	1920
gcaacaatgg ctacttatat gcatcattgg ggaatgtac ctgattgggtc agaaaaatgg	1980
gaggagccaa aaatgcaaac cccaataaat acaccaacag actctcagat ttccacatca	2040
gtgaaaactt cgccagcgga caacaactac gcagcaactc caatacagga ggacctggat	2100
ttagctttag ccttggaagc gtggagcgag ccaacaacac caactttcac caacctgcac	2160
ttactccaa caccgccaga ttcagcaata cggaacacaa gtccaacttg gtcggaaata	2220

CI0043PCTseqlisting.ST25

gaaaccgaca taagagcctg ctttggtgaa aactgtgcac ccacaacaaa ccttgaataa	2280
ggtaggatgg gcgcctctgc aaaaagagca agaggtaagg gtagttttaa gggggtggtg	2340
ggcatacata taaaactaac tgcaataaat tttttatat attacaggac taactctacc	2400
aggatacaaa tactcttggtc caggaaactc actagaccaa ggagaaccaa ctaattccatc	2460
agacgccgca gcaaaagaac acgacgaagc ctacgacaaa tacataaaat ctggaaaaaa	2520
tccatacttc tacttctcag cagctgatga aaaattcata aaagaaactg aacacgcaaa	2580
agactacgga ggtaaaattg gacattactt cttcagagca aagcgtgcct ttgtctccaa	2640
actctcagaa agactactac caactacatc tcaacaacca gaggtaagaa gatcgccgag	2700
aaaacaccca ggggtctaac caccaggaaa aagacctgct ccaagacata tttttataaa	2760
cttagctaaa aaaaagctta aagggacatc taatacaaac tctaactcaa tgagtgaaaa	2820
tgtggaacaa cacaacccta ttaatgcagg cactgaattg tctgcaacag gaaatgaatc	2880
tgggggtggg ggcggcggtg gcgggggtag ggggtctggg ggggttggtg tgtctacagg	2940
tactttcaat aatcaaacag aatttcaata cttgggggag ggcttggtta gaatcactgc	3000
acacgcatca agactcatac atctaataat gccagaacac gaaacataca aaagaataca	3060
tgtactaaat tcagaatcag ggggtggcggg acaaatggta caagacgatg cacacacaca	3120
aatggtaaca ccttggtcac taatagatgc taacgcattg ggagtgtggt tcaatccagc	3180
ggactggcag ttaatatcca acaacatgac agaataaac ttagttagtt ttgaacaaga	3240
aatattcaat gtagtactta aaacaattac agaatcagca acctcaccac caacaaaaat	3300
atataataat gatctaactg caagcttaat ggtcgacta gacaccaata acacacttcc	3360
atacacacca gcagcaccta gaagtgaac acttggtttt tatccatggt tacctacaaa	3420
accaactcaa tacagatatt acctatcatg catcagaac ctaaatccac caacatacac	3480
tggacaatca caacaataaa cagactcaat acaaacagga ctacacagtg acattatggt	3540
ctacaataa gaaaatgcag taccaattca tctctaaaga acaggagatg aattctccac	3600
aggaatatat cactttgaca caaaaccact aaaattaact cactcatggc aaacaacacg	3660
atctctagga ctgcctccaa aactactaac tgaacctacc acagaaggag accaacaccc	3720
aggaacacta ccagcagcta acacaagaaa aggttatcac caacaatta ataatagcta	3780
cacagaagca acagcaatta ggccagctca ggtaggatat aatacaccat acatgaattt	3840
tgaatactcc aatggtggac catttctaac tcctatagta ccaacagcag acacacaata	3900
taatgatgat gaaccaaatg gtgctataag atttacaatg gattaccaac atggacactt	3960
aaccacatct tcacaagagc tagaaagata cacattcaat ccacaaagta aatgtggaag	4020
agctccaaag caacaattta atcaacagc accactaaac ctagaaaata caaataatgg	4080
aaacttttta ccttcagatc caataggagg gaaatctaac atgcatttca tgaatacact	4140
caatacatat ggaccattaa cagcactaaa caatactgca cctgtatttc caaatggta	4200
aatatgggat aaagaacttg atacagatct aaaaacttaga ctacatgta cagctccatt	4260

CI0043PCTseqlisting.ST25

tgtttgtaaa aacaatccac caggacaact atttgtaaaa atagcaccaa acctaacaga	4320
tgatttcaat gctgactctc ctcaacaacc tagaataata acttattcaa acttttgggtg	4380
gaaaggaaca ctaacattca cagcaaaaat gagatccagt aatatgtgga accctattca	4440
acaacacaca acaacagcag aaaacattgg taactatatt cctacaaata ttggtggcat	4500
aagaatgttt ccagaatatt cacaacttat accaagaaaa ttatactaga aataactctg	4560
tataaaaaa ctcagttact tggttaatca tgtactacta tcattgtata cttaataaaa	4620
aataaattgt aaaatcaata aaactaagtt acttagtttc tgtataccta tactagaaat	4680
aactctgtaa ataaaaactc agttacttgg ttaatcatgt actactatca ttgtatactt	4740
caataaaaaat aaattgtaaa atcaataaaa ctaagtactt tagtttctgt atacaatta	4800
tccccaaaaa acaataaaaa tttaaaaaga aacaagctct catgtgttta ctattaacta	4860
aaccaaccac acttatatga ccttatgtct ttaggggtggg tgggtgggaa ttactatgta	4920
ttcctttgag ttagtgtgtc gcctttgggc gactaaccaa gcggtctgc cgcttgggta	4980
gtcgcacggc gaccaactaa ctcaaaggaa tacatagtaa ttcccacca cccacctaa	5040
agacataagg tcataatagt gtggttggtt tagtt	5075

<210> 4
 <211> 11703
 <212> DNA
 <213> Sindbis virus

<400> 4	
attgacggcg tagtacacac tattgaatca aacagccgac caattgcact accatcaca	60
tggagaagcc agtagtaaac gtagacgtag acccccagag tccgtttgtc gtgcaactgc	120
aaaaaagctt cccgcaattt gaggtagtag cacagcaggt cactccaaat gaccatgcta	180
atgcagagc attttcgc atggccagta aactaatcga gctggaggtt cctaccacag	240
cgacgatctt ggacataggc agcgcaccgg ctctagaat gttttccgag caccagtatc	300
attgtgtctg ccccatgcgt agtccagaag acccggaccg catgatgaaa tacgccagta	360
aactggcggg aaaaagcgtgc aagattacaa acaagaactt gcatgagaag attaaggatc	420
tccggaccgt acttgatacg ccggatgctg aaacaccatc gctctgcttt cacaacgatg	480
ttacctgcaa catgcgtgcc gaattattccg tcattgcagga cgtgtatata aacgctccc	540
gaactatcta tcattcaggt atgaaaggcg tgcggaccct gtactggatt ggcttcgaca	600
ccaccaggt catgttctcg gctatggcag gttcgtacc tgcgtacaac accaactggg	660
ccgacgagaa agtccttgaa gcgcgtaaca tcggactttg cagcacaaga ctgagtgaag	720
gtaggacagg aaaattgtcg ataattgagg agaaggagtt gaagcccggt tcgctgggtt	780
attttccgt aggatcgaca ctttatccag aacacagagc cagcttcgag agctggcatc	840
ttccatcggt gttccacttg aatggaaagc agtcgtacac ttgccgtgt gatacagtgg	900
tgagttcgga aggctacgta gtgaagaaaa tcaccatcag tcccgggatc acgggagaaa	960

CI0043PCTseqlisting.ST25

ccgtgggata	cgcggtttaca	cacaatagcg	agggcttctt	gctatgcaaa	gttactgaca	1020
cagtaaaagg	agaacgggta	tcgttccctg	tgtgcacgta	catccgggcc	accatatgcg	1080
atcagatgac	tggtataatg	gccacggata	tatcacctga	cgatgcacaa	aaacttctgg	1140
ttgggctcaa	ccagcgaatt	gtcattaacg	gtaggactaa	caggaacacc	aacaccatgc	1200
aaaattacct	tctgccgac	atagcacaag	ggttcagcaa	atgggctaag	gagcgcaagg	1260
atgatcttga	taacgagaaa	atgctgggta	ctagagaacg	caagcttacg	tatggctgct	1320
tgtgggcgtt	tcgactaag	aaagtacatt	cgttttatcg	cccacctgga	acgcagacct	1380
gcgtaaaagt	cccagctctt	tttagcgctt	ttcccatgtc	gtccgatatg	acgacctctt	1440
tgcccatgtc	gctgaggcag	aaattgaaac	tggcattgca	accaagaag	gagggaaaac	1500
tgctgcaggt	ctcggaggaa	ttagtcatgg	aggccaaggc	tgcttttgag	gatgtctcag	1560
aggaagccag	agcggagaag	ctccgagaag	cacttcacc	attagtggca	gacaaaggca	1620
tcgaggcagc	cgcagaagtt	gtctgcgaag	tggaggggct	ccaggcggac	atcggaagcag	1680
cattagtgtga	aacccccgcg	ggtcacgtaa	ggataatacc	tcaagcaaat	gaccgtatga	1740
tcggacagta	tatcgttgct	tcgccaaact	ctgtgtgtaa	gaatgccaaa	ctcgaccacg	1800
cgcaccgcgt	agcagatcag	gttaagatca	taacacactc	cggaagatca	gggaaggtacg	1860
cggtcgaacc	atacgcgct	aaagtactga	tgccagcagg	agggtgccga	ccatggccag	1920
aattcctagc	actgagttag	agcgccacgt	tagtgtacaa	cgaaagagag	tttgtgaacc	1980
gcaactata	ccacattgcc	atgcatggcc	ccgccaagaa	tacagaagag	gagcagtaca	2040
aggttacaaa	ggcagagcct	gcagaaacag	agtagctggt	tgactgggac	aagaagcgtt	2100
gcgttaagaa	ggaagaagcc	tcaggtctgg	tcctctcggg	agaaactgacc	aacctctcct	2160
atcatgagct	agctctggag	ggactgaaga	cccagctgac	gggtccgtac	aaggctgaaa	2220
caataggagt	gataggcaca	ccggggctcg	gcaagtcagc	tattatcaag	tcaactgtca	2280
cggcacgaga	tcttgttacc	agcggaagaa	aagaaaattg	tcgcgaaatt	gaggccgacg	2340
tgctaagact	gaggggtatg	cagattacgt	cgaagacagt	agattcgggt	atgctcaacg	2400
gatgccacaa	agccgtagaa	gtgctgtacg	ttgacgaagc	gttcgcgtgc	cacgcaggag	2460
cactacttgc	cttgattgct	atcgctagcg	cccgaagaa	ggtagtacta	tgcgagagacc	2520
ccatgcaatg	cggattcttc	aacatgatgc	aactaaaggt	acatttcaat	caccctgaaa	2580
aagacatatg	caccaagaca	ttctacaagt	atatctcccg	gcgttgca	cagccagttg	2640
cagctattgt	atcgacactg	cattacgatg	gaaagatgaa	aaccacgaac	ccgtgcaaga	2700
agaacattga	aatcgatatt	acaggggcca	caaagccgaa	gccaggggat	atcatcctga	2760
catgtttccg	cggtctgggt	aagcaattgc	aaatcgacta	tcccgacat	gaagttaatga	2820
cagccgcgcg	ctacacaagg	ctaaccagaa	aaggagtgtg	tgccgtcccg	caaaaagtca	2880
atgaaaaccc	actgtacgcg	atcacatcag	agcatgtgaa	cgtgttgctc	accgcgactg	2940
aggacaggct	agtggtgaaa	accttgcagg	gcgacccatg	gattaagcag	cccactaaca	3000

CI0043PCTseqlisting.ST25

tacctaaagg	aaactttcag	gctactatag	aggactggga	agctgaacac	aagggaataa	3060
ttgtgcaat	aaacagcccc	actccccgtg	ccaatccgtt	cagctgcaag	accaacgttt	3120
gctgggagaa	agcattggaa	ccgatactag	ccacggccgg	tatcgtactt	accggttgcc	3180
agtgagcga	actgttccca	cagtttgcgg	atgacaaacc	acattcggcc	atttacgcct	3240
tagacgtaat	ttgcattaag	tttttcggca	tggacttgac	aagcggactg	tttttcaaac	3300
agagcatccc	actaacgtac	catcccgccg	attcagcgag	gccggtagct	cattggggaca	3360
acagcccagg	aaccgcgaag	tatgggtacg	atcacgccat	tgccgccgaa	ctctcccgtg	3420
gatttccggt	gttcagccta	gctgggaagg	gcacacaact	tgatttgcag	acggggagaa	3480
ccagagttat	ctctgcacag	cataacctgg	tcccgggtgaa	ccgcaatctt	cctcacgcct	3540
tagtccccga	gtacaaggag	aagcaaccgg	gcccgggtcaa	aaaattcttg	aaccagttca	3600
aacaccactc	agtactttgt	gtatcagagg	aaaaaattga	agctccccgt	aagagaatcg	3660
aatggatcgc	cccgatggcc	atagccggtg	cagataagaa	ctacaacctg	gctttcgggt	3720
ttccgcgcga	ggcagcgtac	gacctggtgt	tcatacaact	tggaaactaa	tacagaaacc	3780
accactttca	gcagtcgcga	gaccatgcgg	cgacccttaa	aaccttttcg	cgttcggccc	3840
tgaattgcct	taaccacgga	ggcaccctcg	tggtgaagtc	ctatggctac	gccgaccgca	3900
acagtgagga	cgtagtcacc	gctcttgcca	gaaagtttgt	cagggtgtct	gcagcgagac	3960
cagattgtgt	ctcaagcaat	acagaaatgt	acctgatttt	ccgacaacta	gacaacagcc	4020
gtacacggca	attcaccccc	caccatctga	attgctgtat	ttcgtccgtg	tatgagggta	4080
caagagatgg	agttggagcc	gcgccgtcat	accgcaccaa	aaggggagaat	attgctgact	4140
gtcaagagga	agcagttgtc	aacgcagcca	atccgctggg	tagaccaggc	gaaggagtct	4200
gccgtgccat	ctataaacgt	tggccgacca	gttttaccca	ttcagccacg	gagacaggca	4260
ccgcaagaat	gactgtgtgc	ctaggaaaag	aagtgatcca	cgcggtcggc	cctgattttc	4320
ggaagcacc	agaagcagaa	gccttgaaat	tgctacaaaa	cgcttaccat	gcagtggcag	4380
acttagtaaa	tgaacataac	atcaagtctg	tcgccattcc	actgctatct	acaggcattt	4440
acgcagccgg	aaaagaccgc	cttgaagtat	cacttaactg	cttgacaacc	gcgctagaca	4500
gaactgcacg	ggagctaacc	atctattgac	tggataagaa	gtggaaggaa	agaatcgacg	4560
cggcactcca	acttaaggag	tctgtaacag	agctgaagga	tgaagatatg	gagatcgacg	4620
atgagttagt	atggatccat	ccagacagtt	gcttgaaggg	aagaaaggga	ttcagttacta	4680
caaaaggaaa	attgtattgc	tacttcgaag	gcaccaaatt	ccatcaagca	gcaaaagaca	4740
tggcgagat	aaaggtcctg	ttccctaagt	accaggaaaag	taatgaacaa	ctgtgtgcct	4800
acatatgggg	tgagaccatg	gaagcaatcc	gcgaaaagtg	cccggtcgac	cataaccgtt	4860
cgcttagccc	gcccaaaacg	ttgccgtgcc	tttgcatgta	tgccatgacg	ccagaaaggg	4920
ttcacagact	tagaagcaat	aacgtcaaag	aagttacagt	atgctcctcc	accccccttc	4980
ctaagcacia	aattaagaat	gttcagaagg	ttcagtcgac	gaaagtagtc	ctgtttaatc	5040

CI0043PCTseqlisting.ST25		
cgcacactcc cgcattcggt ccgcgccgta agtacataga agtgccagaa cagcctaccg	5100	
ctctctctgc acaggcccgag gaggcccccg aagttgtagc gacaccgtca ccatctacag	5160	
ctgataacac ctgccttgat gtcacagaca tctcactgga tatggatgac agtagcgaag	5220	
gctcactttt ttgcagcttt agcggatcgg acaactctat tactagtatg gacagttggt	5280	
cgtcaggacc tagttcacta gagatagtag accgaaggca ggtggtggtg gctgacgttc	5340	
atgccgtcca agagcctgcc cctattccac cgccaaggct aaagaagatg gccgcctgg	5400	
cagcggcaag aaaagagccc actccaccgg caagcaatag ctctgagtc ctcaccctct	5460	
cttttggtgg ggtatccatg tcctcgggat caattttcga cggagagacg gccgcgccag	5520	
cagcgtgaca acccctggga acaggcccca cggatgtgcc tatgtctttt ggatcgtttt	5580	
ccgacggaga gattgatgag ctgagccgca gagtaactga gtccgaacc gtcctgtttg	5640	
gatcatttga accgggcgaa gtgaactcaa ttatatcgtc ccgatcagcc gtatcttttc	5700	
cactacgcaa gcagagacgt agacgcagga gcaggaggac tgaatactga ctaaccgggg	5760	
tagtggggta catattttcg acggacacag gccctgggca cttgcaaaag aagtccgttc	5820	
tgcagaacca gcttacagaa ccgaccttgg agcgcaatgt cctggaaaga attcatgcc	5880	
cgggtgctga cacgtcgaaa gaggaacaac tcaactcag gtaccagatg atgccaccg	5940	
aagccaacaa aagtaggtac cagtctcgta aagtagaaaa tcagaaagcc ataaccactg	6000	
agcgactact gtcaggacta cgactgtata actctgccac agatcagcca gaatgtcata	6060	
agatcaccta tccgaacca ttgtactcca gtacgttacc ggcgaactac tccgatccac	6120	
agttcgtgt agctgtctgt aacaactatc tgcattgaga ctatccgaca gtacatctt	6180	
atcagattac tgacagtagc gatgcttact tggatatggt agacgggaca gtcgcctgcc	6240	
tggatactgc aacctttctg ccgctaagc ttagaagtta cccgaaaaaa catgagtata	6300	
gagccccgaa tatccgcagt gcggttccat cagcagtgca gaacacgcta caaaatgtgc	6360	
tcattgccgc aactaaaaga aattgcaacg tcacgcagat gcgtgaactg ccaactctgg	6420	
actcagcgac attcaatgtc gaatgctttc gaaaatatgc atgtaatgac gagtattggg	6480	
aggagtctgc tcggaagcca attaggatta ccactgagtt tgtcaccgca tatgtagcta	6540	
gactgaaggg ccctaaggcc gccgcactat ttgcaaagac gtataatttg gtcccattgc	6600	
aagaagtgcc tatggataga ttctcatggt acatgaaaa agacgtgaaa gttacaccag	6660	
gcacgaacaa cacagaagaa agaccgaaag tacaagtgat acaagccgca gaacccctgg	6720	
cgactgctta cttatgcggg attcaccggg aattagtgcg taggcttacg gccgtcttgc	6780	
ttccaacact tcacacgctt ttgacatgt cggcggagga tttgatgca atcatagcag	6840	
aacacttcaa gcaaggcgac ccggtactgg agacggatat gcatcattc gacaaagcc	6900	
aagacgacgc tatggcgtta accggctcta tgatcttggg ggacctgggt gtggatcaac	6960	
cactactcga cttgatcgag tgcgcccttg gagaaatata atccacccat ctacctacgg	7020	
gtactcgttt taaattcggg gcgatgatga aatccggaat gttcctcaca cttttgtgca	7080	

CI0043PCTseqlisting.ST25

acacagtttt	gaatgtcggt	atcgccagca	gagtactaga	agagcggctt	aaaacgtcca	7140
gatgtgcagc	gttcattggc	gacgacaaca	tcatacatgg	agtagtatct	gacaaagaaa	7200
tggctgagag	gtgcgccacc	tggctcaaca	tggagggtta	gatcatcgac	gcagtcacg	7260
gtgagagacc	accttacttc	tgcggcggat	ttatcttgca	agattcgggt	acttccacag	7320
cgtgccgcgt	ggcggatccc	ctgaaaaggc	tgtttaagtt	gggtaaaccg	ctcccagccg	7380
acgacgagca	agacgaagac	agaagacgcg	ctctgctaga	tgaacaaaag	gcgtgggtta	7440
gagtaggtat	aacaggcact	ttagcagtgg	ccgtgacgac	ccggtatgag	gtagacaata	7500
ttacacctgt	cctactggca	ttgagaactt	ttgccacgag	caaaagagca	ttccaagcca	7560
tcagagggga	aataaagcat	ctctacgggt	gtcctaaata	gtcagcatag	tacatttcac	7620
ctgactaata	ctacaacacc	accaccatga	atagaggatt	ctttaacatg	ctcggccgcc	7680
gccccttccc	ggccccact	gccatgtgga	ggccgcggag	aaggaggcac	gcggccccga	7740
tgccctgccg	caacgggctg	gcttctcaaa	tccagcaact	gaccacagcc	gtcagtgccc	7800
tagtcattgg	acaggcaact	agacctcaac	ccccacgtcc	acgcccgcga	ccgcgccaga	7860
agaagcaggg	gcccaagcaa	ccaccgaagc	cgaagaaacc	aaaaacgcag	gagaagaaga	7920
agaagcaacc	tgcaaaaccc	aaaccgggaa	agagacacgc	catggcactt	aagtgtggag	7980
ccgacagatt	gttcgacgtc	aagaacgagg	acggagatgt	catcgggcac	gcactggcca	8040
tggaaggaaa	ggtaatgaaa	cctctgcacg	tgaagggaac	catcgaccac	cctgtgctat	8100
caaagtcaaa	atttaccagg	tcgtcagcat	acgacatgga	gttcgcacag	ttagccagtca	8160
acatgagaag	tgaggcattc	acctacacca	gtgaacaccc	cgaaggattc	tataactggc	8220
accacggagc	gggtgcagtat	agtggaggta	gatttaccat	ccctcgcgga	gtaggaggca	8280
gaggagacag	cggtcgctcg	atcatggata	actccggctc	ggtgtgctcg	atagtcctcg	8340
gtggcgctga	tgaaggaaac	cgaaactgcc	tttcggtcgt	cacctggaat	agtaaaggga	8400
agacaattaa	gacgaccccg	gaagggcagc	aagagtggtc	cgacgaccca	ctggtcacgg	8460
caatgtgttt	gctcggaagt	gtgagcttcc	catgcgaccg	cccgccca	tgctataacc	8520
gcgaaccttc	cagagccctc	gacatccttg	aagagaacgt	gaacctgag	gcctacgata	8580
ccctgtctaa	tgccatattg	cggtgcggat	cgctctggac	aagcaaaaga	agcgctcattg	8640
acgactttac	cctgaccagc	ccctacttgg	gcacatgtct	gtactgccac	catactgtac	8700
cgctgctcag	ccctgttaag	atcgagcagg	tctgggacga	agcggacgat	aacaccatac	8760
gcatacagac	ttccgcccg	tttgatacg	accaaagcgg	agcagcaagc	gcaaaccaagt	8820
accgctacat	gtgcgttaag	caggatcaca	ccgttaaaga	aggcaccatg	gatgacatca	8880
agattagcac	ctcaggaccg	tgtagaaggc	ttagctacaa	aggatacttt	ctctctgcaa	8940
aatgcccttc	aggggacagc	gtaacgggta	gcatagtgag	tagcaactca	gcaacgtcat	9000
gtcacctggc	ccgcaagata	aaacccaaat	tcgtgggacg	ggaaaaatat	gatctacctc	9060
ccgttcacgg	taaaaaaatt	ccttgcacag	tgtacgaccg	tctgaaagaa	acaactgcag	9120

CI0043PCTseqlisting.ST25

gctacatcac	tatgcacagg	ccgagaccgc	acgcttatac	atcctacctg	gaagaatcat	9180
cagggaagt	ttacgcaaa	ccgccatctg	ggaagaacat	tacgtatgag	tgcaagtgcg	9240
gcgactacaa	gaccggaacc	gtttcgaccc	gcaccgaaat	actggttgc	accgccatca	9300
agcagtgcgt	cgctataaag	agcgaccaa	cgaagtgggt	cttcaactca	cggacttga	9360
tcagacatga	cgaccacacg	gcccaaggga	aattgcattt	gcctttcaag	ttgatcccg	9420
gtacctgcat	ggtccctggt	gcccacgcgc	cgaatgtaat	acatggcttt	aaacacatca	9480
gcctccaatt	agatacagac	cacttgacat	tgctcaccac	caggagacta	ggggcaaac	9540
cggaaacca	cactgaatgg	atcgtcgga	agacggtcag	aaacttcacc	gtcgaccgag	9600
atggcctgga	atacatatgg	ggaaatcatg	agccagtga	ggtctatgcc	caagagtcag	9660
caccaggaga	ccctcacgga	tggccacacg	aaatagtaca	gcattactac	catcgccatc	9720
ctgtgtacac	catcttagcc	gtcgcacatg	ctaccgtggc	gatgatgatt	ggcgtaactg	9780
ttgcagtgtt	atgtgctctg	aaagcgcgcc	gtgagtgcct	gacgccatac	gccttgccc	9840
aaacgcctg	aatcccaact	tcgctggcac	tcttgtgctg	cgtaggtcg	gccaatgctg	9900
aaacgttcac	cgagaccatg	agttacttgt	ggtcgaacag	tcagccgttc	ttctgggtcc	9960
agttgtgcat	acctttggcc	gctttcatcg	ttctaattcg	ctgctgtccc	tgctgcctgc	10020
cttttttagt	ggttgccggc	gcctacctgg	cgaaggtaga	cgctacgaa	catgcgacca	10080
ctgttccaaa	tgtgccacag	ataccgtata	aggcacttgt	tgaaggggca	gggtatgccc	10140
cgctcaattt	ggagatcact	gtcatgtcct	cggaggtttt	gccttcacc	aaccaagagt	10200
acattacctg	caaattcacc	actgtggctc	ctccccaaa	aatcaaatgc	tgcggtcctt	10260
tggaaatgta	gccggccgct	catgcagact	atactgcaa	ggtcttcgga	ggggtctacc	10320
cttttatgtg	gggaggagcg	caatgttttt	gcgacagtga	gaacagccag	atgagtgaag	10380
cgtacgtcga	attgtcagca	gattgcgcgt	ctgaccacgc	gcaggcgatt	aaggtgcaca	10440
ctgcccgat	gaaagttaga	ctgcgtattg	tgtacgggaa	cactaccagt	ttctagatg	10500
tgtactgtga	cggagtca	ccaggaaact	ctaaagactt	gaaagtcata	gctggaccaa	10560
tttcagcatc	gtttacgcca	ttcgtacata	aggtcgttat	ccatcgcggc	ctggtgtaca	10620
actatgactt	cccgaatat	ggagcgatga	aaccaggagc	gtttgagac	attcaagcta	10680
ctccttgac	tagcaaggat	ctcatcgcca	gcacagacat	taggtactc	aagccttcg	10740
ccaagaactg	gcattgtccc	tacacgcagg	ctcatcagg	atttgatg	tggaaaaaca	10800
actcaggccg	cccactgcag	gaaaccgcac	cttcgggtg	taagattgca	gtaaatccgc	10860
tccgagcgtg	ggaactgtta	tacgggaaca	ttccatttc	tattgaatc	ccgaacgctg	10920
cttttatcag	gacatcagat	gcaccactgg	tctcaacagt	caaatgtgaa	gtcagtgaat	10980
gcacttattc	agcagacttc	ggcgggatgg	ccaccctgca	gtatgtatcc	gaccgcgaag	11040
gtcaatgcc	cgtacattcg	cattcgagca	cagcaactct	ccaagagtcg	acagtacatg	11100
tcctggagaa	aggagcgggtg	acagtacact	ttagcaccgc	gagtcacacg	gcgaacttta	11160

CI0043PCTseqlisting.SR25

tcgtatcgct	gtgtgggaag	aagacaacat	gcaatgcaga	atgtaaacca	ccagctgacc	11220
atatctgtgag	caccccgcac	aaaaatgacc	aagaatttca	agccgccatc	tcaaaaacat	11280
catggagttg	gctgtttgcc	cttttcggcg	gcgcctcgct	gctattaatt	ataggactta	11340
tgatttttgc	ttgcagcatg	atgctgacta	gcacacgaag	atgaccgcta	cgccccaatg	11400
atccgaccag	caaaactcga	tgtacttcgg	aggaactgat	gtgcataatg	catcaggctg	11460
gtacattaga	tccccgctta	ccgcgggcaa	tatagcaaca	ctaaaaactc	gatgtacttc	11520
cgaggaaagc	cagtgcataa	tgctgcgcag	tgttgccaca	taaccactat	attaaccatt	11580
tatctagcgg	acgccaaaaa	ctcaatgtat	ttctgaggaa	gcgtggtgca	taatgccacg	11640
cagcgtctgc	ataactttta	ttatttcttt	tattaatcaa	aaaaattttg	tttttaacat	11700
ttc						11703

<210> 5
 <211> 10945
 <212> DNA
 <213> West Nile virus

<400> 5	
gaggattaac	aacaattaac
aagaaaccag	gagggcccg
cgctgttgt	ccttgattgg
ccaatacgat	ttgtgttggc
cgagcagtg	tggtcagtg
agtttaaga	aggaactagg
aagaaagag	gaggaagac
gcagttacc	tctctaactt
acagatgtca	tcacgattcc
gatgtgggat	acatgtgcga
aatgatccag	aagacatcga
agatgcacca	agacacgcc
ggagaaagca	ctctagcgaa
tatttggtaa	aaacagaatc
gtcattggtt	ggatgcttgg
cttttggtag	ccccagctta
gaaggagtgt	ctggagcaac
atcatgtcta	aggacaagcc
ctggcagagg	tccgcagtta
gcgtgcccca	ccatggggga
agacaaggag	tggtgggacg
	gggctggggc
	aacggctgcg
	gactatttgg
	caaagggaag

CI0043PCTseqlisting.ST25

attgacacat	gcgccaatt	tgctgtctc	accaaggcaa	taggaagaac	catcttgaaa	1320
gagaatatca	agtacgaagt	ggccattttt	gtccatggac	caactactgt	ggagtcgcac	1380
ggaaactact	ccacacaggt	tggagccact	caggcaggga	gattcagcat	cactcctcgc	1440
gcgccttcat	acacactaaa	gcttggagaa	tatggagagg	tgacagtgga	ctgtgaacca	1500
cggtcaggga	ttgacacaa	tgcatactac	gtgatgactg	ttggaacaaa	gacgtctctg	1560
gtccatcgtg	agtgttctat	ggacctcaac	ctcccttgga	gcagtgtctg	aagtactgtg	1620
tggaggaaaca	gagagacgtt	aatggagttt	gaggaaccac	acgccacgaa	gcagtcgtg	1680
atagcattgg	gctcacaa	gggagctctg	catcaagctt	tggctggagc	cattcctgtg	1740
gaattttcaa	gcaactactg	caagttgacg	tcgggtcatt	tgaagtgtag	agtgaagatg	1800
gaaaaattgc	agttgaaggg	aacaacctat	ggcgtctgtt	caaaggcttt	caagtttctt	1860
gggactccgc	cagacacagg	tcacggcact	gtggtgttgg	aattgcagta	cactggcacg	1920
gatggacctt	gcaaagtctc	tatctcgtca	gtggcttcat	tgaacgacct	aacgccagtg	1980
ggcagattgg	tcactgtcaa	cccttttgtt	tcagtggcca	cgccaacgc	taaggtcctg	2040
attgaattgg	aaccaccctt	tggagactca	tacatagtgg	tgggcagagg	agaacaacag	2100
atcaatcacc	attgacaaa	gtctggaagc	agcattggca	aagcctttac	aaccaccctc	2160
aaaggagcgc	agagactagc	cgctctagga	gacacagctt	gggactttgg	atcagttgga	2220
gggtgttca	cctcagttgg	gaaggctgtc	catcaagtgt	tcggaggagc	attccgtcca	2280
ctgttcggag	gcattgtcctg	gataacgcaa	ggattgtctg	gggtctctct	gttgtggatg	2340
ggcatcaatg	ctcgtgatag	gtccatagct	ctcacgtttc	tcgcagttgg	aggagtcttg	2400
ctcttctctc	ccgtgaacct	gcacgctgac	actgggtgtg	ccataaacat	caccggcaca	2460
gagctgagat	gtggaagtgg	agtgttcata	cacaatgatg	tggaggcttg	gatggaccgg	2520
tacaagtatt	accctgaaac	gccacaaggc	ctagccaaga	tcattcagaa	agctcataag	2580
gaaggagatg	gcggtctacg	atcagtttcc	agactggagc	atcaaatgtg	ggaagcagtg	2640
aaggagcagc	tgaacactcc	tttgaaggag	aatggtgtgg	accttagtgt	cgtggttgag	2700
aaacaggagg	gaatgtacaa	gtcagcacct	aaacgcctca	ccgccaccac	ggaaaaattg	2760
gaaattggct	ggaaggcctg	gggaaagagt	attttatttg	caccagaact	cgccaacaac	2820
acctttgtgg	ttgatgggtc	ggagaccaag	gaatgtccga	ctcagaatcg	cgcttggaa	2880
agcttagaag	tggaggattt	tggatttgg	ctcaccagca	ctcggatgtt	cctgaaggct	2940
agagaaggca	acacaactga	atgtgactcg	aagatcattg	gaacggctgt	caagaacaac	3000
ttggcgatcc	acagtgacct	gtcctattgg	attgaaagca	ggctcaatga	tacgtggag	3060
cttgaagggg	cagttctggg	tgaagtcaaa	tcatgtacgt	ggcctgagac	gcatacctg	3120
tggggcgatg	gaatccttga	gagtgacttg	ataataccag	tcacactggc	gggaccacga	3180
agcaatcaca	atcgagagac	tgggtacaag	acacaaaacc	agggcccatg	ggacgaaggc	3240
cgggtagaga	ttgacttcga	ttactgccca	ggaactacgg	tcaccttgag	tgagagctgc	3300

CI0043PCTseqlisting.ST25

ggacaccgtg	gacctgccac	tcgcaccacc	acagagagcg	gaaagtgtgat	aacagattgg	3360
tgctgcagga	gctgcacctt	accaccactg	cgctaccaaa	ctgacagcgg	ctgttgggtat	3420
ggtatggaga	tcagaccaca	gagacatgat	gaaaagacc	tcgtgcagtc	acaagtgaat	3480
gcttataatg	ctgatgatgt	tgacctttt	cagttgggccc	ttctggctgt	gttcttggcc	3540
accaggagg	tccttcgcaa	gaggtggaca	gccaaagatca	gcatgccagc	tatactgatt	3600
gctctgctag	tcttgggtgt	tgggggcatt	acttacactg	atgtgtttacg	ctatgtctac	3660
ttggtggggg	cagctttcgc	agaatctaata	tcggggaggag	acgtgggtaca	ctttgcgctc	3720
atggcgacct	tcaagatata	accagtgttt	atgggtggcat	cgtttctcaa	agcgagatgg	3780
accaaccagg	agaacatttt	gttgatgttg	gcggctgttt	tctttcaaat	ggcttatcac	3840
gatgcccgcc	aaattctgct	ctgggagatc	cctgatgtgt	tgaattcact	ggcggtagct	3900
tggtatgata	tgagagccat	aacattcaca	acgacatcaa	acgtgggtgt	tccgctgcta	3960
gcctctgtaa	caccgggctg	gagatgcttg	aatctggatg	tgtacaggat	actgctgttg	4020
atggtcggaa	taggcagctt	gatcaggagg	aagaggagtg	cagctgcaaa	aaagaaagga	4080
gcaagtctgc	tatgcttggc	tctagcctca	acaggacttt	tcaaccccat	gatccttgct	4140
gctggactga	ttgatgtga	tccaacagt	aaacgggag	ggcccgaac	tgaagtgatg	4200
acagctgtcg	gcctaattgt	tgccatcgtc	ggagggtctg	cagagcttga	cattgactcc	4260
atggccattc	caatgactat	cgcggggctc	atgttttctg	ctttcgtgat	ttctgggaaa	4320
tcaacagata	tgtggattga	gagaacggcg	gacatttctc	gggaaagtga	tgcagaatt	4380
acaggctcga	gcgaaagagt	tgatgtgcgg	cttgatgatg	atggaaactt	ccagctcatg	4440
aatgatccag	gagcaccttg	gaagatatgg	atgctcagaa	tggctctgtc	cgcgattagt	4500
gcgtacaccc	cctgggcaat	cttgccctca	gtagtgggat	ttggataaac	tctccaatac	4560
acaaagagag	gagggcgtgt	gtgggacact	ccctcaccaa	aggagtacaa	aaagggggac	4620
accaccaccg	gcgtttacag	gatcatgact	cgtgggctgc	tcggcagtta	tcaagcagga	4680
gcgggcgtga	tggttgaagg	tggtttccac	accctttggc	atacaacaaa	aggagcgct	4740
ttgatgagcg	gagaggggcg	cctggaccac	tactggggcg	gtgtcaagga	ggatcgactt	4800
tgttacggag	gaccttggaa	attgcagcac	aagtggaaacg	ggcaggatga	ggtgcagatg	4860
attgtgtgtg	aacttggcaa	gaacgttaag	aacgtccaga	cgaaccagg	ggtgttcaaa	4920
acacctgaag	gagaaatcgg	ggcgtgact	ttggacttcc	ccactggaac	atcaggctca	4980
ccaatagtgg	acaaaaacgg	tgatgtgatt	gggctttatg	gcaatggagt	cataatgcc	5040
aacggctcat	acataagcgc	gatagtgcag	ggtgaaagga	tggtatgagcc	aatccagcc	5100
ggattcgaac	ctgagatgct	gaggaaaaaa	cagatcactg	tactggatct	ccatccggcg	5160
gcgggtaaaa	caaggaggat	tctgccacag	atcatcaaa	aggcataaaa	cagaagactg	5220
agaaacagccg	tgctagcacc	aaccagggtt	gtggctgctg	agatggctga	agcactgaga	5280
ggactgcccc	tccggtacca	gacatccgca	gtgccagag	aacataatgg	aaatgagatt	5340

CI0043PCTseqlisting.ST25

gttgatgtca	tgtgtcatgc	taccctcacc	cacaggctga	tgtctcctca	cagggtgccg	5400
aactacaacc	tgttcgtgat	ggatgaggct	catttcaccg	accagcgtag	cattgcagca	5460
agaggttaca	tttccacaaa	ggtcgagcta	ggggaggcgg	cggcaatatt	cgtgacagcc	5520
accgccacga	gcacttcaga	tccattccca	gagtcctaatt	caccaatttc	cgacttacag	5580
actgagatcc	cgatcgcagc	ttggaaactct	ggatacgaat	ggatcacaga	atacacggg	5640
aagacgggtt	ggtttgtgcc	tagtgtcaag	atggggaatg	agattgccct	ttgcctacaa	5700
cgtgctggaa	agaagtagt	ccaattgaac	agaagtcgt	acgagacgga	gtacccaaaa	5760
tgtaagaacg	atgattggga	ctttgttatt	acaacagaca	tatctgaaat	gggggctaac	5820
ttcaaggcga	gcagggtgat	tgacagccgg	aagagtgatga	aaccaacctat	cataacagaa	5880
ggagaaggga	gagtgatcct	gggagaacca	tctgcagtga	cagcagctag	tgccgcccg	5940
agacgtggac	gtatcggtag	aaatccgtcg	caagttgggtg	atgagtactg	ttatgggggg	6000
cacacgaatg	aagacgactc	gaacttcgcc	cattggactg	aggcacgaat	catgctggac	6060
aacatcaaca	tgccaaacgg	actgatcgct	caattctacc	aaccagagcg	tgagaaggta	6120
tataccatgg	atggggaata	ccggctcaga	ggagaagaga	gaaaaaactt	tctggaactg	6180
ttgaggactg	cagatctgcc	agtttggtg	gcttacaagg	ttgcagcgcc	tgagtgctca	6240
taccacgacc	ggaggtggtg	ctttgatggt	cctaggacaa	acacaatttt	agaagacaac	6300
aacgaagtgg	aagtcatcac	gaagcttggt	gaaaggaaga	ttctgaggcc	gcgctggatt	6360
gacgccaggg	tgtactcgga	tcaccaggca	ctaaaggcgt	tcaaggactt	gcctcgggga	6420
aaacgttctc	agatagggtc	cattgaggtt	ctgggaaaga	tgcttgagca	cttcattggg	6480
aagacatggg	aagcacttga	caccatgtac	gttgtggcca	ctgcagagaa	aggaggaaaga	6540
gtccacagaa	tggccctgga	ggaactggca	gatgctcttc	agacaattgc	cttgattggc	6600
ttattgagtg	tgatgacct	gggagtattc	ttctctctca	tgacgcggaa	gggcattgga	6660
aagataggtt	tgggaggcgc	tgctctggga	gtagcgacct	ttttctgttg	gatggctgaa	6720
gttccaggaa	cgaagatcgc	cggaatgttg	ctgctctccc	ttctcttgat	gatttgtgta	6780
attcctgagc	cagagaagca	acgttcgcag	acagacaacc	agctagccgt	gttcttgatt	6840
tgtgtcatga	cccttgtgag	cgcagtggca	gccaacgaga	tggttggtct	agataagacc	6900
aagagtga	taagcagttt	gtttgggcaa	agaattgagg	tcaaggagaa	tttcagcatg	6960
ggagagtttc	tcttgactt	gaggccggca	acagcctggt	cactgtacgc	tgtgacaaca	7020
gcggtctcta	ctccactgct	aaagcatttg	atcacgtcag	attacatcaa	cacctcattg	7080
acctcaataa	acgttcaggc	aagtgcacta	ttcacactcg	cgcgaggctt	cccctctgct	7140
gatgttgtag	tgtcggtctt	cctgctagca	gccggatgct	ggggacaagt	caccctcacc	7200
gttacggtaa	cagcggcaac	actccttttt	tgccactatg	cctacatggt	tcccggttgg	7260
caagctgagg	caatgcctc	agccacgcgg	cggacagcgg	ccggaatcat	gaagaacgct	7320
gtagtggatg	gcactgtggc	cacggacgct	ccagaattag	agcgaccacc	acctcatcatg	7380

CI0043PCTseqIisting.ST25

cagaagaaag	ttggacagat	catgctgac	ttggtgtctc	tagctgcagt	agtagtgaac	7440
ccgtctgtga	agacagtacg	agaagccgga	attttgatca	cggccgcagc	ggtgacgctt	7500
tgggagaatg	gagcaagctc	tgtttggaac	gcaacaactg	ccatcggact	ctgccacatc	7560
atgctgtggg	gttggttgtc	atgtctatcc	ataacatgga	cactcataaa	gaacatggaa	7620
aaaccaggcc	taaaaagagg	tggggcaaaa	ggagcgacct	tgggagaggt	ttggaagaaa	7680
agactcaacc	agatgacaaa	agaagagttc	actaggtacc	gcaaaagggc	catcatcgaa	7740
gtcgatcgct	cagcggcaaa	acacgccagg	aaagaaggca	atgtcactgg	agggcattcca	7800
gtctctaggg	gcacagcaaa	actgagatgg	ctggtcgaac	ggaggtttct	cgaaccggtc	7860
ggaaaagtga	ttgaccttgg	atgtggaaga	ggcggttggt	gttactatat	ggcaacccaa	7920
aaaagagtcc	aagaagtcag	agggtacaca	aaaggcgggc	ccggacatga	agagcccaa	7980
ctagtgcata	gttatggatg	gaacattgtc	accatgaaga	gtggagtggg	tgtgtcttac	8040
agaccttctg	agtgttgtga	cacctctctt	tgtgacatcg	gagagtcctc	gtcaagtgtc	8100
gagggtgaag	agcataggac	gattcgggtc	cttgaatagg	ttgaggactg	gctgcaccga	8160
gggccaaagg	aattttcgct	gaaggtgctc	tgcccctaca	tgccgaagg	catagagaag	8220
atggagctgc	tccaacgcgc	gtatgggggg	ggactggtca	gaaacccact	ctcacgggat	8280
tccacgcacg	agatgtattg	ggtgagtcga	gcttcaggca	atgtgtgtaca	ttcagtgat	8340
atgaccagcc	aggtgtcctc	aggaagaatg	gaaaaaagg	cctggaagg	accccaatac	8400
gaggaagatg	taaacttggg	aagtggaaac	agggcggtgg	gaaaaccctc	gctcaactca	8460
gacaccagta	aaatcaagaa	caggattgaa	cgactcaggc	gtgagtacag	ttcgactgtg	8520
caccacgatg	agaaccaccc	atatagaacc	tggaactacc	acggcagtta	tgatgtgaag	8580
cccacagctc	cgcgcagttc	gctggtcaat	ggagtgtgtc	ggctcctctc	aaaaccatgg	8640
gacaccatca	cgaatgttac	caccatggcc	atgactgaca	ctactccctt	cgggcagcag	8700
cgagtgttca	aagagaaggt	ggacacgaaa	gctcctgaac	gcgcagaagg	agtgaagtac	8760
gtgtctaacg	agaccaccaa	ctggttgtgg	gcgtttttgg	ccagagaaaa	acgtcccaga	8820
atgtgtcttc	gagaggaatt	cataagaaag	gtcaacagca	atgcagcttt	gggtgccatg	8880
tttgaagagc	agaatcaatg	gaggagcgcc	agagaagcag	ttgaagatcc	aaatttttgg	8940
gagatggtgg	atgaggagcg	cgaggcacat	ctgcgggggg	aatgtcacac	ttgcatttac	9000
aacatgatgg	gaaagagaga	gaaaaaaccc	ggagagttcg	gaaaggccaa	gggaagcaga	9060
gccatttgtg	tcatgtggtc	cggagctcgc	tttctggagt	tcgaggtctc	gggttttctc	9120
aatgaagacc	actgtgcttg	aagaagaac	tcaggagagg	gtgtcgaggg	cttgggcctc	9180
caaaaactgg	gttacctcct	gcgtgaagtt	ggcaccgggc	ctgggggcaa	gatctatgct	9240
gatgacacag	ctggctggga	caccgcacac	acgagagctg	acttgaaaa	tgaagctaag	9300
gtgcttgagc	tgcttgatgg	ggaacatcgg	cgtcttgcca	gggccatcat	tgagctcacc	9360
tatcgtcaca	aagttgtgaa	agtgtatgccc	ccggctgctg	atggaagaac	cgctcatggat	9420

CI0043PCTseqlisting.ST25

gttatctcca gagaagatca gagggggagt ggacaagttg tcacctacgc cctaaacact 9480
 ttcaccaacc tggccgtcca gctggtgagg atgatggaag ggaaggaggt gattggccca 9540
 gatgatgtgg agaaactcac aaaagggaaa ggacccaag tcaggacctg gctgtttgag 9600
 aatggggaag aaagactcac cgcgtggt gtcagtggag atgactgtgt ggtaaagccc 9660
 ctggacgatc gctttgccac ctgcgtccac ttcttcaatg ctatgtcaaa ggttcgcata 9720
 gacatccaaag agtggaaacc gtcaactgga tggatgatt ggcagcaggt tccattttgc 9780
 tcaaaccatt tcactgaatt gatcatgaaa gatggaagaa cactggtggt tccatgcga 9840
 ggacaggatg aattggtagg cagagctcgc atatctccag gggccggatg gaacgtccgc 9900
 gacactgctt gtctggctaa gtcttatgcc cagatgtggc tgcttctgta cttccacaga 9960
 agagacctgc ggctcatgac caacgccatt tgctccgctg tccctgtgaa ttgggtccct 10020
 accggaagaa ccacgtggtc catccatgca ggaggagagt ggaatgacaac agaggacatg 10080
 ttggaggctc ggaaccgtgt ttggatagag gagaatgaat ggaatggaaga caaaacccca 10140
 gtggagaagt ggagtacgt cccatattca ggaaaacgag aggacatctg gtgtggcagc 10200
 ctgatttgca caagagccc agccacgtgg gcagaaaaca tccaggtggc tatcaaccaa 10260
 gtcagagcaa tcactcggaga tgagaagtat gtggattaca tgagtccact aaagagatat 10320
 gaagacacaa ctttggttga ggacacagta ctgtagatat ttaatcaatt gtaaatagac 10380
 aataaagta tgcataaaag tgtagtttta tagtagtatt tagtggtggt agtgtaata 10440
 gttaaagaaa ttttgaggag aaagtcaggc cgggaagttc ccgccaccg aaagttgagta 10500
 gacggtgctg cctgcgactc aacccaggga ggactgggtg aacaaagccg cgaagtgtac 10560
 catgtaagcc ctcaagaacc tctcggaaag aggacccac atgttgtaac ttcaagccc 10620
 aatgtcagac cagcgtacgg cgtgctactc tgcggagagt gcagctctgc atagtgtccc 10680
 aggaggtggt ggtttaacaa ggcaaaccaa cgccccacgc ggcctagcc ccgtaatgg 10740
 tgtaaacagg ggcgaagga ctagaggtta gaggagacc cgcgggttaa agtgacggc 10800
 ccagcctggc tgaagtgtga ggtcagggga aggactagag gttagtggag accccgtgcc 10860
 acaaaacacc acaaaaaac agcatattga cacctgggat agactaggag atcttctgct 10920
 ctgcacaacc agccacacgg cacag 10945

<210> 6
 <211> 1542
 <212> DNA
 <213> Escherichia coli 16S Ribosomal RNA

<220>
 <221> misc_feature
 <222> (896)..(896)
 <223> n is a, c, g, or t

<400> 6
 aaattgaaga gtttgatcat ggctcagatt gaacgctggc ggcaggccta acacatgcaa 60

CI0043PCTseqlisting.ST25

gtcgaacggt aacaggaakc agcttgctga ttgtctgacg agtggcgac	gggtgagtaa	120
tgctctggaa actgcctgat ggagggggat aactactgga aacggtagct aataccgcat		180
aacgtcgcaa gaccaagag ggggaccttc gggcctcttg ccactcggatg tgcccagatg		240
ggattagcta gtagggtggg taaaggctca cctaggcgac gatccctagc tggctctgaga		300
ggatgaccag ccactctgga actgagacac ggtccagact cctacgggag gcagcagtgg		360
ggaatattgc acaatggcg caagcctgat gcagccatgc cgcgtgtatg aagaaggcct		420
tcgggttgta aagtactttc agcggggagg aaggagtaa agttaatacc ttgtctcatt		480
gacgttacc gcagaagaag caccggctaa ctccgtgcc aacgccgag taatacggag		540
ggtgcaagcg ttaatcgaa ttactgggag taaagcgac gcaggcggt ttgtaagtca		600
gatgtgaaat ccccgggctc aacctgggaa ctgcattctga tactggcaag cttagtctc		660
gtagaggggg gtagaattcc aggtgtagcg gtgaaatgag tagagatctg gaggaatacc		720
ggtggcgaa gcggcccttc ggacgaagac tgacgctcag gtgcgaaagc gtggggagca		780
aacaggatta gataccctgg tagtccacgc cgtaaacgat gtcgacttgg aggttctgac		840
cttgaggcgt ggcttcgga gctaacgcgt taagtckacc gcctgggagac tacgngcga		900
aggttaaaac tcaaatgaa tgacggggcg ccgcacaagc ggtggagcat gtggtttaat		960
tcgatgaac gcgaagaacc ttacctggtc ttgacatcca cagaacttcc cagagatgga		1020
ttgggtcctt cggaactgt gagacagggt ctgcatggct tcgctcagct cgtgttgta		1080
aatgttgggt taagtccgc aacgagcgca acccttatcc ttgttgcca gcggtccgac		1140
cggaactca aaggagactg ccagtataa actggaggaa ggtggggatg acgtcaagtc		1200
atcatggccc ttacgaccag ggctacacac gtgtacaat ggcgcataca aagagaagcg		1260
ayctcgag agcaagcgga cctcataaag tgcgtcgtag tccggattgg agtctgcaac		1320
tcgactccat gaagtcggaa tcgctagtaa tcgtggatca gaatgccacg gtgaatacgt		1380
tccgggacct tgtacacacc gcccgtcaca ccattggagt gggttgcaa agaagtaggt		1440
agcttaacct tcgggggggc gcttaccact ttgtgattca tgactggggg gaagtctgaa		1500
caaggtaacc gtaggggaac ctgcggttg atcacctcct ta		1542

<210> 7
 <211> 2905
 <212> DNA
 <213> Escherichia coli 23 S Ribosomal RNA

<400> 7	
ggttaagcga ctaagcgtac acggtggatg ccctggcagt cagaggcgat gaaggacgtg	60
ctaattctcg ataagcgtg gtaaggtgat atgaaccgtt ataaccggcg atttcggaat	120
ggggaacc agtgtgtttc gacacactat cattaactga atccataggt taatgaggcg	180
aaccggggga actgaaacat ctaagtaccg cgaggaaaag aaatcaaccg agattccccc	240
agtagcggcg agcgaacggg gagcagccca gagcctgaat cagtgtgtgt gttagtggaa	300
gcgtctggaa aggcgcgcga tacagggtga cagccccgta cacaaaaatg cacatgctgt	360

CI0043PCTseq1isting.ST25

gagctcga	atg	agggcgg	gacacgtg	atcctgtc	aatatgggg	gaccatcctc	420
caaggctaaa	tactcctgac	tgaccgatag	tgaaccagta	ccgtgagggg	aaggcgaaaa		480
gaaccccgcc	gaggggagtg	aaaaagaacc	tgaaccctg	tacgtacaag	cagtgaggagc		540
acgcttaggc	gtgtgactgc	gtacctttg	tataatgggt	cagcgactta	tattctgtag		600
caaggttaac	cgaatagggg	agccgaagg	aaaccgagtc	ttaactgggc	gttaagttgc		660
agggatatga	cccgaacccc	gggtgatctag	ccatggggcag	gttgaaggct	gggtaacact		720
aactggagga	ccgaaccgac	taatgttgaa	aaattagcgg	atgactttgtg	gctgggggtg		780
aaaggccaat	caaaccggga	gatagctggg	tctcccgaa	agctatttag	gtagcgcttc		840
gtgaattcat	ctccgggggt	agagcactgt	ttcggcaagg	gggtcatccc	gacttaccaa		900
cccgatgcaa	actgcgaata	ccggagaatg	ttatcacggg	agacacacgg	cggggtgctaa		960
cgtccgtcgt	gaagagggga	acaaccgaga	ccgccagcta	aggtcccaaa	gtcatgtgta		1020
agtgggaaac	gatgtgggaa	ggcccagaca	gccaggatgt	tggcttagaa	gcagccatca		1080
tttaaaagaaa	gcgttaatag	tcactggtcg	agtcggcctg	cgcggaagat	gtacgggggc		1140
taaacactgc	accgaagctg	cggcagcgac	gcttatgcgt	tggttggttag	gggagcggtc		1200
tgtaagcctg	cgaagggtgtg	ctgtgaggca	tgctggagg	atcagaagtg	cgaatgctga		1260
cataagtaac	gataaaagcg	gtgaaaagcc	gcctcgccgg	aagaccaagg	gttcctgttc		1320
aacgttaatc	ggggcagggt	gagtcgacc	ctaaggcgag	gccgaaaggc	gtagtcgatg		1380
ggaaacaggt	taatatctct	gtacttggtg	ttactgcgaa	ggggggacgg	agaaggctat		1440
gttgccggg	cgacggtgtg	cccggtttaa	gcgtgtaggc	tggttttcca	ggcaaatccg		1500
gaaaaatcaa	gctgaggcgt	gatgacgagg	cactacgggt	ctgaagcaac	aaatgcctg		1560
cttcaggaaa	aagcctcttaa	gcatcaggta	acatcaaatc	gtaccccaaa	ccgacacagg		1620
tggtcaggtg	gagaaatacca	agggcgctga	gagaactcgg	gtgaaggaaac	taggcagaaat		1680
ggtgcccgtg	cttcggggaga	aggcacgctg	atatgtaggt	gaagcgactt	gctcgtggag		1740
ctgaaatcag	tcgaagatac	cagctggctg	caactgttta	ttaaaaaacac	agcactgtgc		1800
aaacacgaaa	gtggacgtat	acggtgtgac	gcctgcccg	tgccggaagg	ttaatgtgatg		1860
gggttagcgg	taacgcgaag	ctcttgatcg	aagccccggt	aaacggcggc	cgtaactata		1920
acggtcctaa	ggtagcgaaa	ttccttgtcg	ggtaagttcc	gacctgcacg	aatggcgtaa		1980
tgatggccag	gctgtctcca	cccagagactc	agtgaaattg	aactcgctgt	gaagatgcag		2040
tgtaccgcg	gcaagacgga	aagaccccg	gaacctttac	tatagcttga	cactgaaacat		2100
tgagccttga	tgtgtaggat	aggtgggagg	ctttgaagt	tgagacccag	tctgcatgga		2160
gcgaccttg	aaataccacc	ctttaatgtt	tgatgttcta	acgttgcccc	gtaataccgg		2220
ttgcggacag	tgtctgggtg	gtagtttgac	tggggcggtc	tcctcctaaa	gagtaaacgga		2280
ggagcacgaa	ggttggtctaa	tcctggctcg	acatcaggag	gttagtgcaa	tggcataagc		2340
cagcttgact	gcgagcgtga	cggcgcgagc	aggtgcgaaa	gcaggtcata	gtgatccggg		2400

CI0043PCTseqlisting.ST25

ggtctgaat ggaaggcca tcgctcaacg gataaaagg tctcgggga taacaggctg	2460
ataccgccca agagttcata tcgacggcgg tgtttgccac ctcatgctcg gctcatcaca	2520
tcttggggct gaagtaggtc ccaagggtat ggctgttcgc catttaaagt ggtacgcgag	2580
ctgggtttag aacgtcgtga gacagttcgg tccctatctg ccgtgggcgc tggagaactg	2640
aggggggctg ctctagtac gagaggaccg gattggacgc atcactggtg ttccgggttg	2700
catgcaatg cactgcccg tagctaaatg cggagagat aagtgcctga agcatctaa	2760
cacgaaactt gcccgagat gagttctccc tgacccttta agggctctga aggaacgtg	2820
aagacgacga cgttgatagg ccgggtgtgt aagcgacgc atgcgttgag ctaaccggta	2880
ctaataaacc gtgaggctta acctt	2905

<210> 8
 <211> 1798
 <212> DNA
 <213> Yeast (*S. cerevisiae*)

<400> 8 tatctgggtg atctctgccag tagtcatatg cttgtctcaa agattaagcc atgcatgtct	60
aagtataagc aatttatata gtgaaactgc gaatggctca ttaaatcagt tatcgtttat	120
ttgatagtct ctttactaca tggataaacc gtggtaatc tagagctaata acatgcttaa	180
aatctcgacc ctttgaaga gatgtattta ttagataaaa aatcaatgtc ttccgactct	240
ttgatgattc ataataactt ttcaatcgc atggccttgt gctggcagat gttcattcaa	300
atttctgccc tatcaacttt cgatggtagg atagtggcct accatgggtt caacgggtaa	360
cggggaataa gggttcgatt ccggagaggg agcctgagaa acggctacca catccaagga	420
aggcagcagg cgcgcaaat acccaatcct aattcagggg ggtagtgaca ataaataacg	480
atacagggcc cattcgggtc ttgtaattgg aatgagtaca atgtaaatat cttaacgagg	540
aacaattgga gggcaagtct ggtgccagca gccgcggtaa ttccagctcc aatagcgtat	600
attaaagtgt ttgcagttaa aaagctcgta gttgaacttt gggcccggtt ggcgggtccg	660
atttttctgt gtactggatt tccaacgggg cttttccttc tggctaacct tgagtccttg	720
tggtctcttg cgaaccagga cttttacttt gaaaaaata gagtggtcaa agcaggcgta	780
ttgtctgaat atattagcat ggaataatg aataggacgt ttggttctat tttgttggtt	840
tctaggacca tcgtaatgat taatagggac ggtcgggggc atcggatttc aattgtcgag	900
gtgaaattct tggatttatt gaagactaac tactcgaaa gcatttgcca aggcagtttt	960
cattaatcaa gaacgaaagt taggggatcg aagatgatct ggtaccgtcg tagtcttaac	1020
cataaactat gccgactaga tcgggtgggtg ttttttaat gaccactcg gtaccttacg	1080
agaaatcaaa gtctttgggt tctgggggga gtatggctgc aaggctgaaa cttaaaggaa	1140
ttgacggaag ggcaccacta ggagtgagc ctgcggctaa tttgactcaa cacggggaaa	1200
ctcaccaggt ccagacacaa taaggattga cagattgaga gctctttctt gattttgtgg	1260

CI0043PTseqlisting.ST25

gtggtggtgc atggccggtt ctcagttggt ggagtgattt gtctgcttaa ttgcgataac	1320
gaacgagacc ttaacctact aaatagtggg gctagcattt gctgggtatc cacttcttag	1380
agggactatc ggtttcaagc cgatggaagt ttgaggcaat aacaggtctg tgatgccctt	1440
agaacgtttc gggccgcacg cgcgtacac tgacggagcc agcaggtcta accttgccg	1500
agaggtcttg gtaatcttgg gaaactccgt cgtgctgggg atagagcatt gtaattattg	1560
ctcttcaacg aggaattcct agtaagcgca agtcatcagc ttgcgttgat tacgtccctg	1620
ccctttgtac acaccgccgc tcgctagtac cgattgaatg gcttagtgag gccctcaggat	1680
ctgcttagag aagggggcaa ctccatctca gacgggagaa tttggacaaa cttggtcatt	1740
tagaggaact aaaagtcgta acaaggtttc cgtaggtgaa cctgcggaag gatcatta	1798

<210> 9

<211> 3911

<212> DNA

<213> Yeast 25S Ribosomal RNA

<400> 9

aattccgtga tgggacctta ggttttacca actgcggcta atcttttttt atactgagcg	60
tattggaacg ttatcgataa gaagagagcg tctaggcgaa caatgttctt aaagtgtgac	120
ctcaaatcag gtaggagtag ccgctgaact taagcatatc aataagcggg ggaagaagaa	180
ccaaccggat tgctcttagta acggcgagtg aagcggcaaa agctcaaatt tgaatatctg	240
taccttcggt gcccgagttg taatttgagg agggcaactt tggggccgtt ccttgtctat	300
gttccttgga acaggacgtc atagaggggt agcatcccggt gtggcgagga gtgcggttct	360
ttgtaaaagt ccttcgaaga gtcgagttgt ttgggaatgc agctctaagt ggggtgtaaa	420
ttccatctaa agctaaatat tggcgagaga ccgatagcga acaagtacag tgatggaaa	480
atgaaaagaa ctttgaaaag agagtgaata agtacgtgaa attgttgaaa ggaaggggca	540
tttgatcaga catggtgttt tgtgccctct gtccttggtg ggtaggggaa tctcgattt	600
cactgggcca gcacagttt tgggtggcagg ataaatccat aggaatgtag cttgcctcgg	660
taagtattat agcctgtggg aatactgcca gctgggactg aggactgcga cgtaatcaa	720
ggatgtctggc ataattggtta tatgccgcc gtcttgaaac acggaccaag gagtctaacg	780
tctatcgag tggttgggtg taaaaccat acgcgtaatg aaagtgaacg taggtgggg	840
cctcgcaaga ggtgcacaa cgaccgatcc tgatgtcttc ggatggattt gagtaagagc	900
atagctgttg ggacccgaaa gatggtgaac tatgcctgaa tagggtgaag ccagaggaaa	960
ctctggtgga ggctcgtagc ggttctgacg tgcaaatcga tcgtcgaatt tgggtatagg	1020
ggcgaaagac taatcgaacc atctagtagc tggttcctgc cgaagtttcc ctacagatag	1080
cagaagctcg tatcagtttt atgagtgaaa gcgaatgatt agaggttccg gggctgaaat	1140
gaccttgacc tattctcaaa ctttaaatat gtaagaagtc cttgttacct aattgaacgt	1200
ggacatttga atgaagagct tttagtgggc catttttggt aagcagaact ggcatgacgg	1260
gatgaaccga acgtagagtt aaggtgccgg aatacacgct catcagacac cacaagaagt	1320

CI0043PCTseqlisting.ST25

gttagttcat	ctagacagcc	ggacggtggc	catggaagtc	ggaatccgct	aaggagtgtg	1380
taacaactca	ccggccgaat	gaactagccc	tgaaaatgga	tggcgcgtcaa	gcgtgttacc	1440
tatactctac	cgtcaggggt	gatatgatgc	cctgcagagt	aggcaggcgt	ggaggtcagt	1500
gacgaagcct	agaccgtaag	gtcgggtcga	acggcctcta	gtgcagatct	tggtggtagt	1560
agcaaatatt	caaatgagaa	ctttgaagac	tgaagtgggg	aaagggttcca	cgtcaacagc	1620
agttggacgt	gggttagtgc	atcctaagag	atggggaagc	tccgtttcaa	tatggtgatt	1680
ttatgcagcg	caccatcgaa	agggaaatccg	gtaagattcc	ggaacttgga	tatggtattct	1740
tcacggtaac	gtaactgaat	gtggagacgt	cggcgcgagc	cctgggagga	gttatctttt	1800
cttcttaaca	gcttatcacc	ccggaattgg	tttatccgga	gatggggtct	tatggctgga	1860
agagggcagc	acctttgctg	gtctccggtgc	gcttgtgacg	gcccggtgaaa	atccacagga	1920
aggaatagtt	ttcatgctag	gtcgtactga	taaccgcagc	aggcttccaa	ggtagaacagc	1980
ctctagttga	tagaataatg	tagataaggg	aagtcggcaa	aatagatccg	taacttcggg	2040
ataaggattg	gtcttaaggg	tcgggtagtg	agggccttgg	tcagacgcag	cgggcgtgct	2100
tgtgactgcg	ttggtggggc	ttgctctgct	aggcggacta	cttgctgctc	ttgtgttaga	2160
cggccttggt	aggtctcttg	tagaccgtcg	cttgctacaa	ttaacagatc	aacttagaac	2220
tggtacggac	aaggggaatc	tgactgtcta	attaaaacat	agcattgcga	tggtcagaaa	2280
gtgatgttga	cgcaatgtga	tttctgccca	gtgctctgaa	tgtcaaaagt	aagaaattca	2340
accaagcgcg	agtaaacggc	gggagtaact	atgactctct	taaggtagcc	aaatgcctcg	2400
tcacttaatt	agtgcgcgcg	atgaatggat	taacgagatt	cccactgtcc	ctatctacta	2460
tctagcgaaa	ccacagccaa	gggaacgggc	ttggcagaat	cagcggggaa	agaagaccct	2520
gttgagcttg	actctagttt	gacattgtga	agagacatag	aggggtgtaga	ataagtgggg	2580
gcttcggcgc	cagtgaataa	ccactacctt	tatagtttct	ttacttattc	aatgaagcgg	2640
agctggaatt	cattttccac	gttctagcat	tcaaggctcc	attcggggct	gatccgggtt	2700
gaagacattg	tcagggtggg	agtttggtcg	gggcggcaca	tctgttaaac	gataacgcag	2760
atgtcctaag	gggggtctat	ggagaacaga	aatctccagt	agacaaaag	ggtaaagccc	2820
cttagtttga	tttcagtggt	aatacaaac	attgaaagt	tggcctatcg	atcctttagt	2880
ccctcggaat	ttgaggtcag	agggtccaga	aaagttacca	cagggataac	tggtctgtgg	2940
cagtcaagcg	ttcatagcga	cattgctttt	tgattcttcg	atgtcggctc	ttcctatcat	3000
accgaagcag	aattcggtaa	gcgttggatt	gttaccacc	taatagggaa	catgagctgg	3060
gtttagaccg	tcgtgagaca	ggttagtttt	accctactga	tgaatgttac	cagcaaatagt	3120
aattgaacct	agtagcagag	gaacagttca	ttcggataat	tggtttttgc	ggctgtctga	3180
tcaggcattg	ccgcgaagca	ccatccgctg	gattatggct	gaacgcctct	aagtcagaat	3240
ccatgctaga	acgcggtgat	ttctttgctc	cacacaatat	agatggatag	gaataaggcg	3300
tccttgtggc	gtcgtgtaac	catagcagcg	tagcaacggg	gcacttggcg	gaaagccctt	3360

CI0043PCTseqlisting.ST25

ggggtgcttg tggcgaattg caatgtcatt ttgcgtgggg ataatcatt tgtatacgac 3420
 ttatagtgac aacggggat tgtaagcggg agagtagcct tgtgtgtacg atctgctgag 3480
 attaagcctt tgtgtctga tttgtttttt atttctttct aagtgggtac tggcaggagc 3540
 cggggcctag tttagagaga agtagactca acaagtcctc ataaatttta tttgtcttaa 3600
 gaattctatg atccgggtaa aaacatgtat tgatatatc tattataata tacgatgagg 3660
 atgatagtgt gtaagagtgt accatttact aatgtatgta agttactatt tactatttgg 3720
 tctttttatt tttttttttt tttttttttt tcgttgcaaa gatgggttga aagagaaggg 3780
 ctttcacaaa gcttcccgag cgtgaaagga ttgcccga cagtttgctt catggagcag 3840
 tttttccgc accatcagag cggcaaacat gagtgcctgt ataagtttag agaattgaga 3900
 aaagctcatt t 3911

<210> 10
 <211> 16569
 <212> DNA
 <213> Human mitochondrial DNA

<400> 10
 gatcacaggc ctatcacctt attaacctt caccggagct ctccatgcat ttggtatttt 60
 cgtctggggg gtatgcacgc gatagcattg cgagacgctg gagccggagc accctatgtc 120
 gcagtatctg tctttgattc ctgcctcacc ctattattta tcgcacctac gttcaatatt 180
 acaggcgaac atacttacta aagtgtgtta attaatatt gctttagtaga cataataata 240
 acaattgaat gtctgcacgc ccactttcca cacagacatc ataacaaaaa atttccacca 300
 aacccccctt ccccgcttc tggccacagc acttaaacac atctctgcca aacccccaaa 360
 acaagaacc ctaaccaccg cctaaccaga tttaaaattt tatcttttgg cggtagtcac 420
 ttttaacagt caccccccta ctaacacatt attttccctt cccactccca tactactaat 480
 ctcatcaata caacccccgc ccactctacc cagcacacac acaccgctgc taaccccata 540
 cccgaacca accaaacccc aaagacaccc ccacagttt atgtagctta cctcctcaaa 600
 gcaatacact gaaaatgttt agacgggctc acatcacccc ataaacaaat aggtttggtc 660
 ctageccttc tattagctct tagtaagatt acacatgcaa gcatccccgt tccagttagt 720
 tcaccctcta aatcacacgc atcaaaaggg acaagcatca agcagcagc aatgcagctc 780
 aaaaagctta gcctagccac acccccacgg gaaacagcag tgattaacct ttagcaataa 840
 acgaaagtgt aactaagcta tactaacccc agggttggct aatttcgtgc cagccaccgc 900
 ggtcacagta ttaacccaag tcaatagaag cggcgtaaa gagtgtttta gatcaccccc 960
 tccccataa agctaaaact cacctgagtt gtaaaaaact ccagttgaca caaaatagac 1020
 tacgaaagtg gctttaacat atctgaacac acaatagcta agacccaac tgggattaga 1080
 taccacctta tgcttagccc taaacctcaa cagttaaatc aacaaaaactg ctgccagaa 1140
 cactacgagc cacagcttaa aactcaaggg acctggcggt gcttcataac cctctagagg 1200

CI0043PCTseqlisting.ST25			
agcctgttct gtaatcgata aaccccgatc aacctcacca cctcttgctc agcctatata	1260		
ccgccattct cagcaaaccc tgatgaaggc tacaaagtaa gcgcaagtac ccacgtaaaag	1320		
acgttaggtc aaggtgtagc ccatgaggtg gcaagaaatg ggctacattt tctacccag	1380		
aaaactcaga tagcccttat gaaacttaag ggtcgaaggt ggatttagca gtaactaag	1440		
agtagagtgc ttagtgtgaa agggccctga agcgcgtaca caccgccgt caccctctc	1500		
aagtatactt caaaggacat ttaactaaaa cccctacgca ttatataga ggagacaagt	1560		
cgtaacatgg taagtgtact ggaaagtgca cttggacgaa ccagagtgtg gcttaacaca	1620		
aagcacccaa cttacactta ggagatttca acttaacttg accgctctga gctaaacctt	1680		
gccccaaacc cactccacct tactaccaga caaccttagc caaacattt acccaataa	1740		
agtataggcg atagaaattg aaacctggcg caatagatat agtaccgcaa gggaaagatg	1800		
aaaaattata accaagcata atatagcaag gactaacccc tataccttct gcataatgaa	1860		
ttaactagaa ataactttgc aaggagagcc aaagctaaga cccccgaaac cagacgagct	1920		
acctagaac agctaaaaga gcacacccgt ctatgtagca aaatagtggg aagatttata	1980		
ggtagaggcg acaaacctac cgagcctgtg gatagctgtt tgtcaagat agaactcttag	2040		
ttcaacttta aatttgccta cagaaccttc taaatccct tghtaaatta actgttagtc	2100		
caagaggaa cagctcttg gacactagga aaaaaccttg tagagagagt aaaaaattta	2160		
acaccatag taggcctaaa agcagccacc aattaagaaa cggttcaagc tcaacacca	2220		
ctacctaaaa aatcccaaac atataactga actcctcaca ccaatttga ccaatctatc	2280		
accctataga agaactaatg ttagtataag taacatgaaa acatttctct ccgcataagc	2340		
ctgcgtcaga ttaaaacact gaactgaaa ttaacagccc aatatctaca atcaaccaac	2400		
aagtcattat tacctcact gtcaacccaa cacaggcatg ctcataagga aaggttaaaa	2460		
aaagtaaaag gaactcgga aatcttacc cgctgttta ccaaaaacat cacccttagc	2520		
atcaccagta ttagaggcac cgcctgccc gtgacacatg ttaacggcc gcggtaccct	2580		
aaccgtgcaa aggtagcata atcacttgtt ctttaaatag ggacctgtat gaatggctcc	2640		
acgaggggtc agctgtctct tacttttaac cagtgaatt gacctgccg tgaagaggcg	2700		
ggcataaac agcaagcga gaagacccta tggagcttta atttattaat gcaaacagta	2760		
cctaacaac ccacaggtcc taaactacca aacctgcatt aaaaatttcg gttggggcga	2820		
cctcgagca gaacccaacc tccgagcagt acatgctaag acttcaccag tcaaacgcaa	2880		
ctactatatt caattgatcc aataacttga ccaacggaac aagttaacct agggataaca	2940		
gcgcaatcct attctagagt ccatatcaac aatagggttt acgacctcga tgttggaatc	3000		
ggacatccc atgggtgacg cgctattaaa ggttcgtttg ttcaacgatt aaagtctac	3060		
gtgactctgag ttcagaccgg agtaatccag gtcggtttct atctaccttc aaattctctc	3120		
ctgtacgaaa ggacaagaga aataaggcct acttcacaaa gcgccttccc ccgtaaatga	3180		
tatcatctca acttagtatt ataccacac ccaccaaga acagggtttg ttaagatggc	3240		

CI0043PTseqIisting.ST25

agagcccggt aatcgcataa aacttaaaac ttacagtcga gaggttcaat tcctcttctt	3300
aacaacatac ccatggccaa cctctactc ctcattgtac ccatttcta cgaatggca	3360
ttcctaatac ttaccgaacg aaaaattcta ggctatatac aactacgcaa agggcccaac	3420
gttgtagggc cctacgggct actacaaccc ttctgtgacg ccataaaact cttcaccaa	3480
gagccctaa aaccggccac atctaccatc accctctaca tcaccgcccc gaccttagct	3540
ctcaccatcg ctcttctact atgaaccccc ctccccatc ccaaccccc ttgtcaacctc	3600
aacctaggcc tcctatttat tctagccacc tctagcctag ccgtttactc aatctctga	3660
tcagggtgag catcaaactc aaactacgac ctgatcggcg cactgcgagc agtagcccaa	3720
acaatctcat atgaagtcac cctagccatc attctactat caacattact aataagtggc	3780
tcctttaacc tctccacctc tatcacaaca caagaacacc tctgattact cctgccatca	3840
tgacccttgg ccataatatg atttatctcc acactagcag agaccaaccg aacccccctc	3900
gaccttgccg aaggggagtc cgaactagtc tcaggcttca acatcgaata cgccgcaggc	3960
cccttcgccc tatttctcat agccgaatac acaaacatta ttataataaa caccctcacc	4020
actacaatct tcttaggaac aacatatgac gcactctccc ctgaactcta cacaacatat	4080
ttgtgcacca agaccttact tctaaccctc ctgttcttat gaattcgaac agcatacccc	4140
cgattccgct acgaccaact catacacctc ctatgaaaaa acttctctacc actcaccta	4200
gcattactta tatgatattg ctccataccc attacaatct ccagcattcc ccttcaaacc	4260
taagaaatat gtcgtataaa agagttactt tgatagagta aataatagga gcttaaaccc	4320
ccttatttct aggactatga gaatcgaacc catccctgag aatccaaaat tctccgtgcc	4380
acctatcaca ccccatccta aagtaaggtc agctaataa gctatcgggc ccataccccg	4440
aaaatgttgg ttataccctt cccgtactaa ttaatcccct ggcccaaccc gtcatttact	4500
ctaccatctt tgcaggcaca ctcatcacag cgctaagctc gcactgattt ttacctgag	4560
taggcctaga aataaacatg ctagctttta ttccagtctt aaccaaaaaa ataaaccttc	4620
gttcacaga agctgccatc aagtatttcc tcacgcaagc aaccgcattc ataactcttc	4680
taatagctat cctcttcaac aatatactct ccggacaatg aaccataacc aatactacca	4740
atcaatactc atcattaata atcataatg ctatagcaat aaaactagga atagccccct	4800
ttcacttctg agtcccagag gttaccaagc gcacccctct gacatccggc ctgtcttctc	4860
tcacatgaca aaaactagcc cccatctcaa tcataacca aatctctccc tcaataaacg	4920
taagccttct cctcactctc tcaatcttat ccataatgc aggcagttga ggtggattaa	4980
accgagccca gctacgcaa atcttagcat actcttcaat taccacata ggatgaataa	5040
tagcagttct accgtacaa cctaacataa ccattcttaa tttaactatt tatattacc	5100
taactactac cgatttctta ctactcaact taaactccag caccacgacc ctactactat	5160
ctcgacctg aaacaagcta acatgactaa cacccttaat tccatccacc ctctctctcc	5220
taggaggcct gccccgccta accggctttt tgcccaaatg ggccattatc gaagaattca	5280

CI0043PCTseqlisting.ST25

caaaaaacaa tagcctcatc atccccacca tcatagccac catcacccctc cttaacctct	5340
actttcactc acgcctaate tactccacct caatcacact actcccata tctaacaacg	5400
taaaaataaa atgacagttt gaacatacaa aaccaccccc attcctcccc acactcatcg	5460
cccttaccac gctactccta cctatctccc cttttatact aataatctta tagaaattta	5520
ggttaaatac agaccaagag ccttcaaagc cctcagtaag ttgcaatact taatttctgt	5580
aacagctaag gactgcaaaa ccccactctg catcaactga acgcaaatca gccactttaa	5640
ttaagctaag cccttactag accaatggga cttaaaccga caaacactta gttaacagct	5700
aagcaccta atcaactggc ttcaatctac ttctcccgcc gccgggaaaa aaggcgggag	5760
aagccccgc aggtttgaag ctgcttcttc gaatttgcaa ttcaatatga aatcacctc	5820
ggagctggta aaaagagggc taaccctgt ctttagattt acagtccaat gcttactca	5880
gccattttac ctacccccca ctgatgttcg ccgaccgttg actattctct acaaaccaca	5940
aagacattgg aacctatac ctattattcg gcgcatgagc tggagtccta ggcacagctc	6000
taagcctcct tattcgagcc gagctgggcc agccaggcaa cttcttaggt aacgaccaca	6060
tcacaacgt tatcgtcaca gccatgcat ttgtaataat ctcttcata gtaataccca	6120
tcataactcg aggccttgcc aactgactag ttccccta atcctgtgcc ccgatatgg	6180
cgtttcccg cataaacaac ataagcttct gactcttacc tccctctctc ctactcctgc	6240
tcgcatctgc tatagtggag gccggagcag gaacagggtt aacagctac cctcccttag	6300
caggggaacta ctcccacct ggagcctcgg tagacctaac catcttctcc ttacacctag	6360
cagggtgtctc ctctatctta ggggccatca atttcatcac aacaattatc aataaaaaac	6420
ccctgccat aaccaatac caaacgcccc tcttcgtctg atccgtccta atcacagcag	6480
tcctacttct cctatctctc ccagtcctag ctgctggcat cactatacta ctacagacc	6540
gcaacctcaa caccaccttc ttcgaccccg ccggaggagg agacccatt ctataccaac	6600
acctattctg atttttcggt caccctgaag ttatatattc tatcctacca ggcttcggaa	6660
taatctccca tattgtaact tactactccg gaaaaaaga accatttgga tacataggta	6720
tggtctgagc tatgatatca attggcttcc tagggtttat cgtgtgagca caccatatat	6780
ttacagtagg aatagacgta gacacacgag catatttcac ctccgctacc ataactatcg	6840
ctatccccac cggcgctaaa gtatttagct gactcgccac actccacgga agcaatatga	6900
aatgatctgc tgcagtgctc tgagccctag gattcatctt ctttttacc gtagggtgcc	6960
tgatggcat tgtattagca aactcatcac tagacatcgt actacagac acgtactacg	7020
ttgtagccca cttccactat gtctatcaa taggagctgt atttgccatc ataggaggct	7080
tcattcactg atttccccta ttctcaggct acaccctaga ccaaacctac gccaaaatcc	7140
atttcactat catattcatc ggcgtaaatc taactttctt cccacaacac tttctcgcc	7200
tatccggaat gccccgagct tactcggact accccgatgc atacaccaca tgaacatcc	7260
tatcatctgt aggcctattc atttctctaa cagcagtaat attaataatt ttcatgattt	7320

CI0043PCTseqlisting.ST25

gagaagcctt cgcttcgaag cgaaaagtcc taatagtaga agaaccctcc ataaacctgg	7380
agtgactata tggatgcccc ccaccctacc acacattcga agaaccgta tacataaaat	7440
ctagacaaaa aaggaaggaa tcgaaccccc caaagctggt ttcaagccaa ccccatggcc	7500
tccatgactt tttaaaaaa gtattagaaa aaccatttca taactttgtc aaagttaa	7560
tataggctaa atcctatata tcttaatggc acatgcagcg caagtaggtc tacaagcgc	7620
tacttccctt atcatagaag agcttatcac ctctcatgat cagccctca taatcatttt	7680
ccttatctgc ttcctatgct tgtatgcctt tttcctaaca ctcaacaa aactaactaa	7740
tactaacatc tcagacgctc aggaataga aaccgtctga actatcctgc ccgccatcat	7800
cctagtcttc atcgccctcc catccctacg catcctttac ataacagacg aggtcaacga	7860
tccctccctt accatcaaat caattggcca ccaatggtac tgaacctacg agtacaccga	7920
ctacggcgga ctaattctca actcctacat acttccccca ttattcctag aaccaggcga	7980
cctgcgactc ctgacgttg acaatcgagt agtactcccg attgaagccc ccattcgat	8040
aataattaca tcacaagacg tcttgcactc atgagctgtc cccacattag gcttaaaaa	8100
agatgcaatt cccggacgtc taaaccaaac cactttcacc gctacacgac cgggggtata	8160
ctacggctaa tgctctgaaa tctgtggagc aaaccacagt ttcatgccca tcgtcctaga	8220
attaattccc ctaaaaatct ttgaaatagg gcccgatttt accctatagc accccctcta	8280
cccccttag agccccactgt aaagctaact tagcattaac cttttaagtt aaagattaag	8340
agaaccaaca cctctttaca gtgaaatgcc ccaactaaat actaccgtat ggcccaccat	8400
aattaccccc atactcctca cactattcct catcaccaa ctaaaaatat taacacaaa	8460
ctaccaccta cctccctcac caaagcccat aaaaataaaa aattataaca aacctgaga	8520
accaaaatga acgaaaatct gttcgcttca ttcatgtccc ccacaatcct aggcctaccc	8580
gccgcagtac tgatcatctt atttccccct ctattgatcc ccacctccaa atatctctc	8640
aacaaccgac taatcaccac ccaacaatga ctaatcaaac taacctcaaa acaaatgata	8700
accatacaca acactaaagg acgaacctga tctcttatac tagtatcctt aatcattttt	8760
attgccacaa ctaacctcct cggactcctg cctcactcat ttacaccaac caccacaacta	8820
tctataaacc tagccatggc catcccctta tgagcgggca cagtattat aggttttcgc	8880
tctaagatta aaaatgccct agcctcttc ttaccacaga gcacacctac accccttatc	8940
cccatactag ttattatcga aaccatcagc ctactcttc aaccaatagc cctggcgcta	9000
cgcctaaccg ctaacattac tgcaggccac ctactctgc acctaatgg aagcgccac	9060
ctagcaatat caaccattaa ctttccctct acacttatca tcttcacaa tctaatttcta	9120
ctgactatcc tagaaatcgc tgtcgcttca atccaagcct acgttttcac acttctagta	9180
agcctctacc tgcacgacaa cacataatga cccaccaatc acatgcctat catatagtaa	9240
aaccagccc atgaccccta acaggggccc tctcagccct cctaagacc tccggcctag	9300
ccatgtgatt tcacttccac tccataacgc tctcatact aggcctacta accaacacac	9360

CI0043PCTseqlisting.ST25

taacatatata ccaatgatgg cgcatgttaa cacgagaaag cacatatccaa ggcaccacaca	9420
caccacctgt ccaaaaaggc cttcgatacg ggataatcct atttattacc tcagaagttt	9480
ttttcttcgc aggatttttc tgagcctttt accactccag ctagccctt acccccaat	9540
tagggaggca ctggccccc acaggcatca ccccgctaaa tcccttagaa gtcccaactcc	9600
taaacacatc cgtattactc gcatcaggag tatcaatcac ctgagctcac catagtctaa	9660
tagaaaaaa cgaacacaa ataattcaag cactgcttat tacaatttta ctgggtctct	9720
attttaccct cctacaagcc tcagagtact tcgagtctcc cttcaccatt tccgacggca	9780
tctacggctc aacatttttt gtaccacag gcttcacgg acttcacgctc attattggct	9840
caactttctt cactatctgc ttcatccgcc aactaatatt tcactttaca tccaacatc	9900
actttggctt cgaagcgcc gctgatact ggcattttgt agatgtggtt tgactatttc	9960
tgtagtctc catctattga tgagggtctt actcttttag tataaatagt accgttaact	10020
tccaattaac tagttttgac aacattcaaa aaagagtaat aaacttcgcc ttaattttaa	10080
taatcaacac cctcctagcc ttactactaa taattattac attttgacta ccacaactca	10140
acggctacat agaaaaatcc accccttagc agtgcggctt cgaccctata tccccgcc	10200
gcgtcccttt ctccataaaa ttcttcttag tagctattac cttcttatta tttagctag	10260
aaattgccct ccttttacc ctaccatgag ccttcaaac aactaacctg ccactaatag	10320
ttatgtcatc cctcttatta atcatcatcc tagccctaag tctggcctat gagtgtactc	10380
aaaaaggatt agactgaacc gaattggtat atagtttaaa caaacgaat gatttcgact	10440
cattaaatta tgataatcat atttacaaa tgcccctcat ttacataaat attatactag	10500
catttaccat ctacttcta ggaatactag tatatcgctc acactcata tcctccctac	10560
tatgcctaga aggaataata ctatcgctgt tcattatagc tactctcata accctcaaca	10620
cccactccct cttagccaat attgtgccta ttgccatact agtctttgcc gcctgcgaag	10680
cagcgggtgg ctagcccta ctagtctcaa tctccaacac atatggccta gactacgtac	10740
ataacctaaa cctactccaa tgctaaaact aatcgtccca acaattatat tactaccact	10800
gacatgactt tccaaaaaac acataatttg aatcaacaca accaccacaca gcctaattat	10860
tagcatcatc cctctactat tttttaacca aatcaacaac aactatttta gctgttcccc	10920
aaccttttcc tccgacccc taacaacccc cctcctaata ctaactacct gactcctacc	10980
cctcacaate atggcaagcc aacgccactt atccagtgaa ccaactatcac gaaaaaaact	11040
ctactctctc atactaatct ccctacaaat ctcttaatt ataacattca cagccacaga	11100
actaatcata ttttatatct tcttcgaac cacacttatc cccacttggt ctatcatcac	11160
ccgatgagcc aaccagccag aacgcctgaa cgcaggcaca tacttcttat tctacacct	11220
agtaggctcc cttccctac tcatcgcact aatttacct cacaacacc taggctcact	11280
aaacattcta ctactcactc tcactgccca agaactatca aactcctgag ccaataactt	11340
aatatgacta gcttacacaa tagcttttat agtaaagata cctctttacg gactccactt	11400

CI0043PCTseqlisting.ST25

atgactccct	aaagcccatg	tcgaagcccc	catcgctggg	tcaatagtac	ttgccgcagt	11460
actcttaaaa	ctaggcggct	atgggtataat	acgcctcaca	ctcattctca	accccctgac	11520
aaaacacata	gcctaccctt	tccttgact	atccctatga	ggcataatta	taacaagctc	11580
catctgccta	cgacaacag	acctaatac	gctcattgca	tactcttcaa	tcagccacat	11640
agccctcgta	gtaacagcca	ttctcatcca	aacccccgta	agcttcaccg	gcgcagtcac	11700
ttctcataatc	gccacggg	ttacatctc	attactattc	tgcctagcaa	actcaaaacta	11760
cgaacgcact	cacagtcgca	tcataatcct	ctctcaagga	cttcaaaactc	tactcccaact	11820
aatagctttt	tgatgacttc	tagcaagcct	cgtaaacctc	gccttacccc	ccactattaa	11880
cctactggga	gaactctctg	tgctagtaac	caggttctcc	tgatcaataa	tcactctcct	11940
acttacagga	ctaacatac	tagtcacagc	cctatactcc	ctctacatat	ttaccacaac	12000
acaatggggc	tcactcacc	accacattaa	caacataaaa	ccctcattca	cacgagaaaa	12060
caccctcatg	ttcatacacc	tatcccccat	tctctccta	tcctcaacc	ccgacatcat	12120
taccgggttt	tcctcttgta	aatatagtgt	aaccataaaa	tcagattgtg	aatctgacaa	12180
cagaggctta	cgacccttta	tttaccgaga	aagctcaca	gaactgctaa	ctcatgcccc	12240
catgtctaac	aacatggctt	tctcaacttt	taaggataa	cagctatcca	ttggctcttag	12300
gccccaaaa	ttttgtgca	actccaata	aaagtaataa	ccatgcacac	tactataacc	12360
accctaacc	tgacttccct	aattcccccc	atccttacca	ccctcgtaa	ccctaacaaa	12420
aaaaactcat	acccccatta	tgtaaaatcc	attgtcgcac	ccactttat	tatcagtcct	12480
ttccccacaa	caatattcat	gtgcctagac	caagaagtta	ttatctcgaa	ctgacactga	12540
gccacaacc	aaacaacca	gctctcccta	agcttcaaac	tagactactt	ctccataata	12600
ttcatccctg	tagcatgtgt	cgttacatgg	tccatcatag	aattctcact	gtgatataata	12660
aactcagacc	caaacattaa	tcagtctctc	aaatatctac	tcactctctc	aattaccata	12720
ctaactcttag	ttaccgctaa	caactatttc	caactgttca	tcggctgaga	ggcgctagga	12780
attatatcct	tctgtctcat	cagttgatga	tacgcccgag	cagatgccaa	cacagcagcc	12840
attcaagcaa	tcctatacaa	ccgtatcggc	gatatcggtt	tcactctcgc	cttagcatga	12900
tttatcttac	actccaactc	atgagaccga	caacaaatag	cccttctaaa	cgtaaatcca	12960
agcctcacc	caactactag	ctctctccta	gcagcagcag	gcaaatcagc	ccaattaggt	13020
ctccaccctt	gactccccct	agccatagaa	ggccccacc	cagtcctcagc	ctactctcac	13080
tcaagcacta	tagttgtagc	aggaatcttc	ttactcatcc	gcttccacc	cttagcagaa	13140
aatagccccc	taatccaacc	tctaaccata	tgcttagggc	ctatcaccac	tctgttcgca	13200
gcagctgcg	cccttacaca	aaatgacatc	aaaaaaatcg	tagccttctc	cacttcaagt	13260
caactaggac	tcataatagt	tacaatcggc	atcaaccaac	cacacctagc	attcctgcac	13320
atctgtacc	acgccttctt	caaagccata	ctatttatgt	gctccgggtc	catcatccac	13380
aaccttaaca	atgaacaaga	tattcgaaaa	ataggaggac	tactcaaaac	catacctctc	13440

CI0043PCTseqlisting.ST25

acttcaacct ccctcaccat tggcagccta gcatttagcag gaataccttt cctcacaggt 13500
 ttctactcca aagaccacat catcgaaacc gcaaacatat catacacaaa cgcttgagcc 13560
 ctatctatta ctctcatcgc tacctccctg acaagcgcct atagcactcg aataattctt 13620
 ctacacctaa caggtcaacc tcgcttcccc acccttacta acattaacga aataacccc 13680
 accctactaa accccattaa acgcttggca gccggaagcc tattcgagg atttctcatt 13740
 actaacaaca tttccccgc atcccccttc caaacaacaa tccccctcta cctaaaactc 13800
 acagccctcg ctgtcacttt ctaggactt ctaacagccc tagacctcaa ctacctaac 13860
 aacaaactta aataaaaatc ccactatgc acattttatt tctccaacat actcggattc 13920
 taccctagca tcacacacgg cacaatcccc tatctaggcc ttcttacgag ccaaacctg 13980
 cccctactcc tcttagacct aacctgacta gaaaagctat tacctaaaac aatttcacag 14040
 caccaaatct ccacctccat catcacctca acccaaaaag gcataattaa actttacttc 14100
 ctctcttttt tcttccact catcctaacc ctactcctaa tcacataacc tattccccg 14160
 agcaatctca attacaatat atacaccaac aaacaatggt caaccagtaa ctactactaa 14220
 tcaacgccca taatcataca aagccccgcg accaatagga tctctccgaa tcaacctga 14280
 cccctctctt tcataaatta ttcagcttcc tacactatta aagtttacc caaccaccac 14340
 cccatcatac tctttcacc acagcaccaa tctactctc atcgctaacc ccactaaaac 14400
 actcaccaag acctcaacc ctgaccccc tgctcagga tactctctaa tagccatcgc 14460
 tgtagtatat ccaagacaa ccatcattcc ccctaataa attaaaaaa ctattaaacc 14520
 catataacct ccccaaaaat tcagaataat aacacaccg accacaccg taacaatcaa 14580
 tactaaacc ccataaatag gagaaggctt agaagaaaac ccacaaaacc ccattactaa 14640
 acccacactc aacagaaca aagcatacat cattattctc gcacggacta caaccacgac 14700
 caatgatatg aaaaaccatc gttgtatttc aactacaaga acaccaatga cccaatcacg 14760
 caaaattaac ccctaataa aattaattaa ccactcattc atcgactctc ccaccccatc 14820
 caacatctcc gcatgatgaa acttcggctc actccttggc gcctgcctga tcttccaat 14880
 caccacagga ctattcttag ccatgacta ctaccagac gcctcaaccg cctttctatc 14940
 aatcgccac atcactcgag acgtaaatta tggctgaatc atccgctacc ttacgcca 15000
 tggcgctca atattcttta tctgcctctt cctacacatc gggcgaggcc tatattacg 15060
 atcatttctc tactcagaaa cctgaaacat cggcattatc ctcttgcctg caactatagc 15120
 aacagccttc ataggctatg tcctcccggt aggcacaata tcattctgag gggccacagt 15180
 aattacaac ttactatccg ccatcccata cattgggaca gacctagttc aatgaactg 15240
 aggaggctac tcagtagaca gtccaccct cacacgattc ttacactttc acttcattct 15300
 gcccttcatt attgcagccc tagcaacact ccactccta ttcttgacg aaacgggac 15360
 aaacaacccc ctaggaaatc cctccattc cgataaaatc accttccacc cttactacac 15420
 aatcaaagac gccctcggt tactttctt cttctctctc ttaatgacat taacactatt 15480

CI0043PCTseqlisting.ST25

ctcaccagac ctccctaggcg acccagacaa ttatacccta gccaaaccct taaacacccc 15540
 tccccacatc aagcccgaat gatatttctt attcgcctac acaattcttc gatccgtccc 15600
 taacaaacta ggaggcgtcc ttgccctatt actatccatc ctcatcctag caataatccc 15660
 catctctcat atatccaaac aacaaagcat aatatttcgc cactaagcc aatcacttta 15720
 ttgactctca gccgcagacc tcctcattct aacctgaatc ggaggacaac cagtaagcta 15780
 cctctttacc atcattggac aagtagcatc cgtactatac ttcacaacaa tcctaatacct 15840
 aataccaact atctccctaa ttgaaaacaa aataactcaa tgggcctgtc cttgtagtat 15900
 aaactaatac accagtcctg taaaccggag atgaaaacct ttttccaagg acaaatcaga 15960
 gaagaagtct ttaactccac cattagcacc caaagctaag attctaattt aaactattct 16020
 ctgtctcttc atggggaagc agatttgggt accaccaag tattgactca cccatcaaca 16080
 accgcatagt atttcgtaca ttactgccag ccaccatgaa tattgtacgg taccataaat 16140
 acttgaccac ctgtagtaca taaaaaccca atccacatca aaacccctc cccatgctta 16200
 caagcaagta cagcaatcaa cctcaacta tcacacatca actgcaactc caaagccacc 16260
 cctcaccac taggatacca acaaacctac ccacccttaa cagtacatag tacataaagc 16320
 catttaccgt acatagcaca ttacagtcaa atcccttctc gtcctcatgg atgaccccc 16380
 tcagataggg gtcctctgac caccatctc cgtgaaatca atatcccgca caagagtgtc 16440
 actctctcgt ctccgggcc ataacacttg ggggtagcta aagtgaactg tatccgacat 16500
 ctggttctca cttcagggtc ataaagccta aatagccac acgttccct taaataagac 16560
 atcacgatg 16569

<210> 11
 <211> 17
 <212> DNA
 <213> B19 virus

<400> 11
 tggctcggga tgaaggt 17

<210> 12
 <211> 23
 <212> DNA
 <213> B19 virus

<400> 12
 ccattttagg cgggcaacc acc 23

<210> 13
 <211> 21
 <212> DNA
 <213> B19 virus

<400> 13
 tgggaagtgt gctgtgcctg g 21

<210> 14
 <211> 23

CI0043PCTseqlisting.ST25

<212> DNA
 <213> B19 virus
 <400> 14
 agaatcattt gtcggaagct cag 23

<210> 15
 <211> 20
 <212> DNA
 <213> B19 virus
 <400> 15
 acaagcctgg gcaagttagc 20

<210> 16
 <211> 21
 <212> DNA
 <213> B19 virus
 <400> 16
 acaatgccag tggaaaggag g 21

<210> 17
 <211> 23
 <212> DNA
 <213> B19 virus
 <400> 17
 ctttaacaca tgaagaccat gca 23

<210> 18
 <211> 28
 <212> DNA
 <213> B19 virus
 <400> 18
 cctctcaaaa cactagaata tccttacg 28

<210> 19
 <211> 27
 <212> DNA
 <213> B19 virus
 <400> 19
 cagccatacc accactggga cacagat 27

<210> 20
 <211> 23
 <212> DNA
 <213> B19 virus
 <400> 20
 aatgccattt ctcatggta gac 23

<210> 21
 <211> 20
 <212> DNA
 <213> B19 virus
 <400> 21
 gcaaaacaac accacaggca 20

CI0043PCTseqlisting.ST25

<210> 22
 <211> 22
 <212> DNA
 <213> Hepatitis B virus
 <400> 22
 caacctccaa tcactcacca ac 22

<210> 23
 <211> 24
 <212> DNA
 <213> Hepatitis B virus
 <400> 23
 cctccaattt gtcctgggta tcgc 24

<210> 24
 <211> 23
 <212> DNA
 <213> Hepatitis B virus
 <400> 24
 gtgtctgcg cgttttatca tat 23

<210> 25
 <211> 23
 <212> DNA
 <213> Hepatitis B virus
 <400> 25
 tgtttggtt tcagctatat gga 23

<210> 26
 <211> 22
 <212> DNA
 <213> Hepatitis B virus
 <400> 26
 aattgtgggt cttttgggct tt 22

<210> 27
 <211> 18
 <212> DNA
 <213> Hepatitis B virus
 <400> 27
 ttctccgtct gccgttcc 18

<210> 28
 <211> 21
 <212> DNA
 <213> Hepatitis B virus
 <400> 28
 accagcacca tgcaactttt t 21

<210> 29
 <211> 25
 <212> DNA

CI0043PCTseqlisting.ST25

<213> Hepatitis B virus

<400> 29
 tttttcacct ctgcctaatac atctc 25

<210> 30
 <211> 16
 <212> DNA
 <213> Hepatitis B virus

<400> 30
 tcccactgtt caagcc 16

<210> 31
 <211> 21
 <212> DNA
 <213> Hepatitis B virus

<400> 31
 acctcaccat accgcactca g 21

<210> 32
 <211> 25
 <212> DNA
 <213> Hepatitis B virus

<400> 32
 ggggaattgat gactctagct acctg 25

<210> 33
 <211> 22
 <212> DNA
 <213> Hepatitis B virus

<400> 33
 atcctgaatg gcaaactcct tc 22

<210> 34
 <211> 20
 <212> DNA
 <213> Hepatitis B virus

<400> 34
 gagaaacac acgtagcgca 20

<210> 35
 <211> 16
 <212> DNA
 <213> Hepatitis B virus

<400> 35
 caccctcca cacggc 16

<210> 36
 <211> 27
 <212> DNA
 <213> Hepatitis B virus

<400> 36
 atctctccac ctctaagaga cagtcac 27

CI0043PCTseqlisting.ST25

<210> 37
 <211> 22
 <212> DNA
 <213> Porcine parvovirus
 <400> 37
 cctcacaaaa cggcaagtac tg 22

<210> 38
 <211> 36
 <212> DNA
 <213> Porcine parvovirus
 <400> 38
 acctaagtcc aagtgactgc tactgggtca tacagc 36

<210> 39
 <211> 29
 <212> DNA
 <213> Porcine parvovirus
 <400> 39
 gttaataatg caatgcaaag tacctctaa 29

<210> 40
 <211> 25
 <212> DNA
 <213> Porcine parvovirus
 <400> 40
 aaagacaact gaaagagagc atgga 25

<210> 41
 <211> 30
 <212> DNA
 <213> Porcine parvovirus
 <400> 41
 tctcagctca gattctggct tcatgacaaa 30

<210> 42
 <211> 22
 <212> DNA
 <213> Porcine parvovirus
 <400> 42
 caattctatt tcattgggcca gc 22

<210> 43
 <211> 17
 <212> DNA
 <213> Porcine parvovirus
 <400> 43
 cgtggagcga gccaca 17

<210> 44
 <211> 28
 <212> DNA
 <213> Porcine parvovirus

CI0043PCTseqlisting.ST25

<400> 44	
ctgcacttaa ctccaacacc gccagatt	28
<210> 45	
<211> 24	
<212> DNA	
<213> Porcine parvovirus	
<400> 45	
gcaatacggg caccaagtcc aact	24
<210> 46	
<211> 23	
<212> DNA	
<213> Porcine parvovirus	
<400> 46	
gaggtaagaa gatcgccgag aaa	23
<210> 47	
<211> 28	
<212> DNA	
<213> Porcine parvovirus	
<400> 47	
aacctcacca ccaacaaaa tatataat	28
<210> 48	
<211> 29	
<212> DNA	
<213> Porcine parvovirus	
<400> 48	
actactaact gaacctacca cagaaggag	29
<210> 49	
<211> 26	
<212> DNA	
<213> Porcine parvovirus	
<400> 49	
cttttacctt cagatccaat aggagg	26
<210> 50	
<211> 18	
<212> DNA	
<213> Sindbis virus	
<400> 50	
gcgtgaggac cctgtact	18
<210> 51	
<211> 25	
<212> DNA	
<213> Sindbis virus	
<400> 51	
attggcttcg acaccacca gtcca	25

CI0043PCTseqlisting.ST25

<210> 52
 <211> 20
 <212> DNA
 <213> Sindbis virus
 <400> 52
 ttctcggtta tggcaggttc 20

<210> 53
 <211> 25
 <212> DNA
 <213> Sindbis virus
 <400> 53
 gtttatttct ccgtaggatc gacac 25

<210> 54
 <211> 20
 <212> DNA
 <213> Sindbis virus
 <400> 54
 aaaactgctg caggtctcgg 20

<210> 55
 <211> 22
 <212> DNA
 <213> Sindbis virus
 <400> 55
 gaaatcgata ttacaggggc ca 22

<210> 56
 <211> 21
 <212> DNA
 <213> Sindbis virus
 <400> 56
 gcattaagtt ttctggcatg g 21

<210> 57
 <211> 18
 <212> DNA
 <213> Sindbis virus
 <400> 57
 cgattggcat agccggtg 18

<210> 58
 <211> 21
 <212> DNA
 <213> West Nile virus
 <400> 58
 tcagcgatct ctccaccaaa g 21

<210> 59
 <211> 22
 <212> DNA
 <213> West Nile virus

CI0043PCTseq1isting.ST25

<400> 59
 tgcccgacca tgggggaagg cc 22

<210> 60
 <211> 21
 <212> DNA
 <213> West Nile virus

<400> 60
 caatgacaaa cgtgctgacc c 21

<210> 61
 <211> 20
 <212> DNA
 <213> West Nile virus

<400> 61
 gctagtcctg gtgtttgggg 20

<210> 62
 <211> 24
 <212> DNA
 <213> Escherichia coli 16S Ribosomal RNA

<400> 62
 agagtttgat catggctcag attg 24

<210> 63
 <211> 24
 <212> DNA
 <213> Escherichia coli 16S Ribosomal RNA

<400> 63
 ctggcggcag gcctaacaca tgca 24

<210> 64
 <211> 21
 <212> DNA
 <213> Escherichia coli 16S Ribosomal RNA

<400> 64
 aataccgcat aacgtcgcaa g 21

<210> 65
 <211> 20
 <212> DNA
 <213> Escherichia coli 16S Ribosomal RNA

<400> 65
 gatgcaacgc gaagaacctt 20

<210> 66
 <211> 23
 <212> DNA
 <213> Escherichia coli 16S Ribosomal RNA

<400> 66
 gactgggggtg aagtcgtaac aag 23

<210> 67

CI0043PCTseqlisting.ST25

<211> 24
 <212> DNA
 <213> Escherichia coli 16S Ribosomal RNA
 <400> 67
 gtaacaaggt aaccgtaggg gaac 24

<210> 68
 <211> 19
 <212> DNA
 <213> Escherichia coli 16S Ribosomal RNA
 <400> 68
 gcggttgat cacctcctt 19

<210> 69
 <211> 22
 <212> DNA
 <213> Escherichia coli 23S Ribosomal RNA
 <400> 69
 ccgatatga accagtaccg tg 22

<210> 70
 <211> 25
 <212> DNA
 <213> Escherichia coli 23S Ribosomal RNA
 <400> 70
 atgttgaaaa attagcggat gactt 25

<210> 71
 <211> 18
 <212> DNA
 <213> Escherichia coli 23S Ribosomal RNA
 <400> 71
 gcactgtttc ggcaaggg 18

<210> 72
 <211> 18
 <212> DNA
 <213> Escherichia coli 23S Ribosomal RNA
 <400> 72
 gccggaagac caagggtt 18

<210> 73
 <211> 24
 <212> DNA
 <213> Escherichia coli 23S Ribosomal RNA
 <400> 73
 ggccgtaact ataacggtcc taag 24

<210> 74
 <211> 26
 <212> DNA
 <213> Escherichia coli 23S Ribosomal RNA
 <400> 74

CI0043PCTseqlisting.ST25
gataagtgc gaaagcatct aagcac 26

<210> 75
<211> 25
<212> DNA
<213> Yeast (S. cerevisiae)

<400> 75
ctgccagtag tcatatgctt gtctc 25

<210> 76
<211> 36
<212> DNA
<213> Yeast (S. cerevisiae)

<400> 76
tacagtgaac ctgcgaatgg ctcatataat cagtta 36

<210> 77
<211> 27
<212> DNA
<213> Yeast (S. cerevisiae)

<400> 77
taatacatgc ttaaaatctc gaccctt 27

<210> 78
<211> 24
<212> DNA
<213> Yeast (S. cerevisiae)

<400> 78
gtcttcggac tctttgatga ttca 24

<210> 79
<211> 17
<212> DNA
<213> Yeast (S. cerevisiae)

<400> 79
gcagccgcgg taattcc 17

<210> 80
<211> 24
<212> DNA
<213> Yeast (S. cerevisiae)

<400> 80
gctgaaactt aaaggaattg acgg 24

<210> 81
<211> 23
<212> DNA
<213> Yeast (S. cerevisiae)

<400> 81
tggaagtgtt aggcaataac agg 23

<210> 82
<211> 19

CI0043PCTseqlisting.ST25

<212> DNA
 <213> Yeast (*S. cerevisiae*)
 <400> 82
 tgaacctgcg gaaggatca 19

<210> 83
 <211> 24
 <212> DNA
 <213> Yeast 25S Ribosomal RNA
 <400> 83
 aagcatatca ataagcggag gaaa 24

<210> 84
 <211> 20
 <212> DNA
 <213> Yeast 25S Ribosomal RNA
 <400> 84
 ctctggtgga ggctcgtagc 20

<210> 85
 <211> 18
 <212> DNA
 <213> Yeast 25S Ribosomal RNA
 <400> 85
 aatggatggc gctcaagc 18

<210> 86
 <211> 25
 <212> DNA
 <213> Yeast 25S Ribosomal RNA
 <400> 86
 tgaaatcca caggaaggaa tagtt 25

<210> 87
 <211> 21
 <212> DNA
 <213> Yeast 25S Ribosomal RNA
 <400> 87
 ctaagggtcg ggtagtgagg g 21

<210> 88
 <211> 20
 <212> DNA
 <213> Yeast 25S Ribosomal RNA
 <400> 88
 agaaattcaa ccaagcgcga 20

<210> 89
 <211> 19
 <212> DNA
 <213> Yeast 25S Ribosomal RNA
 <400> 89
 atgtcatttt gcgtgggga 19

CI0043PCTseqlisting.ST25

<210> 90
 <211> 23
 <212> DNA
 <213> Human mitochondrial DNA
 <400> 90
 gttcaccctc taaatcacca cga 23

<210> 91
 <211> 23
 <212> DNA
 <213> Human mitochondrial DNA
 <400> 91
 caagcacgca gcaatgcagc tca 23

<210> 92
 <211> 26
 <212> DNA
 <213> Human mitochondrial DNA
 <400> 92
 ggaacacgca gtgattaacc tttagc 26

<210> 93
 <211> 28
 <212> DNA
 <213> Human mitochondrial DNA
 <400> 93
 gactacgaaa gtggctttaa catatctg 28

<210> 94
 <211> 24
 <212> DNA
 <213> Human mitochondrial DNA
 <400> 94
 tagagtgcctt agttgaacag ggcc 24

<210> 95
 <211> 24
 <212> DNA
 <213> Human mitochondrial DNA
 <400> 95
 taggcgatag aaattgaaac ctgg 24

<210> 96
 <211> 21
 <212> DNA
 <213> Human mitochondrial DNA
 <400> 96
 tttgttaaga tggcagagcc c 21

<210> 97
 <211> 20
 <212> DNA

CI0043PCTseqlisting.ST25

<213> Human mitochondrial DNA
<400> 97
agaatcgaac ccatccctga 20

<210> 98
<211> 19
<212> DNA
<213> Human mitochondrial DNA

<400> 98
tttcaccgta ggtggcctg 19

<210> 99
<211> 20
<212> DNA
<213> Human mitochondrial DNA

<400> 99
aatcgctgtc gccttaatcc 20